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Chondroitin sulfotransferase 3 (CHST3) is involved in the biosynthesis of 
chondroitin sulfate (CS), which has been implicated to be involved in tumor 
progression. CHST3 specifically catalyzes carbon 6 sulfation of the CS molecule, 
and has not been studied of its effects in breast cancer. In this study, the expression 
and functional roles of CHST3 are evaluated in breast cancer.  
 
CHST3 expression is found to be significantly lower in malignant breast cells in 
comparison to that of the normal breast cells. Following that, in the in vitro studies, 
CHST3-silenced cells showed significant increases in cell migration and invasion 
whereas CHST3-over-expressed cells showed the opposite trends that are decreases 
in cell migration and invasion. Changes in cell adhesion, proliferation, and 
apoptosis are much lesser in comparison to cell migration and invasion. It is 
observed that CHST3 enhances cell adhesion and cell apoptosis, as well as 
suppresses cell proliferation. Therefore, the results show that there is a negative 
association between CHST3 expression and the metastatic, proliferative capabilities 
of breast cancer cells.  
 
Subsequently molecular pathway studies were carried out. GPNMB and FLRT3 are 
shown to be up-regulated after down-regulation of CHST3. A double knockdown 
of either CHST3 and GPNMB or CHST3 and FLRT3 abolished the cell migration, 
invasion, proliferation, and adhesion changes initially observed in the CHST3 
single silencing experiments. Hence, CHST3/GPNMB and CHST3 /FLRT3 pairings 
work together in modulating the cancer cells’ behaviors and both GPNMB and 
FLRT3 are downstream targets of CHST3. Additionally, epithelial-mesenchymal 
transition (EMT) markers (E-cadherin and β-catenin) decreased in expression after 
silencing of CHST3. Also, there is a decrease in pBAD/BAD level indicating that 
the changes observed in cell proliferation and apoptosis seen in the CHST3 
phenotypic experiments could be due to the BAD survival pathway. 
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Evaluation of CHST3 and FLRT3 expressions through immunohistochemistry in 
invasive ductal carcinoma tissues revealed enhanced CHST3 and reduced FLRT3 
expression in normal tissues in comparison to malignant tissues. The decrease in 
CHST3 level is also correlated with higher tumor stage and larger tumor size. As 
for FLRT3, its high expression was associated with patients with older age as well 
as enhanced staging of lymphovascular invasion. No trend is observed between 
CHST3 and FLRT3 expression levels. This initial study of CHST3 and FLRT3 
hence suggest that both molecules may participate in breast cancer as a tumor 
suppressor and tumor promoter respectively.   
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1.1 The Breast and Breast Cancer 
1.1.1 Introduction to Breast Carcinoma 
 
Breast cancer is the most commonly diagnosed carcinoma as well as one of the top-
ranked causes of cancer death, among females worldwide. The cancer of the breast 
may develop from different parts of the mammary gland and can be classified into 
different groups, as will be further discussed in this chapter. Breast tumors have 
also been long known to be a heterogeneous disease, as shown from molecular 
profiling, with varying clinical outcomes. It is hence essential and critical to gain 
knowledge on not only the anatomical and morphological characteristics of a 
normal breast and malignant breast tissues, but also the molecular features involved 
in breast tumor progression.     
 
1.1.2 The Development and Anatomy of the Breast 
 
Breast development in the embryo usually starts at the 5th week. The mammary 
ridges will form on the ventral surface, lengthening from the axilla to the medial 
thigh (Howard and Gusterson, 2000). After which, epithelial cells will focus at the 
center of each mammary ridge, forming the mammary bud (Watson and Khaled, 
2008). In the 15th week of development, mesenchymal cells will accumulate around 
the mammary bud, triggering its outgrowth and sprouting into the mesenchymal 
tissue (Howard and Gusterson, 2000, Mikkola and Millar, 2006). This would lead 
to the formation of lobes and ultimately lobules. The mammary bud will become 
canalized, forming lactiferous ducts. Approximately 15 to 20 lobes will be present 
in each breast, with their lactiferous ducts converging at the mammary pit that will 
later on form the nipple (Cowin and Wysolmerski, 2010).   
 
Post-natal, the mammary glands will be structurally similar in both males and 
females till puberty. For males, the mammary glands will remain rudimentary 
(Russo et al., 2001). The female breast changes continuously in structure 
throughout her lifetime, as caused by major physiological factors like puberty, 
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menstrual cycle, pregnancy, and menopause. When females hit puberty, hormonal 
secretion will change causing development and structural modifications within the 
glands (Naccarato et al., 2000). Estrogen and progesterone secretions from the 
ovaries as well as prolactin from the anterior pituitary gland will instigate further 
developments of the lobules and ducts (Howard and Gusterson, 2000) Additional 
hormones such as glucocorticoids and somatotropin are needed for full 
development of the ducts (Knight and Sorensen, 2001). Simultaneously, the 
mammary glands will enlarge due to an increase in connective and adipose tissues 
within the stroma. The female breast will encounter full development at around 20 
years of age, with minor cyclical changes during menstrual period and major 
changes during pregnancy and lactation period (Russo et al., 2001).  
 
The mature breast (as shown in Figure 1.1) is positioned upon the deep pectoral 
fascia, which in turn overlies the pectoralis major muscle of the chest wall, 
extending from the second to the sixth ribs in the vertical axis (Abrahams et al., 
2013, Standring, 2008). The breast is held by the suspensor-like ligaments of 
Cooper to the skin, of which provides support for the breast parenchyma (Hoda, 
2012, O'Rahilly and Muller, 2004, Standring, 2008). It consists of 15 to 20 lobules, 
which are responsible for producing and secreting milk into the lactiferous ducts 
that converge and lead out to the nipple, which is the greatest prominence of the 
breast (Kossoff et al., 1973, Ramsay et al., 2005). The nipple is surrounded by a 
circular pigmented area called the areola. Before getting to the nipple, each of the 
ducts is dilated, forming a lactiferous sinus used for storage of milk during 
lactation; after which, the ductal passage narrows before passing through the nipple 
(Love and Barsky, 2004, Doucet et al., 2009).  Histologically, the lactiferous duct 
in the lobe is lined by a double layer of cells (cuboidal or low columnar epithelial 
cells) that makes up the interior as well as the outer myoepithelial layers, and 
enclosed by the basal lamina. The lobules constitute alveolar acini that regulate 
milk production (Kierszenbaum and Tres, 2011). The lobules and ducts are 
surrounded by the connective tissue stroma, consisting of adipose and collagenous 
connective tissues  (American Cancer Society, 2012a, O'Rahilly and Muller, 2004, 
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Hoda, 2012, Nawaz, 2011, Moore and Agur, 2007, Gartner and Hiatt, 2007).  The 
stroma region that surrounds the lobules is dense and fibro-collagenous, while the 
intralobular stroma region has distinctively more loose texture to allow rapid 
expansion of the secretory tissue especially during pregnancy (Standring, 2008).  
 
During pregnancy, the terminal ducts and lobules will further differentiate causing 
extensive glandular expansion. Subsequently, the lobules will enlarge and the 
amount of both adipose and connective fibrous tissues will reduce. After the age of 
40 or so, the ducts, lobules, and connective tissues of the breasts will start to atrophy, 
giving rise to replacement by fatty adipose tissues. This process will continue 
throughout menopause (Hoda, 2012, Gartner and Hiatt, 2007).  
  
 
Figure 1.1: Anatomy of the breast.  




1.1.3 Epidemiology of Breast Cancer 
 
Breast cancer is the most frequently diagnosed cancer and a top cancer-related 
death among females worldwide, accounting for 22.9% and 13.7% of all cancers 
respectively (American Cancer Society, 2011). The diagnosis and mortality rate in 
developing countries (20% diagnosis rate and 12.7% mortality rate, of which both 
are lower than the global means) is lower than that of developed countries (26% 
diagnosis rate and 15.5% mortality rate, of which both are higher than the global 
means) (American Cancer Society, 2011). In the United States of America, breast 
cancer continues to be the top cancer among females constituting 29% or one third 
of female cancer cases, much higher than the global mean (American Cancer 
Society, 2012b). In terms of cancer-related death, breast cancer makes up 
approximately 14% of all cancer deaths in women, second only to lung cancers 
(26%) (American Cancer Society, 2012a). Nevertheless, the death rate for breast 
carcinoma has decreased over the past twenty years by ~30%, reflecting the 
improvements in early breast cancer detection and treatment options. It has been 
observed that Caucasian females have an overall elevated breast cancer incidence 
rate in comparison to females of other races, due to later first pregnancies, more 
frequent use of hormonal therapy, and higher mammography check-ups (Siegel et 
al., 2013).  
 
In Singapore, breast cancer is also the most frequently diagnosed cancer affecting 
females, accounting for almost 30% of all cancers in Singaporean women (Teo and 
Soo, 2013). Furthermore, it is the most common female cancer in the three different 
main ethnic groups in Singapore that are the Chinese, Malay, and Indian. In 
addition, from year 1968 to 2002, statistics showed that the Chinese in comparison 
to Malays and Indians have elevated risk of being diagnosed with cancer of the 
breast. Similar to global cancer statistics trend, breast carcinoma in Singapore is the 
top cancer-related death accounting for 18.0% of all female cancer mortalities 
(National Registry of Diseases Office, 2012). The rise in breast cancer incidence 
can be attributed to better awareness of breast cancer and wider use of 
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mammography for the detection of breast carcinoma. Nevertheless, it is also caused 
by urbanization in Singapore, of which females tend to adopt Western lifestyle and 
diet, as well as having low and late parity (Verkooijen et al., 2009, Rastogi et al., 
2008).  
 
1.1.4 Risk Factors of Breast Cancer 
 
It is hence necessary for females to be aware of the risk factors concerned with 
breast cancer.  The risk factors can be separated into the non-modifiable factors as 
well as the modifiable factors groups. The non-modifiable risk factors would 
comprise of patients’ age, family history of breast cancer, inherited gene mutations 
in BRCA1 and BRCA2 which are breast cancer susceptibility genes, early menarche 
and late onset of menopause. On the other hand, modifiable risk factors include late 






Age in females is a main non-modifiable risk factor of breast carcinoma. The 
incidence risk in females aged 25 and below is usually very low. However, the risk 
will double with every 10 years of age (Hamajima et al., 2002) with the risk 
increasing substantially as females transition though menopause (American Cancer 
Society, 2011). In the United States of America, females aged 40 years old and 
older accounted for 95% of all new breast cancer cases, whereas the lowest risk 
group was in females aged 20 to 24 years old. Additionally, 97% of breast cancer 
deaths often occur among females of 40 years old and above (American Cancer 
Society, 2012a). In Singapore, from year 1968 to 2002, almost half of all breast 
carcinoma cases were diagnosed in females aged 50 years old and above, with 




1.1.4.2 Family history of breast cancer 
 
Another key risk factor of breast cancer is the genetic predisposition or inheritance 
of gene mutations in the female. She is more susceptible to breast cancer if she has 
a positive family history of the disease (Collaborative Group on Hormonal Factors 
in Breast Cancer, 2001). The degree of the risk involved is also dependent upon her 
connection with the affected family member or relative, as well as the number of 
family members or relatives diagnosed with the cancer (Singletary, 2003). An 
analysis involving 52 epidemiological studies found that 13% of breast carcinoma 
cases had family history of breast cancer (Hamajima et al., 2002). BRCA1 and 
BRCA2 are the two most established hereditary genes in breast cancer. Females 
with inherited BRCA1 mutations are more susceptible of getting breast cancer at 
around the age of 35 years old, whereas those with inherited BRCA2 mutations will 
have a 25% to 45% increased risk of developing breast carcinoma (Ferla et al., 2007, 
Antoniou et al., 2003).  
 
1.1.4.3 Early Menarche and Late Menopause  
 
Studies have established that most breast cancer risk factors are attributed to 
elevated exposure to estrogen (Collaborative Group on Hormonal Factors in Breast 
Cancer, 2012). Females having early onset of menarche and late onset of 
menopause are at higher risk of developing breast cancer due to prolonged exposure 
to high levels of estrogen during the menstrual cycle (Singletary, 2003). In fact, 
females with early menarche at age less than 12 years old have a 10 to 20% elevated 
risk of breast cancer occurrence. Additionally, females with delayed menopause 
after the age of 55 years old are more predisposed to getting breast carcinoma 
(Dumitrescu and Cotarla, 2005, Titus-Ernstoff et al., 1998).  
 
1.1.4.4 Late or Low Parity  
 
Moving on to the modifiable risk factors, a female having her first pregnancy at a 
younger age and having more children has lower risk of developing breast cancer 
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(Brinton et al., 1988). On the other hand, null-parity and first pregnancy after the 
age of 30 years old are two modifiable risk factors that can contribute to increased 
risk of developing breast cancer (Hulka and Moorman, 2008).  
 
1.1.4.5 Use of Hormonal Pills  
 
Use of oral contraceptives as well as hormone replacement therapy (HRT) is 
another two modifiable risks that can contribute to higher breast cancer incidence 
rate (Collaborative Group on Hormonal Factors in Breast Cancer, 1996). A slight 
increase in risk of developing breast cancer has been reported in females using oral 
contraceptives especially those with higher amounts of estrogen; nevertheless, the 
risk is observed to reduce after termination of the oral contraceptive intake  (Hulka 
and Moorman, 2008). The risk of breast cancer development also decreases in 
females after a 5-year cessation of HRT usage (Boyle, 2005).  
 
1.1.4.6 High Fat Diet and Sedentary Lifestyle  
 
Certain breast cancer risk factors such as physical activity and diet type are 
modifiable. Alcohol intake has been correlated with enhanced breast cancer risk 
(Zhang et al., 2007, Terry et al., 2006) due to possible increment in estrogen levels 
upon intake (Singletary and Gapstur, 2001). Obesity in post-menopausal females is 
also positively associated with elevated breast cancer risk. The high fat 
consumption in meals and its accumulation of body fat in these females can have 
an effect on the incidence of hormonally dependent breast cancer as fats in the 
plasma can significantly increase the levels of circulating estrogens (McTiernan et 
al., 2003). Apart from that, there have been controversies on soy intake as certain 
studies associated soy intake with decreased risk of breast cancer development as 
soy-based products contain isoflavones (or phyto-estrogen) while some studies 
showed otherwise (Boyle, 2005). Also, though there is no consistent significant 
correlation between breast cancer risk and physical activity, it is still suggested that 
physical activity has an indirect impact on body fats, which can contribute to 
estrogen levels (Colditz et al., 2003).  
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Hence, females should reduce the incidence of breast cancer by increasing physical 
activity, eating low-fat foods, minimizing alcoholic beverage intake, maintaining a 
healthy body weight, and reducing hormone intake. Breast-feeding by mothers is 
also encouraged as it decreases estrogen production due to suppression of the 
ovulatory cycle and increases secretion of prolactin, giving it a protective effect 
against breast cancer (Vogel, 2012).  
 
1.1.5 Symptoms of Breast Cancer 
 
For early detection of breast cancer, all females should be familiar with both 
appearance and feel of their breasts in order to promptly report any changes to a 
doctor. The most frequent physical symptom of a potential breast cancer case is a 
painless lump in the breast (American Cancer Society, 2012a). At times, the tumor 
mass can be felt at the axillary lymph nodes (underarm) before the primary breast 
tumor is sufficiently large to be felt. Other less frequent symptoms consist of breast 
pain, changes to the breast (swelling, thickening, skin irritation, skin distortion), 
and abnormalities at the nipple (bleeding discharge, erosion, inversion) (Osteen, 
2001, American Cancer Society, 2012a). 
 
1.1.6 Classification of Breast Cancer 
 
Classification of breast carcinoma provides details on the extent of the disease at 
the point of diagnosis i.e. the size and location of the primary tumor as well as 
presence and extent of metastasis to other parts of the body. The classification of a 
breast cancer tumor is vital in determining the therapy choice and estimating the 
prognosis of the patient. The tumor-node-metastasis (TNM) staging system, 
proposed by Pierre Denoix, is commonly used in clinical settings and it evaluates 
tumors in three aspects: (T) assesses size and extent of the primary tumor; (N) 
investigates the absence or presence of regional lymph node involvement; (M) 
evaluates the absence or presence of distant metastases (Arnone et al., 2010, 
Escobar et al., 2007). Upon determination of the TNM characteristics, stages are 
assigned with stage 0 being in situ while stage IV being invasive carcinoma (Sobin 
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et al., 2009, American Cancer Society, 2012a). Table 1.1 gives a brief description 
of the various TNM staging:  
 
Table 1.1 Various TNM staging 
Stage Description 
0 The breast tumor is at in situ stage, whereby the cancer cells are still contained within 
the duct or lobule. 
I The breast tumor is relatively small with a maximum size of 2cm. No lymph node 
metastasis is involved at this stage. 
II The breast tumor size is between 2 and 5cm, with lymph node metastasis to the ipsilateral 
axillary nodes. Breast tumors larger than 5cm with negative lymph node involvement 
are also categorized as Stage II. 
IIIA The breast tumor is of any size or more than 5cm, with lymph node metastasis to the 
ipsilateral axillary lymph nodes or other surrounding structures. 
IIIB Inflammatory carcinoma usually occurs at this stage. The breast tumor can be of any size 
with metastasis to the ipsilateral lymph nodes. 
IV The breast tumor is of any size with metastasis beyond the ipsilateral supraclavicular 
lymph nodes. 
 
Breast tumor originates in the breast tissue, mostly from the epithelia of ducts and 
lobules. Most lumps or masses are benign, that is they do not have uncontrolled 
growth or spread and are not life-threatening. Breast cancer of in situ stage is 
characterized by tumor cells that are still confined within their site of origin: ducts 
(ductal carcinoma in situ or DCIS, as shown in Figure 1.2) and lobules (lobular 
carcinoma in situ or LCIS). DCIS accounts for majority of the in situ breast cancer 
cases, accounting about 83%, while LCIS takes up 11% of in situ cases. The 
remaining in situ types have features of both DCIS and LCIS or have unspecified 
site of origin. Most breast cancer cases are of the invasive type, whereby the tumor 
cells from the ducts or lobules have broken through the basement membrane to 
invade into the surrounding breast tissues, and if left undiagnosed, metastasis may 
occur (American Cancer Society, 2012a). Metastatic spread occurs mainly through 
lymphatic drainage of the breast. The lymph passes from the nipple, ducts and 
lobules to the subareolar lymphatic plexus; after which, majority (more than 75%) 
of lymph drains through the axillary lymph nodes (Nawaz, 2011, Moore and Agur, 
2007). The remainder of the lymph will drains into the internal mammary nodes. 
(Hoda, 2012).  
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Apart from ductal carcinoma and lobular carcinoma, there are other various types 
of breast cancer including inflammatory breast cancer, triple negative breast cancer, 
phyllodes tumor, mucinous carcinoma, and medullary carcinoma (van Bogaert, 
1981). In this study, I will be focusing on invasive ductal carcinoma (IDC) tumors. 
Hence, the details of IDC tumors will be discussed in greater detail.  
 
1.1.7 Invasive Ductal Carcinoma 
 
IDC is the most frequently diagnosed breast carcinoma, constituting 60 to 80% of 
all breast cancer cases (Rosen, 2009). IDC cases make up 79.2% of all breast cancer 
cases in Singapore (Seow et al., 1996). IDC is marked by its characteristics of 
having malignant ductal epithelial cells with abnormal growth and their invasion 
into the surrounding breast stromal tissue (as depict in Figure 1.2). The gross 
appearance of the breast tumor is often a fibrous and solid lump. At the histology 
level of IDC, the tumorigenic ductal cells would often invade in an irregular manner 
and are at times correlated with lymphoplasmacytic infiltrate. It is hence important 
for histopathologists to utilize a grading system to evaluate the breast tumor.  
 
The grading system of IDC tissues can be performed based on three histological 
factors, namely mitotic frequency, degree of nuclear pleomorphism, and extent of 
tubule formation. Each of these three factors is given a score of 1 to 3. After which, 
the scorings of the three factors will be added up to give the Bloom-Richardson 
score (Meyer et al., 2005). Table 1.2 shows a description of the score range. 
Classifying IDC patient tumors into their respective grades will aid physicians in 
predicting treatment response to chemotherapy as well as patient’s prognosis. 
 
Table 1.2 Classification of tumor by Bloom-Richardson score 
Tumor Grade Bloom-Richardson Score Description 
1 3 to 5 Well-differentiated 
2 6 to 7 Intermediate 





Figure 1.2: Histopathology of ductal carcinoma.  
(A) depicts ductal carcinoma in situ, whereby the malignant ductal epithelial cells are still 
within the basement membrane. (B) illustrates IDC, whereby the malignant ductal 
epithelial cells have broken passed the basement membrane and invaded into the 
surrounding breast tissues. [This image is free from copyright and is free to be shared] 
 
1.1.8 Detection of Breast Cancer 
 
Apart from reducing risk factors involved, every female above age 40 years old 
should consider annual clinical breast examination and standard radiological 
imaging (such as mammography, ultrasound scan, and magnetic resonance 
imaging) for early breast cancer detection to increase their survival rate (Saslow et 
al., 2007). Early breast cancer detection can help reduce breast tumor recurrence as 
well as breast cancer-related mortality as treatment is more effective in patients at 




stages will give rise to poorer patient prognosis. For US females, the overall five-
year survival for those with early breast cancer stage is 98% in comparison to those 
with late breast cancer stage with the tumor cells spread to regional lymph nodes 
(84%) or distant organs (23%) (American Cancer Society, 2011). Therefore, public 
health campaigns are constantly carried out to raise awareness of the importance of 
early detection for breast cancer. 
  
1.1.8.1 Breast Self-Examination  
 
Every female is able to perform their own breast examination, of which is non-
invasive and it can be done comfortably on a regular basis to detect any changes in 
the breast. It is recommended that females be taught the correct techniques by their 
physicians for breast self-examination.  In developing countries, as mammography 
screening can be costly, the recommended early detection strategies there are to 
create awareness of breast cancer, its signs and symptoms, and carry out self breast 
examination (Anderson et al., 2008).  
 
1.1.8.2 Mammography  
 
Mammography screening has been shown of its capability in detecting breast 
cancer at an earlier stage when more treatment options are available; the 
treatment(s) would also be more effective and survival rate is higher (American 
Cancer Society, 2011). Mammography will specifically aid in detecting the 
presence of potential malignant masses seen as a stellate opacity, accompanied with 
architectural distortion of the surrounding parenchyma. At times, a DCIS mass may 
appear as micro-calcification on the mammogram (Standring, 2008). In the United 
States of America female population, mammography screening done every 1 to 2 
years showed a decrease in breast cancer-related mortality especially for females 
aged 40 years old and beyond (Smith et al., 2004).  In Singapore, 64% of breast 
cancer cases detected were of the early stage (Tan et al., 1999). The Singapore 
Health Promotion Board has subsequently held nation wide mammography 
screenings in order to decrease breast cancer-related mortality (Wang, 2003).  
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1.1.8.3 Ultrasound  
 
Ultrasound is another method used to help detect solid form of cystic masses, as 
well as differentiate malignant mass from benign lumps through different 
attenuation features of the ultrasound waves and blood flow patterns (Gabriel and 
Domchek, 2010). Nowadays, ultrasound is used as an additional important aid to 
mammography for breast cancer detection. It is usually used on females with 
potentially higher risk of breast cancer or with high breast tissue density (Irwig et 
al., 2004).  
 
1.1.8.4 Magnetic Resonance Imaging  
 
Magnetic resonance imaging (MRI) is sometimes used to further define the extent 
of the cancer (Saslow et al., 2007). MRI has higher sensitivity but lower specificity 
of tumor detection; hence, it is lesser used compared to mammography and 
ultrasound scan, and is particularly used in younger females having more dense 
breasts (Standring, 2008). Nevertheless, it can be used to follow tumor response 
after a patient undergoes chemotherapy (Hakim et al., 2012). 
 
1.1.9 Definitive Diagnosis of Breast Cancer 
 
After acquiring a plausible detection/diagnosis using radiological imaging, 
microscopic examination of the breast tissue would be required to give a definitive 
diagnosis of breast cancer as well as to determine the type of breast cancer, such as 
whether the cancer is of in situ or invasive type, and if the tumor is of ductal or 
lobular carcinoma type (American Cancer Society, 2012a).  
1.1.9.1 Tumor Biopsies  
 
Fine needle aspiration is able to achieve a cytological diagnosis of the breast lump, 
providing information on the cellular component of the lump. It can also be used to 
drain symptomatic breast cysts (Abati and Simsir, 2005). Wide-bore needle biopsy, 
on the other hand, is performed under local anaesthetic to attain specimen samples 
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for a histological diagnosis, permitting diagnosis of the tumor subtype through 
evaluation of various pathological characteristics (Standring, 2008).   
 
1.1.9.2 Prognostic Markers for Breast Cancer  
 
Even though lymph node status and primary tumor size are two powerful prognostic 
factors, at times, they can give inaccurate predictions of the survival outcome of the 
patients (Chen et al., 2009a, Gebauer et al., 2002). This may lead physicians to be 
more cautious in eradicating all possible tumors and hence recommending 
chemotherapy, of which patients may or may not benefit from.   
 
Tumor biomarkers are increasingly being used in the clinical setting to aid in the 
estimation of patients’ prognosis, determination of treatment choices, prediction of 
treatment outcome, and for better treatment response monitoring (American Cancer 
Society, 2012a). Some of the more well-known validated biomarkers for breast 
carcinoma include estrogen receptor (ER), progesterone receptor (PR), human 
epidermal receptor 2 (HER2), BRCA1, uPa/PAI1, and Ki67.  
 
Breast cancer cells with ER and/or PR are dependent on their respective ligands, 
estrogen and progesterone, for cell growth. ER, in the form of ERα, is present in 
70% of breast cancer cases. Evaluation for ER and PR status in patients’ tumor 
samples can be carried out to determine if the tumor can be successfully treated 
with hormone therapy, such as tamoxifen.  ER+ and PR+ will generally offer better 
survival outcome as well as better response to hormone therapy (Onitilo et al., 
2009). Tamoxifen will block ER and give rise to anti-malignant properties such as 
reduction in cancer cell growth. Tamoxifen is able to significantly decrease tumor 
recurrence risk within 5 years by 40% and increase overall survival by 31% (Early 
Breast Cancer Trialists' Collaborative Group, 2005). Other than that, aromatase 
inhibitors such as anastrozole work through the inhibition of conversion of 
precursor molecules to estradiol. Besides that, the presence of ER in a patient’s 
tumor is usually correlated with less beneficial effects from adjuvant chemotherapy. 
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This would help avoid unnecessary over-treatment and possible adverse side effects 
in the patient. As for PR, it is strongly dependent upon ER activity. Hence, PR+ 
breast tumors also have better patient survival outcome in comparison with PR- 
breast tumors (Anderson et al., 2001). Both ER and PR status in breast cancer 
tissues can be evaluated through immunohistochemistry by a pathologist.  
 
Human epidermal growth factor receptor 2 (HER2 or ERBB2), a transmembrane 
receptor with constitutive tyrosine kinase activity, is another well-established 
biomarker (Weigelt et al., 2005). HER2 has been reported to be involved in cell 
motility, adhesion, and differentiation. Clinical studies have generally shown that 
HER2 is over-expressed in breast tumors of higher grade (Slamon et al., 1987, 
Slamon et al., 2001). In addition, high expression of HER2 has been associated with 
higher risk of tumor recurrence and worse prognosis (Slamon et al., 1987, Ross and 
Fletcher, 1998). The finding of HER2 has an important biomarker has led to the 
development of a humanized monoclonal antibody (trastuzumab), designed against 
HER2 (Baselga et al., 1998). Trastuzumab is used in combination with 
chemotherapy in breast cancer patients diagnosed with over-expression of HER2 
antigen (Weigelt et al., 2005). Studies including randomized clinical trials have 
demonstrated reduced risk of tumor recurrence, decreased metastasis and improved 
survival rate in patients given trastuzumab treatment in comparison to those not 
receiving trastuzumab therapy (Slamon et al., 2001, Viani et al., 2007).  
 
BRCA1 gene is a well-known hereditary marker in breast cancer (Scully and Puget, 
2002). It is involved in the regulation of cell cycle, chromosomal remodeling and 
DNA repair. Loss of BRCA1 in breast carcinoma would not only cause decreased 
expression of BRCA1, but also incorrect sub-cellular localization (Rebbeck et al., 
1996). This in turn would lead to worse prognosis in breast cancer patients. 
Additionally, loss of BRCA1 has been correlated with tumors of higher grade and 
larger size, advanced lymph node involvement, vascular invasion, as well as ER 
and PR negative statuses (Heisey et al., 1999). 
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Urokinase plasminogen activator (uPa) and plasminogen activator inhibitor (PAI-
1), involved in the plasminogen activating system, have crucial roles in cell 
invasion, metastasis and angiogenesis (Stephens et al., 1998). Both uPa and PAI-1 
are highly expressed in breast cancer tissues (Duffy, 2002). In addition, both 
biomarkers have been validated of their prognostic importance in several 
retrospective studies as well as in a multi-center randomized prospective clinical 
trial (Janicke et al., 2001, Look et al., 2003). According to the American Society of 
Clinical Oncology (ASCO), both biomarkers can be utilized to determine patients’ 
prognosis, especially for those diagnosed with node-negative breast carcinoma 
(Duffy, 2013). In general, patients with high expression of uPa and PAI-1 have 
been associated with significantly higher risk of tumor recurrence. For these 
patients, adjuvant chemotherapy, specifically CMF-based which consists of 
cyclophosphamide, methotrexate, and fluorouracil, would be more beneficial 
compared to observation alone (Harris et al., 2007).  
 
Ki67 is a prognostic biomarker involved in tumor cell proliferation. Its expression 
level has been reported to be elevated in malignant breast tissues (Harper-Wynne 
et al., 2002), its expression increasing progressively from DCIS to IDC breast 
cancer type (Kontzoglou et al., 2013).  Therefore, high expression of Ki67 is 
associated with better therapeutic response towards chemotherapy as well as being 
a good biomarker for poor prognosis.  
 
Developing single gold-standard biomarkers is however difficult as tumor cells are 
known for their genetic instability and plasticity, which help in the tumor cells’ 
change and response towards the host defense system. It would also make it tricky 
for physicians to determine a patient’s relapse risk after treatment. Therefore, 
having biomarker panels and developing more improved panels that are able to 
identify high-risk and low-risk groups by providing a “yes” or “no” answer on 
tumor recurrence in a patient will significantly improve disease management. 
Hence, it is crucial for the cancer research community to understand a network of 
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genes significantly involved in breast cancer tumor progression, in order to improve 
disease management.  
 
Some biomarker panel assays available include the 70-gene MammaPrint® 
signature assay and the 21-gene Oncotype DX panel, both of which are able to 
determine the risk of tumor recurrence and prognosis outcome in a patient (Manjili 
et al., 2012, Espinosa et al., 2012). As an example, the assays can generate gene 
signatures that will determine that a patient in the high risk group has 30% chance 
of having tumor recurrence while a patient in the intermediate risk group will have 
a 14.3% chance of tumor recurrence within 5 to 10 years (Manjili et al., 2012). As 
for patients in the low risk group, they have a recurrence free survival rate of over 
90% without having the need to receive chemotherapy (Espinosa et al., 2012).  
 
The MammaPrint® assay has been cleared for use by the US Food and Drug 
Administration (FDA) in patients with lymph node negative status (and ER+ or ER- 
status) and tumors smaller than 5cm to determine the prognosis outcome of the 
patients (van 't Veer et al., 2002, van de Vijver et al., 2002). The assay can help in 
refining the prognostic value of traditionally-used biomarkers such as HER2. 
Recent studies also suggest that the MammaPrint® assay has predictive value, 
being able to predict the patients’ treatment response (Straver et al., 2010). The 
microarray-based assay utilizes high quality RNA, obtained from patients’ tumor 
tissue samples, which would then be processed to be used to obtain 70 gene 
expression levels. The 70-gene signature includes genes associated with cell 
invasion, metastasis, proliferation, and angiogenesis, of which would be used to 
determine if a patient has low or high risk of tumor recurrence. This is beneficial 
for patients as it would prevent over-treatment in patients with a low risk cancer 
and under-treatment of patients with high risk cancer (Gokmen-Polar and Badve, 
2012). Generally, patients of high risk, as determined by standard 
clinicopathological parameters (such as tumor grade and tumor size) and 
MammaPrint® gene signature would be administered with chemotherapy. On the 
other hand, patients identified with low risk will receive hormonal therapy. The 
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MammaPrint assay helps these patients with low risk avoid unnecessary 
chemotherapy, giving them a maximum 10% risk of tumor recurrence within a 
minimum of 5 years (Manjili et al., 2012).  
 
The 21-gene Oncotype DX assay is able to evaluate 16 cancer-related and 5 control 
genes through RT-PCR using RNA isolated from paraffin-embedded breast cancer 
tissue (Elloumi et al., 2011). The assay is mainly used among patients with lymph 
node negative and ER+ status, of which cancer-associated genes such as ER, PR, 
HER2, and Ki-67 are evaluated. A recurrence score will be generated with heavier 
weightage on ER and proliferation-related genes. Studies have shown that the 
Oncotype DX assay is better than standard clinicopathological parameters in 
predicting tumor recurrence (Gokmen-Polar and Badve, 2012). From the 
retrospective case-control clinical trial (NSABP Trial B-20), results showed that 
patients with high recurrence risk score benefit significantly from chemotherapy, 
compared to patients with low recurrence risk score who had minimal benefit (Paik 
et al., 2006). Moreover, adjuvant chemotherapy improved recurrence-free survival 
in 30% of patients with high recurrence risk score. While the Oncotype DX test is 
recommended by expert panels, it is not validated in a large prospective, 
randomized clinical trial. The TAILORx clinical trial is currently being carried out 
to address this validation (Manjili et al., 2012).  
  
1.1.10 Treatment for Breast Cancer 
 
Treatment options are dependent upon the stage, size and other clinical 
characteristics of the tumor, as well as patient preference. 
 
1.1.10.1 Surgery  
 
Surgery methods comprise of lumpectomy (removal of the tumor within the breast) 
or mastectomy (removal of the whole breast) with removal of some axillary lymph 
nodes. The surgical method to be used is dependable upon the stage and distribution 
of the tumor as well as the patient’s choice (American Cancer Society, 2012a). At 
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present times, lumpectomy is more often carried out compared to mastectomy to 
extract out only the tumor and surrounding tissues following radiation therapy as 
part of breast conserving surgery (Anderson et al., 2008, Moore and Agur, 2007). 
 
1.1.10.2 Radiation Therapy  
 
Radiation therapy can be administered prior to and after surgery in order to reduce 
the patient’s tumor size and to eliminate remaining cancer cells respectively (Clarke 
et al., 2005). Reports showed that tumor recurrence is reduced and patient’s survival 
is improved following radiation therapy that is used after surgery (Ragaz et al., 
1997).  
 
1.1.10.3 Chemotherapy  
 
Chemotherapy is administered before or after surgery, and is often given to patients 
with metastasis, to reduce the risk of tumor recurrence in the patients (Falo et al., 
2005). Some more common chemotherapeutic drugs used in treating breast cancer 
include doxorubicin, methotrexate, and 5-fluorouracil (Falo et al., 2005). Also, a 
combination of different chemotherapeutic drugs is more effective compared to a 
single drug for therapy (Hortobagyi, 1998). Some examples of successful drug 
combinations include doxorubicin and cyclophosphamide as well as methotrexate, 
5-fluorouracil and cyclophosphamide [Brennan 2005].  
 
1.1.10.4 Hormonal/Biological Therapy   
 
Hormonal or biological therapy is administered, for example, when the patient’s 
breast tumor is positive for ER/PR. The basis of this therapy is to introduce an agent 
that will bind to ER, inhibiting the binding of estrogen ligand with ER, and hence 
decreasing estrogen levels to the cancer cells. Tamoxifen is a common hormonal 
therapeutic drug given to both pre- and post-menopausal females (Fabian, 2007). 
HER2 biomarker is another well-known example involved in hormonal/biological 
therapy. As HER2 is over-expressed in 20 to 25% of breast cancer cases, 
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trastuzumab, a humanized monoclonal antibody, has been developed to directly 
target HER2 (Slamon et al., 1987). The binding of the antibody to the receptor will 
inhibit tumor cell proliferation in breast cancer cells over-expressing HER2. 
Another approach in hormonal therapy is to inhibit the formation of estrogen by 
introducing aromatase inhibitors; the inhibitors will inhibit cytochrome P450 
activity, of which will subsequently prevent androgens from converting to 
estrogens (Chumsri et al., 2011). This approach however can only be used in post-
menopausal females, as pre-menopausal females still have functional ovaries which 
are still able to generate estrogen (Milla-Santos et al., 2003, Mouridsen et al., 2003).  
 
1.1.11 Current Challenges in Breast Cancer 
 
Conventionally, physicians use well-established breast cancer clinical parameters 
such as tumor size, tumor grade, lymph node stage, and well-studied biomarkers – 
hormonal markers (ER, PR, and HER2) (Hatsell et al., 2005), hereditary molecules 
(BRCA1 and BRCA2) (Parsons, 2005) – to diagnose, determine suitable treatment 
options for patients and estimate the survival outcome of the patients. In the current 
medical world, although these characteristics are useful, basing diagnosis, therapy, 
and prognosis solely on them alone is not enough. Breast cancer is a heterogeneous 
disease with, at times, unpredictable survival outcome. There are still groups of 
breast cancer patients that do nor respond well to current available treatments or 
encounter tumor recurrence at a shorter period of time. It is therefore critical to 
achieve more reliable characterization of the tumor to enable more accurate 
diagnosis of the breast cancer subtype and hence improved treatment options and 
prediction of treatment response and survival outcome. Breast tumors cannot be 
oversimplified of its classification by just separating tumor cases by carcinoma in 
situ and invasive carcinoma, or ER+ and ER- tumor types. More specific 
biomarkers for screening in conjunction with current clinicopathological 
parameters are hence needed to identify the patient’s breast tumor subtype more 
accurately (Masood and Dabbs, 2012).  
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1.2 Glycosaminoglycans and Proteoglycans 
 
The ongoing need to discover additional distinctiveness of breast cancer is critical 
to further understand breast cancer and to help patients cope with the cancer more 
effectively through a more personalized treatment option, thus improving their 
quality of life. Biomarkers has been gaining potentiality to help in diagnosis, 
prognosis, and treatment of the patients. Knowing the expression of the marker can 
aid in determining the stage of the cancer, estimate the survival rate and tumor 
progression of the patient, and provide targeted therapy options to effectively 
reduce the tumor size and increase the patient’s survival rate. Glycosaminoglycan 
molecules have recently been of great interest to researchers studying their 
associations to breast cancer. Initial findings have related changes in 
glycosaminoglycan expression levels to breast tumorigenesis. 
 
1.2.1 Structure of Glycosaminoglycans and Proteoglycans 
 
Glycosaminoglycans (GAG) are heteropolysaccharides, composed of alternating 
uronic acid units and hexoamine amino sugars, found in various tissues (Yip et al., 
2006, Feldner et al., 2006). There are four major classes of GAGs constituting of 
chondroitin/dermatan sulfate, heparan sulfate, keratan sulfate, and hyaluronan (Yip 
et al., 2006). GAGs, except hyaluronan, are expressed in tissues as proteoglycans, 
of which are covalently bounded sulfated GAGs on core proteins (Yip et al., 2006, 
Berto et al., 2003). The GAG chains would be attached to a serine residue on the 
core protein via a tetrasaccharide linkage region as shown in Figure 1.4 (Yip et al., 
2006).  
 
Proteoglycans (PG) are principal structures found on cell surfaces and in the 
extracellular matrix (Berto et al., 2003). PGs play vital roles in the regulation of 
multiple signaling pathways and in the interactions between cells and their 
environment (Wade et al., 2013). They have major roles in cell proliferation, 
migration, adhesion, and angiogenesis (Raman et al., 2005, Cecchi et al., 2012).  
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GAGs and PGs have garnered much interest as their expression can potentially 
indicate diagnostic and prognostic values in cancer, and pave the way for novel 
targeted therapeutics (Yip et al., 2006). For example, studies have indicated that 
alterations in CS/CSPG expression and structure are seen in a wide variety of 
cancers such as breast cancer, prostate cancer, gastric cancer, pancreatic cancer, 
and melanoma (Suwiwat et al., 2004, Yang et al., 2004, Pirinen et al., 2005, Pukkila 
et al., 2007). In this study, chondroitin sulfate is my GAG of interest; hence, its 
characteristics will be elaborated.  
 
1.2.2 Chondroitin Sulfate and Chondroitin Sulfate Proteoglycans 
 
Chondroitin sulfate (CS) is located mainly on the cell surface and in the 
extracellular matrix (ECM) (Huang, 1974). CS consists of repeating disaccharide 
units of alternating N-acetyl-galactosamine (GalNAc) and glucuronic acid (GlcA) 
(Sugahara et al., 2003, Silbert and Sugumaran, 2002). There are various forms of 
CS molecules, including CS-A, CS-C, CS-D, and CS-E (CS-B is reclassified as 
dermatan sulfate (DS)).  Each of these CS molecules is distinctive of one another 
by its sulfation patterns (Sugahara et al., 2003, Kusche-Gullberg and Kjellen, 2003). 
The various CS molecule forms of different sulfation configurations are formed 
through sulfation modification. Figure 1.3 illustrates the differences in sulfation 
patterns between the various CS molecules. CS-A and CS-E are sulfated at carbon 
4 of the GalNAc unit, whereas CS-C and CS-D have a sulfated site at carbon 6 of 
the GalNAc unit (Grande-Allen et al., 2007). Additionally, CS-D and CS-E have 
an extra sulfation site in their disaccharide units; the additional sulfate site for CS-
D is located at the carbon 2 of GlcA while CS-E is also sulfated at carbon 6 of 
GalNAc (Sugahara et al., 2003, Kusche-Gullberg and Kjellen, 2003). Hence, at 
times, CS-A, CS-C, CS-D, and CS-E are sometimes known as C4S, C6S, C-2,6-S, 
and C-4,6-S respectively. The distinctive sulfation patterns would not only give rise 
to structural diversity of the CS molecules, but also cause a variety of ligand-
binding capacities, diverse signaling effects, and hence varied modulations of 
cellular behaviors (Kusche-Gullberg and Kjellen, 2003).  
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The CS molecules are usually attached to a core protein, therefore forming CS 
proteoglycan (CSPG) (Souza-Fernandes et al., 2006). The attachment is possible 
via a protein scaffold (as depicted in Figure 1.4) (Parcell, 2002, Bali et al., 2001).  
The CSPG family also has a variety of family members, ranging from CSPG1 to 
CSPG8, some of which have been implicated to have major functional roles in 
breast cancer.  
 
Figure 1.3: Various forms of CS molecules.  
 
Figure 1.4: Structure of CPSG. The CS molecules are attached to the core protein via a 
short tetrasaccharide glycan chain, consisting of one xylose, two galactose units, and one 
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GlcA, at the serine residue of the core protein. After which, polymerization of the CS 
disaccharide units (GalNAc and GlcA) would follow on. The CS molecules then undergo 
modification through sulfation to form variable CS forms (Sugahara et al., 2003, Silbert 
and Sugumaran, 2002).   
 
 
1.2.3 Biosynthesis of Chondroitin Sulfate and Chondroitin Sulfate 
Proteoglycan 
 
CS and CSPG expression is regulated by a wide range of enzymes in a complex 
biosynthesis pathway, leading to their variability in structure and function. Briefly, 
the tetrasaccharide glycan linkage is firstly synthesized by Xylotransferase 1 
(XYL1) and Xylotransferase 2 (XYL2) through the addition of xylose to the serine 
residue of the core protein (Gotting et al., 2000). The addition of two galactose units 
to xylose is next catalyzed by two galactosyltransferases, coded by B3GALT6 and 
B4GALT7 (Bai et al., 2001). The last unit of the glycan linkage, glucuronic acid, 
is added by glucuronyltransferase I, which is coded by B3GAT3 (Potapenko et al., 
2010, Kitagawa et al., 1998). 
 
The synthesis of the CS chain is next initiated by chondroitin sulfate N-
acetylgalactosaminyltransferase 1 (CSGALNACT-1), which adds a galactosamine 
to the linkage region (Sato et al., 2003, Uyama et al., 2002). Subsequent chain 
polymerization of CS (i.e. the elongation of CS chain through addition of the 
disaccharide units of glucuronic acid and galactosamine) is catalyzed by 
chondroitin sulfate N-acetylgalactosaminyltransferase 2 (CSGALNACT-2), 
chondroitin sulfate glucuronyltransferase (CSGLCAT), chondroitin synthase 1 
(CHSY1), chondroitin synthase 3 (CHSY3), and chondroitin polymerizing factor 
(CHPF) (Potapenko et al., 2010). 
 
Sulfation modifications subsequently take place to generate the various types of CS 
chains. The modifications are catalyzed by chondroitin sulfotransferases (CHSTs) 
(Potapenko et al., 2010). Some examples of CHSTs include CHST3 and CHST7 as 
well as CHST11 and CHST13, which aid in the transfer of the sulfate group from 
3’-phosphoadenosine-5’-phosphosulfate (PAPS) to the galactosamine unit 
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specifically at carbon 6 and carbon 4 respectively (Hiraoka et al., 2000, Kitagawa 
et al., 2000, Cooney et al., 2011). 
 
1.2.4 Functions of Chondroitin Sulfate and Chondroitin Sulfate 
Proteoglycans  
 
GAGs were once thought to only serve as space-filling function required for the 
orientation and organization of the exogenous matrix (Meyer and Palmer, 1934). 
CSPGs via their CS chains would interact with the extracellular matrix substances 
such as fibronectin, collagen, and laminin, generating stabilization in structure 
(Bernfield et al., 1999) (Jalkanen., 1992). Advances in glycobiology have shown 
otherwise.   
 
CS is a major component of cartilages, making it vital in maintaining elasticity and 
integrity of the cartilage matrix in the joints. In the form of CSPG, CS within the 
interfibrillar collagen matrix have great affinity for water and capable of generating 
compressive resilience, giving rise to cartilages with shock-absorbing properties 
(Chan et al., 2005). Also, CS is important in inhibiting proteases and cytokines 
responsible for cartilage destruction, of which would cause arthritis (Lesjak and 
Ghosh, 1984). In the clinical setting, the chondroprotective properties of CS make 
it possible for clinicians to use them as alternative agents in the treatment of 
osteoarthritis.  Apart from the cartilage, CS is also found naturally in other parts of 
the human body such as bones and skin (Parcell, 2002).  
 
Additionally, CS/CSPGs have been discovered to be vital regulators of various 
cellular signaling processes affecting cell proliferation, migration, and adhesion 
(Yin, 2005). Deregulation of the CS/CSPGs cause significant functional 
repercussions, including skeletal disorders, viral and bacterial infections, and 




1.2.5 Chondroitin Sulfate and Chondroitin Sulfate Proteoglycans in Cancer 
 
Studies conducted have shown significant associations of CS expression with 
regard to breast cancer. The alterations in cell surface CS expression and 
consequently, ECM-degradative enzymes, such as matrix metalloproteinases, can 
change the cell’s invasiveness and cell-matrix interactions (Yip et al., 2006). From 
in vitro studies, breast cancer cells have been observed to have a general increase 
in CS expression, of which has been correlated to enhanced cell proliferation and 
migration (Kieber-Emmons et al., 2011, Alini and Losa, 1991, Olsen et al., 1988). 
At the tissue level, CS in general are significantly highly elevated in the stromal 
compartment of breast tumors (Ricciardelli et al., 2002, Suwiwat et al., 2004). 
Supporting this, MDA-MB-231 breast cancer cells releases high amounts of CSPGs 
into the culture medium, suggesting the enhanced level of CS in the stromal 
compartment. Additionally, in general, high CS level in breast cancer cells is linked 
to shorter overall survival and recurrence-free survival (Svensson et al., 2011). CS 
expression has been shown to be an independent predictive prognostic factor, with 
high CS expression levels having a hazard ratio of 1.71 to 2.28 in the cohort of 
breast cancer patients studied (Svensson et al., 2011). A mouse model study 
demonstrated that removal of cell surface CS from mouse breast cancer cells led to 
decreased tumor progression after intravenous injection (Cooney et al., 2011). This 
highly suggests that cell surface CS may have pivotal role in promoting metastasis 
and hence, may potentially lead to higher mortality risk. Looking into specific CS 
molecule type, CS-A chain has been shown to have increased expression level in 
human breast cancer cells with high metastatic capability (MDA-MB-231 and 
MDA-MET) compared to less aggressive breast cancer cells, MCF7 (Cooney et al., 
2011). CS-E has also been marked as a tumor promoter (Cooney et al., 2011); 
functional studies  in vitro showed that the over-expression of CS-E promotes 
angiogenesis and anti-apoptotic cell behavior (Grose and Dickson, 2005). On the 
other hand, the opposite trend has been observed for CS-C and CS-D chains; both 
of these CS molecules are reported to be down-regualted in breast carcinomas 
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(Potapenko et al., 2010), making them characterized as tumor suppressors instead, 
unlike their other two CS counterparts.  
 
At the core protein level, studies have also described breast tumor biopsies to have 
general increases in CSPG expression, particularly CSPG2 and CSPG4, compared 
against the adjacent normal breast tissues of patients (Vijayagopal et al., 1998). 
This would hence suggest the possibility of an association between CSPG levels 
and their role in tumor progression and metastases (Vijayagopal et al., 1998, 
Delehedde et al., 1997). Two CSPG members have been well-studied in breast 
cancer, which are versican (CSPG2) and NG2 (CSPG4).  
 
Versican (VCAN or CSPG2) is a large CSPG, which regulates cell adhesion, cell 
motility, and cell proliferation (Yee et al., 2007, Beck et al., 2008, Bhardwaj et al., 
2008). Its role in the regulation of different cellular behaviors is possible through 
its interactions, via the CS chains (Hirose et al., 2001, Wu et al., 2005, Suwan et al., 
2009) with a wide variety of ligands including collagen, fibronectin, chemokines, 
and epidermal growth factor receptor (EGFR) (Hirose et al., 2001, Zimmermann, 
2000). VCAN is up-regulated in malignant breast tissues and is associated with the 
severity of the cancer (Yee et al., 2007, Brown et al., 1999). Cox regression survival 
analysis indicated that VCAN expression is a good predictor of relapse-free 
survival; enhanced expression of VCAN is correlated with higher risk and rate of 
relapse in patients diagnosed with node-negative breast cancer (Ricciardelli et al., 
2002, Suwiwat et al., 2004).  
 
NG2 (or CSPG4) is a cell surface proteoglycan, with enhanced expression levels in 
malignant breast tissues compared against normal breast tissues. From an in vitro 
study, CSPG4 is up-regulated in triple negative breast cancer cells (MDA-MB-231, 
MDA-MB-435, HS578T, and SUM149) in comparison to luminal breast cancer 
cells (MCF7, T47D, and SK-BR-3), which are less aggressive. Further evaluation 
on primary breast lesions showed that majority (>70%) of triple negative breast 
cancer tissues displayed higher expression levels of CSPG4 against ER+/HER2+ 
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breast cancer tissues (of which 30% has immunoreactivity to CSPG4 antibody). 
Moreover, CSPG4 protein was enhanced in breast cancer cells extracted from 
pleural effusion of patients diagnosed with metastatic breast cancer (Wang et al., 
2010b, Wang et al., 2010a). With CSPG4 emerging as a potential diagnostic and 
prognostic marker, scientists have looked into the development of a CSPG4 
antibody-based immunotherapy. In vitro evaluation showed that CSPG4-specific 
antibody regressed cancer cell growth and cell migration. More importantly, in in 
vivo, CSPG-4 specific antibody inhibited tumor growth and metastasis (Wang et al., 
2010a). As such, CSPG4 is one promising target for monoclonal antibody-based 
treatment especially for patients with high CSPG4 expression in their tumor.  
 
1.2.6 Chondroitin Sulfotransferase 3 in Cancer 
 
Chondroitin sulfotransferase 3 (CHST3 or sometimes known as chondroitin-6-
sulfotransferase 1 (C6ST1)) gene is located at chromosome 10, with an mRNA and 
protein size of 1440 base pairs and 55 kDa. CHST3 is one of the many enzymes 
involved in the sulfation modification of CS molecules, specifically forming CS-C 
(C6S) and CS-D (C-2,6-S). Its principal role is in catalyzing the transfer of sulfate 
from 3’-phosphoadenosine-5’-phosphosulfate (PAPS) to the carbon 6 of 
galactosamine unit (Silbert and Sugumaran, 2002). CHST3 has been reported to be 
involved in extracellular matrix remodeling (Deeken et al., 2010), hence it is 
suggested that CHST3 has roles in cell adhesion as well as cell invasion and 
metastasis. 
 
The role of CHST3 has not been widely studied in cancer. In laryngeal carcinoma, 
CHST3 expression level was reduced in malignant tissues compared to normal 
tissues. Also, lower level of C-6 sulfation was observed to be correlated with higher 
tumor stage, suggesting CHST3 to have a potential tumor suppressor role in 
laryngeal cancer (Kalathas et al., 2010). In prostate cancer, single nucleotide 
polymorphisms in CHST3 were seen to be associated with toxicity of 
chemotherapeutic drugs, thalidomide or docetaxel, used on prostate cancer patients. 
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In pancreatic cancer, CHST3 expression is postulated to be involved in TGFβ-
induced epithelial-mesenchymal transition (EMT) model, indicating CHST3 
potential role in metastasis (Maupin et al., 2010). To date, there is a lack of 
understanding of CHST3 in breast cancer. 
 
1.3 Scope of Study 
 
Therefore, in this study, CHST3 expression and functional roles are investigated in 
breast cancer. The outcomes from this study may provide a novel pathway map for 
the downstream gene(s) involved in cell migration, invasion, adhesion, and 
proliferation of the breast cancer cells after alteration of CHST3 expression. 
Additionally, immunohistochemical expression of CHST3 was examined on 
clinical tissue samples of IDC. This would allow a possible novel diagnostic and 
prognostic biomarker for breast cancer and potentially other cancers. Specific 
objectives of this study are as follows: 
 
 To examine the expression of CHST3 in various normal and malignant 
breast cells 
 To study the functional role of CHST3 in breast cancer cells through 
silencing and over-expression of CHST3 
 To explore the downstream molecular pathways involving CHST3 that 
regulate the phenotypic behavior changes 
 To determine the correlations between CHST3 expression and various 
clinicopathological parameters of patients with IDC 
 To evaluate if CHST3 expression could be a potential diagnostic or 


















CHAPTER 2  




2 MATERIALS AND METHODS 
2.1 Cell Culture of Breast Cancer Cells  
 
Non-malignant MCF12A as well as malignant T47D, MCF7 and MDA-MB-231 
breast epithelial cell lines were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) for this study. MCF12A is an 
immortalized, non-malignant cell lines, established after a long-term cultivation of 
MCF12M mortal cells, that were harvested at reduction mammoplasty from 
fibrocystic breast tissue with focal areas of intraductal hyperplasia (Paine et al., 
1992). The MCF12A cells were maintained in DMEM-F12 medium supplemented 
with 5% fetal bovine serum (FBS), 20ng/ml human epidermal growth factor, 
100ng/ml cholera toxin, 0.01 mg/ml bovine insulin, and 500ng/ml hydrocortisone. 
T47D, a Grade 1 IDC cell line, was obtained from the pleural effusion of a 54-year-
old female diagnosed with IDC (Keydar et al., 1979). MCF7, another Grade 1 IDC 
cell line, was derived from the pleural effusion of a 69-year-old female who had 
metastasis even after having two mastectomies in a span of 5 years (Dickson et al., 
1986).  Compared to T47D and MCF7 cell lines that are poorly invasive, MDA-
MB-231 cell line is a highly invasive human breast adenocarcinoma cell line and is 
representative of Grade 3 IDC.  MDA-MB-231 cells were harvested from a pleural 
effusion of a 51-year old female (Cailleau et al., 1978). T47D and MDA-MB-231 
cells were cultured in RPMI medium while MCF7 cells were given DMEM 
medium. Both medium were supplemented with 10% FBS. All cell lines were 
grown at 37oC in a 5% CO2 atmosphere.  
 
2.1.1 Subculture of Cells  
 
Subculture was performed when cells reach 80 to 90% confluency. Firstly, the 
culture medium from the flask was aspirated out. This is followed by washing with 
PBS, to remove residual culture supernatant. The cells were then incubated with 
trypsin/EDTA for 5 to 10 min at 37oC, for cell detachment. Following incubation, 
the trypsin activity was neutralized using culture medium. The cell suspension was 
transferred into a 15ml tube for centrifugation at 1000rpm for 5 minutes. Fresh 
 48 
culture medium was used to re-suspend the cell pellet and an appropriate volume 
of cell suspension was transferred into a T25 or T75 flask. Cells above passage 
number of 30 were discarded.  
 
2.1.2 Cryopreservation of Cells 
 
Cell detachment through trypsinization from culture flasks was firstly carried out. 
After the centrifugation step and removal of the culture medium, the cell pellet was 
re-suspended with culture medium containing 20% FBS and 10% dimethyl 
sulphoxide (DMSO). The cell suspension was transferred into cryovials, which 
were then placed in a freezing container, Mr Frosty (Nalgene, Rochester, NY, USA). 
The freezing container will enable uniform cooling of the cryovials at a rate of 1oC 
per minute in a -80oC freezer. After an overnight storage in the -80oC freezer, the 
cryovials were placed in a liquid nitrogen storage tank for long term storage.  
 
2.1.3 Thawing of Cells 
 
Frozen vials of cells, taken out from liquid nitrogen storage tank, were thawed 
immediately. The thawed cell suspension was transferred into a 15 ml tube and re-
suspended with 5ml of culture medium. The cell suspension was next centrifuged 
at 1000rpm for 5 minutes to remove the cytotoxic, cryoprotective DMSO 
component. After disposing the culture medium supernatant, the cell pellet was re-
suspended with 5ml culture medium and transferred into a 25cm2 culture flask (T25 
flask). The cell culture was incubated at 37oC in a 5% CO2 environment.  
 
2.2 siRNA Transfection  
 
Silencing experiments were carried out using T47D and MDA-MB-231 cell lines. 
One day prior to siRNA transfection, T47D and MDA-MB-231 cells were seeded 
in 6-well plates at cell densities of 3.0 x 105 cells/well and 2.0 x 105 cells/well 
respectively. The cells were transfected with siRNA targeting the gene of interest 
(Ambion, CA, USA) or scrambled siRNA (Ambion, CA, USA) as negative control 
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using Oligofectamine transfection reagent (Invitrogen, Carlsbad, USA) following 
the manufacturer’s protocol. Cells were exposed to the siRNAs in OPTIMEM for 
8 hours, after which the medium was replaced with RPMI containing 10% FBS. 
The transfected cells were then incubated for 48 hours before subsequent assays. 
Table 2.1 and Table 2.2 show the sequences of the siRNAs specifically targeting 
the genes of interest used as well as the final siRNA concentrations used 
respectively. 
 
Table 2.1: siRNA sequences  







Forward 5'–GAC UGG AUC CAA AAG AAC ATT–3' 
Reverse 5’–UGU UCU UUU GGA UCC AGU CTT–3' 
siRNA 
sequence 2 
Forward 5'–CAU GUA CAC CAU ACA UAG ATT–3' 






Forward 5'–GGA AUA CAA CCC AAU AGA ATT–3' 






Forward 5'–CAA CCA CCC UCA AUC GAG ATT–3' 










Table 2.2: Volume and concentration of reagents used for siRNA transfection 
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 Reagent Volume per well (µl) 
CHST3 
(Final concentration 10nM) 




(Final concentration 5nM) 




(Final concentration 5nM) 








2.3 CHST3 Over-expression  
 
2.3.1 CHST3 Over-expression Plasmid Preparation 
 
CHST3 over-expression plasmid (OriGene, Rockville, MD, USA) and the 
corresponding pCMV6-AC-GFP empty vector (OriGene, Rockville, MD, USA) 
used as negative control were purchased. The maps of the plasmids are shown in 
Figure 2.1. 1ul of the plasmids (100ng/ul) were used for bacteria transformation 
into 50ul of DH5α competent Escherichia coli cells. The transformed DH5α 
bacteria were spread on to LB plates containing 100g/ml ampicillin. The LB plates 
were then incubated overnight at 37oC. Subsequently, colony PCR was carried out 
using CHST3 qPCR primer for the colonies containing CHST3 over-expression 
plasmid. As for colonies transformed with the empty vector, VP1.5 and XL39 
primers provided by OriGene were used for the colony PCR procedure. Upon 
confirmation of the plasmid transformation by colony PCR, the same colonies were 
picked and expanded in 5ml of LB medium containing 100ug/ml ampicillin. The 
LB/Amp culture was incubated on a shaker (200rpm) overnight at 37oC. The 
following day, bacterial stocks were preserved in glycerol and stored at -80oC. The 
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remaining bacterial culture was used for plasmid extraction using QIAprep Spin 
Miniprep kit (Qiagen, Hilden, Germany). After which, the concentrations of both 
plasmids were determined using nanodrop spectrophotometry (Thermo Scientific, 




Figure 2.1: Plasmid maps for CHST3 over-expression study.  
(A) shows the plasmid map of the CHST3-over-expression plasmid, of which CHST3 gene 
is within the empty vector plasmid, pCMV-AC-GFP depicted in (B).  
 
2.3.2 CHST3 Over-expression Plasmid Transfection 
 
Plasmid transfection into two breast cancer cell lines, MCF7 and MDA-MB-231, 
were carried out using Lipofectamine 2000. Cells were first seeded onto a 6-well 
plate at cell density of 2 x 105 cells per well. Upon 80 to 90% cell confluency at the 
time of transfection, 1ug of the plasmid topped up with OPTIMEM to 100ul and 
3ul of Lipofectamine 2000 in 97ul OPTIMEM were incubated separately at room 
temperature for 5min. The two mixtures were then combined and incubated for 
20min at room temperature to allow formation of plasmid-Lipofectamine 
complexes. A total of 200ul plasmid-Lipofectamine complexes were added drop-
by-drop into 800ul OPTIMEM in each well of the 6-well plate. The transfected 
culture was then incubated at 37oC, 5% CO2 for 5 hours before the medium was 
changed to medium consisting of 10% FBS and 450ug/ml geneticin. The following 
(A) (B) 
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day, the cells were re-seeded into a 24-well plate. The medium was changed every 
2-3 days for two weeks to allow selection of cells with the over-expression plasmid 
or empty vector. After two weeks of selection, a single colony of cells was picked 
from each well and grown in a 96-well plate. Fresh medium supplemented with 
10% FBS and 450ug/ml geneticin was replaced in the well every 2-3 days. Upon 
80-90% cell confluency, the cells were subcultured into a 24-well plate and 
subsequently, 6-well plate. The over-expression efficiencies were then measured 
through qPCR. The cells were subcultured for further experiment use and for 
generation of frozen stock.   
 
2.4 RNA Extraction  
 
Total RNA was isolated from breast cancer cells using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Cells grown 
in 6-well plates were washed with PBS before adding RNA lysis buffer, consisting 
a 1:100 ratio of 1% β-mercaptoethanol:Buffer RLT, at a volume of 350ul per well. 
After one minute incubation at room temperature, a disposable cell scraper was 
used to detach the cells from the 6-well plate. The cell contents were transferred 
into microcentrifuge tubes. Homogenization was performed using needles and 
syringes. The homogenized cell lysate was then mixed with 1 volume (350ul) of 
70% ethanol. The mixture was next transferred into RNeasy MiniElute spin column. 
Centrifugation was carried out at 13,000rpm for 30 seconds. After the flow through 
was discarded, 350ul of Buffer RW1 was used to wash the membrane in the spin 
column. Centrifugation was carried out at 13,000rpm for 30 seconds. The RNA was 
subsequently treated with 10ul DNase I diluted in 70ul Buffer RDD for 15 minutes 
at room temperature, to remove any traces of DNA contamination. Prior to 
centrifugation, 350ul Buffer RW1 was added to wash the spin column membrane. 
Further washing of the column was performed using 500ul of Buffer RPE. 
Centrifugation was repeated twice to ensure no carryover of the Buffer residuals. 
For the elution step, the total RNA was eluted out in 32ul RNase-free water through 
centrifugation. The RNA concentration and purity was determined using nanodrop 
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ND-100 spectrophotometer (Thermo Scientific, Asheville, NC, USA). 2ul of the 
eluted total RNA was loaded onto the pedestal containing fibre optic cable, that is 
able to generate a spectral measurement. The RNA integrity and purity can be 
obtained from the absorbance value at A260/280 ratio. An A260/280 ratio between 
1.8 and 2.0 indicates relatively pure RNA. The total RNA was stored at -80oC for 
future use.  
 
2.5 cDNA Synthesis  
 
The synthesis of first strand cDNA was achieved through reverse transcription of 
1000ng RNA diluted in RNase-free water. The mastermix reaction consists of 50ng 
random primers, 10nM dNTP mix, 5x First Strand buffer, 0.1M DTT, 40U 
RNaseOUTTM and 1U SuperScriptTM III Reverse Transcriptase, bringing the final 
reaction volume to 20ul. SuperScriptTM III First Strand Synthesis System 
(Invitrogen, Carlsbad, CA, USA) was performed according to the manufacturer’s 
protocol and used according to the reaction conditions in Table 2.3.  
 
Table 2.3: cDNA synthesis reaction conditions 
Temperature Time 
65°C 5 min 
0°C 3 min 
25°C 10 min 
50°C 60 min 
70°C 15 min 
 
2.6 Primers  
 
PCR grade oligonucleotides specific to genes of interest were purchased from 1st 
Base (Singapore). The primers were designed using Primer 3 v.0.4.0 to span across 
introns for detection of genomic contamination. They also have optimal amplicon 
size between 100 to 200 base pairs, target all transcript variants at their coding 
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regions, and have optimal BLAST values. Table 2.4 shows the primer sequences 
used to amplify and evaluate the gene expression of interest.  
 







Forward 5’ – ACGCCCTTTTCTTGGTTTTT – 3’ 
107 
Reverse 5’ – AGAGCTTGGGGAATCTGCTT – 3’ 
GAPDH 
Forward 5' – GAAGGTGAAGGTCGGAGTCAACG – 3’ 
158 
Reverse 5' – TGCCATGGGTGGAATCATATTGG – 3’ 
GPNMB 
Forward 5’ – TGTGAACACAGCCAATGTGA – 3’ 
196 
Reverse 5’ – GGGGAGATCTTTGAGGAAGG – 3’  
FLRT3 
Forward 5’ – GCTCATCTGCTCCTGCTTCT – 3’ 
127 
Reverse 5’ – AGGGGACTTGAGGATGACCT – 3’ 
 
2.7 Quantitative Real-Time Polymerase Chain Reaction  
 
Quantitative real-time PCR was performed using SYBR Green Master Mix (Qiagen, 
Hilden, Germany). The final reaction of 10ul consists of SYBR Green, 10ng of 
cDNA template, and 0.5µM of specific primers. Amplification was performed on 
the LightCycler 1.5 (Roche Diagnostics, Indianapolis, USA) following the protocol 
in Table 2.5. Normalization was calculated using GAPDH values and the relative 
expression levels were calculated through the 2-ΔΔCT formula (Livak and 
Schmittgen, 2001) as shown below.  
 
ΔCTTarget gene = CTTarget gene in treatment group – CTTarget gene in control group 
ΔCTHousekeeping gene = CTHousekeeping gene in treatment group – CTHousekeeping gene in control group 
ΔΔCT = ΔCTTarget gene –Δ CTHousekeeping gene 






Table 2.5: RT-PCR conditions 
 Temperature Time Cycles 
Initial denaturation 95°C 15 min - 
Denaturation 94°C 15sec 
45 Annealing 60°C 25sec 
Extension 72°C 15sec 
Hold 4°C Forever 
 
2.8 Protein Electrophoresis  
 
2.8.1 Protein Extraction  
 
Cells were washed in ice-cold PBS before adding a mix of Mammalian Protein 
Extraction Reagent (Thermos Scientific, Asheville, NC, USA), HALTTM Protease 
Inhibitor (Pierce, Illinois, USA), and EDTA (Pierce, Illinois, USA). After a minute 
incubation on ice, a disposable cell scraper was used to detach the cells. The cell 
lysates was collected into microcentrifuge tubes. Subsequently, centrifugation was 
performed at 13,000rpm for 10 minutes at 4oC to pellet the cell debris. Collected 
supernatants containing cell proteins were stored in -80oC for future use.  
 
2.8.2 Protein Quantitation 
 
Protein concentration was determined using the bicinchoninic acid (BCA) protein 
assay kit (Pierce, Illinois, USA), which also adopts colorimetric method. The basis 
behind this kit is the reduction occurrence of Cu2+ to Cu+ by protein available. 
Hence, the protein concentration would be proportional the amount of reduction 
(generation of purple coloration). Extracted protein samples were diluted and added 
to BCATM Reagent A and B (Pierce, Illinois, USA), which were mixed at a ratio of 
50:1 respectively. Millipore water was used as a blank. The mixture in a 96-well 
plate was incubated in the dark on an orbital shaker (180rpm, 30 min, 37oC). The 
absorbance values for the protein samples were obtained using a microplate reader 
(Tecan, Switzerland). Protein standard (bovine serum albumin) of different 
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dilutions were also measured of their concentrations to obtain a protein standard 
curve, which would be used to determine the protein concentrations of each sample. 
 
2.8.3 Preparation of SDS-Polyacrylamide Gel  
 
The Western blot gel was firstly cast using gel casting frames, glass plates, and 
spacers. A 10% resolving gel, that makes up the bottom three quarter of the entire 
gel, was prepared through the mixture of deionized water, 30% acrylamide mix, 
1.5M Tris at pH8.8, 10% sodium dodecyl sulfate (SDS), 10% ammonium persulfate 
(APS), and N,N,N',N'-tetramethylethylenediamine (TEMED). Isopropanol was 
used to even out the surface of the resolving gel. The gel was then left to polymerize 
for approximately 30 minutes.  
 
Following that, the gel casting stand was inverted to drain out the isopropanol. A 
5% stacking gel, which makes up the top one quarter of the entire gel, was next 
prepared using a mixture of deionized water, 30% acrylamide mix, 1.0M Tris at 
pH6.8, 10% SDS, 10% APS, and TEMED. After overlaying the stacking gel 
mixture on the resolving gel, a well comb was gently inserted into the stacking gel. 
The gel was then left to polymerize for another 30 minutes.  
 
2.8.4 Electrophoresis of SDS-Polyacrylamide Gel  
 
Protein samples at 30µg each were used; the samples were diluted in 5x SDS gel-
loading buffer, consisting of 250mM Tris-Cl (pH 6.8), 10 % SDS, 30% glycerol, 
5% dithiothretol (DTT) and 0.02% bromophenol blue. The diluted samples were 
heated at 95oC for 3 minutes. After polymerization of the SDS-polyacrylamide gel, 
the well comb was removed. Subsequently, the electrophoresis module was 
assembled. Tris-glycine buffer was used in the electrophoresis run. The protein 
samples as well as the protein ladder (Precision Plus Protein dual color marker 
(Biorad, Hercules, CA, USA)) were loaded into the wells. The gel electrophoresis 
was then allowed to run at 100V for protein separation.  
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2.8.5 Semi-Dry Electro-Transfer  
 
The separated proteins on the gel were next electro-transferred onto a polyvinyl 
difluoride (PVDF) membrane. The membrane was firstly activated through soaking 
in methanol for 10 seconds. It was next soaked in deionized water for one minute 
before soaking in transfer buffer. Additionally, two thick filter pads were pre-
soaked in the transfer buffer. After the completion of the gel electrophoresis run, 
the gel was removed from the electrophoresis module. A gel-sandwich was 
assembled using the sequence of the first filter pad at the bottom, followed by the 
PVDF membrane, gel and lastly, the second filter pad. Trapped air bubbles were 
released by rolling over the filter pad surface. The electro-transfer was carried out 
using the TransBlot Semi-Dry Transfer Cell (Biorad, Hercules, CA, USA) at 15V 
for 45 minutes.  
 
2.8.6 Western Blot  
 
Following electro-transfer, the membranes were blocked overnight at 4oC using 5% 
fat-free milk in Tris-buffered saline containing 0.05% Tween-20 (TBS-T). The next 
day, the membrane was incubated with the primary antibody of interest at 1:500 
dilution factor for 1 hour at room temperature. Primary antibodies used were anti-
CHST3 (Proteintech, Catalog No. 18242-1-AP), anti-GPNMB (R&D Systems, 
Catalog No. AF2550), anti-FLRT3 (Abcam, Catalog No. ab97267), anti-E-
cadherin (Santa Cruz, Catalog No. sc-8426), anti-β-catenin (Santa Cruz, Catalog 
No. sc-7963), anti-BAD (Cell Signaling, Catalog No. #9268), anti-phospho-BAD 
(Cell Signaling, Catalog No. #5284), anti-JAK2 (Cell Signaling, Catalog No. 
#3230), anti-phospho-JAK2 (Cell Signaling, Catalog No. #3771), anti-STAT3 
(Cell Signaling, Catalog No. #4904), anti-phospho-STAT3 (Cell Signaling, Catalog 
No. #9145), anti-β-actin (Sigma, Catalog No. A2228). After which, the membranes 
were incubated with their respective horseradish peroxidase conjugated secondary 
antibodies for 1 hour at room temperature: anti-mouse (GE Healthcare; 1:5000 
dilution) and anti-rabbit (Dako; 1:3000 dilution). The blots were developed using 
chemiluminescence substrate solution (Pierce) and visualized with an image 
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analyzer. The intensities of the protein bands were obtained through ImageJ 
software. Each protein sample was normalized against house-keeping protein β-
actin.  
 
2.9 Immunofluorescence of Breast Cancer Cells 
 
Cells were seeded onto cover slips placed in 6-well plates. After a 72-hour 
transfection period, the attached cells on the cover slips were fixed with ice-cold 
methanol or 4% paraformaldehyde for 15 minutes. The fixed cells were then 
blocked with 5% BSA in PBS. Subsequently, the primary antibody of interest was 
added and incubation was carried out for 2 hours at room temperature: anti-CHST3 
(1:100 dilution), anti-E-cadherin (1:100 dilution), and anti-β-catenin (1:100 
dilution). Specific secondary antibody incubation was next carried out for 1 hour at 
room temperature at 1:400 dilution. The cover slips with the stained cells were 
mounted onto glass slides using DAPI-containing mounting medium (DAKO). 
Fluorescence microscopy was used to view the fluorescent cells.  
 
Image J software (National Institutes of Health, USA) was used to quantify the 
immunofluorescence level. The fluorescence intensity of the targeted protein was 
quantified for each cell. Background intensity was subtracted off the initial intensity 
score. The intensity was averaged out against total number of cells quantified.  
 
2.10 Functional Analysis of CHST3 in Breast Cancer Cells 
 
2.10.1 Cell Migration and Invasion Assays 
 
Cell migration and invasion were assessed using 24-well transwell system (8um 
pore size) with Transwell migration chambers (BD Biosciences, CA, USA) and 
Matrigel chambers (BD Biosciences, CA, USA) respectively. The chambers were 
firstly hydrated with culture medium for 1 hour at 37oC. The culture medium was 
aspirated out prior to cell seeding. Cells were seeded into the chambers at a cell 
density of 5 x 104 cells/well for migration chambers and 1 x 105 cells/well for 
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Matrigel chambers, using 0.2ml of serum-free medium. A total of 0.6ml medium 
containing 20% FBS was added below the chamber to allow cell migration/invasion 
via chemotaxis. After a 24-hour incubation at 37oC in 5% CO2 atmosphere, cells on 
the transwells were fixed with methanol for 15 minutes and stained with 0.5% 
crystal violet for 30 minutes. Non-migrated cells inside the chamber were removed 
using a cotton swab. Cells that had migrated/invaded to the underside of the 
membrane were counted in five different fields under light microscope.  
 
2.10.2 Cell Proliferation Assay 
 
To evaluate cell proliferation, cultured cells was first serum-starved (using culture 
medium without FBS) for 24 hours to induce G1 cell cycle phase arrest in all cells. 
After which, the serum-free medium was replaced with culture medium 
supplemented with 10% FBS to allow the cell growth. Subsequently, after 48 hours, 
cell proliferation was evaluated using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay kit (Promega, Madison, WI, USA), which is a colorimetric 
method used to analyze the amount of viable cells in proliferation. The kit utilizes 
a tetrazolium compound or more commonly known as MTS. Mitochondrial 
dehydrogenase from viable cells will bioreduce the yellow-colored MTS compound 
into purple-caolored formazan. Hence, the amount of formazan formed would be 
proportional to the amount of living cells. Following the manufacturer’s protocol, 
cells were incubated with MTS solution and culture medium at a ratio of 1:5 for 3 
hours at 37oC before the absorbance level was measured at 490nm using a plate 
reader (Tecan, Switzerland).  
 
2.10.3 Cell Adhesion Assay 
 
Collagen and fibronectin were used to coat the wells of 96-well plates at final 
concentration of 20µg/ml. Cells were seeded into the coated plates at cell density 
of 5 x 104 cells/well and incubated for 30 min. After which, cells were washed twice 
with PBS to remove non-adherent cells. The amount of remaining cells was 
measured using CellTiter 96® AQueous One Solution Cell Proliferation Assay kit, 
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as mentioned in Section 2.10.2. Absorbance level was assessed at 490nm using a 
plate reader (Tecan, Switzerland).  
 
2.10.4 Cell Cycle Assay 
 
Cell cycle analysis (Cunningham, 1994) was carried out using a flow cytometer 
(Becton Dickinson, NJ, USA). Post 48-hour siRNA transfection, the culture 
medium was first collected into 15ml tubes (to collect the dead cells).  The culture 
cells were next detached from the well through trypsinization. The cells were 
transferred into the corresponding 15ml tubes. The collected dead and live cells 
were centrifuged at 1000rpm for 5min. After the supernatant was discarded, the 
cells were washed with PBS and centrifuged. This washing step was repeated to 
allow removal of the culture medium. After which, the pelleted cells were 
resuspended in 500ul of PBS. The cell suspension was added drop-by-drop into a 
new 15ml tube containing 4.5ml of ice cold ethanol. The cells were then left 
overnight at 4oC for fixation process.  
 
The following day, the tubes were centrifuged. The pelleted cells were then washed 
with PBS and centrifuged twice to remove the ethanol. The cells in each tube were 
subsequently resuspended in a 1ml cocktail containing propidium iodide (1mg/ml), 
PBS, Triton X-100 (0.1%), and RNase A. The propidium iodide-stained DNA of 
the fixed cells were measured using the Dako Cytomation Cyan LX (Dako, CA, 
USA) flow cytometer with laser excitation at 488nm wavelength. Analysis was 
performed comparing the DNA content of the silenced and control groups at 
different cell cycle phases.  
 
2.10.5 Cell Apoptosis Assay 
 
Caspase 3/7 assay kit (Promega, Madison, WI, USA) was used to evaluate cell 
apoptosis. Cells were seeded into a black 96-well plate at 8 x 103 cells/well and 
incubated for 48 hours at 37oC. The assay solution was then added to the cell culture 
and absorbance was measured using a plate reader (Tecan, Switzerland).  
 61 
2.10.6 Statistical Analyses 
 
Results were performed with at least triplicates from one experiment set or two 
independent experiment sets and data obtained were expressed as mean ± standard 
error mean (SEM). The student’s t-test (using GraphPad Prism 5.0) was used to 
perform statistical analysis on experiments with two different treatment groups. For 
experiments with more than two treatment groups, 1-way ANOVA was utilized. P-
values of less than 0.05 were deemed as statistically significant, with p-values < 
0.05, < 0.01, and < 0.001 represented as *, **, and *** respectively. All error bars 
shown on graphs represent SEM.  
 
2.11 Immunohistochemistry of Human Breast Tissues 
 
2.11.1 Tissue Specimens 
 
Tissue microarray (TMA) slides consisting of 255 IDC cases and 77 normal ductal 
tissue cases were obtained from the Department of Pathology, Singapore General 
Hospital. Clinicopathological parameters of the cases were acquired for statistical 
analyses, inclusive of patients’ age, tumor size, histological grade of the tumor, 
lymphovascular invasion, stage of lymph node metastasis, ER status, PR status, and 
HER2 status. The age of the patients ranged from 23 to 89 years old, with a mean 
of 56.1 years and a median of 55.5 years. As for patient follow-up, the follow-up 
period ranged from 0 to 175.5 months. Ethics approval for the project was obtained 





Briefly, the TMA slides were de-paraffinized in clearene and re-hydrated through 
a graded series of ethanol. Endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide for 30 minutes. The TMA slides were then blocked with goat 
serum (DAKO) for 1 hour prior to overnight incubation at 4oC with the primary 
antibodies (CHST3 antibody from Proteintech, FLRT3 antibody from Abcam) 
using 1:100 dilution factor. The following day, the secondary antibody (DAKO 
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Polymer Kit) was added and incubated for 1 hour at room temperature. The tissue 
sections on the TMA were visualized using diaminobenzidine as the substrate and 
counterstained with Shandon’s haematoxylin. The stained TMA sections were 
assessed by two independent blinded observers. 
 
2.11.3 Evaluation of Staining Intensities 
 
 
The staining intensities of the epithelial components in the IDC tissues were noted 
as: 0 (no staining), 1+ (weak), 2+ (moderate), and 3+ (strong). The percentage of 
cells that were stained was also recorded. The figures were converted into weighted 
average score (WAI) using the following equation, of which the total of different 
staining intensities multiplied with the percentage of each intensity are divided 
against percentage of positively stained area (Lo et al., 2011). WAI score was 
utilized in this study as it considers the staining intensities of the protein expression 




(% 𝑜𝑓 𝑛𝑜 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝑥 0) + (% 𝑜𝑓 𝑤𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑥 1)
+(% 𝑜𝑓 𝑚𝑜𝑑𝑒𝑟𝑎𝑡𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑥 2) + (% 𝑜𝑓 𝑠𝑡𝑟𝑜𝑛𝑔 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑥 3)
]
% 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑙𝑦 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑎𝑟𝑒𝑎
 
 
2.11.4 Selection of Cut-Off Score 
 
 
The cut-off score was determined based on the median intensity and receiver 
operating characteristic (ROC) curve analysis. Selecting the cut-off score from 
median or mean would allow a better selection of a representative score for the 
cohort of patients studied. As the staining intensity values follow a skewed 
distribution, the median intensity was selected as the cut-off score to represent the 
average expression level in the patients’ breast tissues.  
 
ROC curve analysis (staining intensity against tissue type – normal and malignant) 
was also performed to consider both sensitivity and specificity of the median 
intensity. Maximum sensitivity and specificity are signified from the score being 
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closer to the curve following the left hand border and then the top border of the 
ROC curve space. The area under the ROC curve will depict the discriminatory 
power of the biomarker with values of 0.5 indicating lower power and value nearer 
to 1.0 indicating higher power (Greiner et al., 2000, Zweig and Campbell, 1993).  
 
2.11.5 IHC Statistical Analysis 
 
 
Statistical analyses were carried out using SPSS Statistics 17 software (SPSS). 
Associations between the immunostaining in the IDC tissues and various 
clinicopathological parameters were analyzed using Fisher’s Exact and Kendall 
Tau’s tests. In addition, Kaplan Meier and Cox regression analyses were performed 
to evaluate possible correlations between the immunostaining in the IDC tissues 
with patients’ survival outcome. Disease-free survival (DFS), overall survival (OS), 
and survival after recurrence (SAR) durations were used for the survival analyses. 
DFS and OS define the duration from date of diagnosis to the date of first tumor 
recurrence and death respectively. SAR describes the duration from the date of first 
tumor recurrence to date of death. In addition, patient cases that did not reach the 
defined end-points of interest (first tumor recurrence and death) were censored at 
the last follow-up date. Statistical significance was defined when p-value was less 
than 0.05. 
 
2.12 Genome-wide Expression Profiling using Microarray Gene Chip 
 
2.12.1 Microarray Processing using Affymetrix Human Gene U133 Plus 2.0 
Array 
 
Total RNA were extracted from cultured cells using RNeasy Mini Kit. The RNA 
concentration and purity (260/280 OD) were measured by nanodrop. The silencing 
or over-expression efficiency was checked through qPCR before the RNA samples 
were sent to Origen (Origen, Singapore) for microarray processing. Briefly, the 
quality of the RNAs was further evaluated using an Agilent Bioanalyzer. The RNA 
samples were then processed based on Affymetrix recommended protocol for 
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whole transcript analysis. 300ng of total RNA was reverse transcribed to cDNA, 
which was used as a template to produce cRNA. The cRNA was then converted to 
single stranded DNA, which was biotin-labeled, fragmented, and hybridized to the 
Affymetric Human Gene U133 Plus 2.0 Array for 16 hours at 45oC with rotation at 
60rpm. Subsequently, the array was washed and stained using FS450_0007 fluidics 
protocol and visualized using Affymetrix 30007G scanner. Hybridization 
efficiency was inspected through the scanned images. CEL files generated from 
GeneChip Operating Software (GCOS) were imported into Expression Console 
software for array quality control. RMA normalization was carried out on the 
samples to create a quality control metrics.  
 
2.12.2 Microarray Gene Expression Analysis 
 
Genespring 7.0 (Silicon Genetics, CA, USA) and Expression Console 1.1.1 
(Affymetrix, CA, USA) softwares were used to analyze the microarray gene 
expression. Genespring 7.0 was used to normalize the CEL files generated from the 
Human Gene U133 Plus 2.0 Array to the median intensity of the same array. 
Following that, the median value of genes in the control samples was used to 
normalize the intensity of corresponding genes in the treatment group. Algorithmic 
model (RMA) was performed in Genespring to process the CEL files.  
 
Expression Console 1.1.1 summarized the probe set and checked the initial data 
quality. Algorithmic model (RMA) was also used for probe summarization and 
gene expression analysis. Upon completion of the data processing, CHP files are 
generated and intensities of all probe sets (genes) were reported after normalization.  
 
2.12.3 Filtering Criteria for Gene Selection 
 
After obtaining the intensities of the probe sets, filtering was carried out to select 
genes for further study.  
Filter 1: Fold change of at least 2 for relative gene expression was considered 
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Filter 2: p-value below 0.05 from unpaired t-test was considered after comparing 
the intensities of control and treated groups. 
Filter 3: Overlapped genes obtained from softwares used with different algorithmic 
models were selected. 
 
2.12.4 Gene Pathway Analysis 
 
Extensive literature review was carried out to find relevant gene(s) to justify the 
phenotypic changes observed upon silencing or over-expression of CHST3. The 
functional linkage between CHST3 and potential downstream genes was validated 






















3.1 Expression Analysis of CHST3 in Human Breast Cells  
 
As CHST3 has not been studied in breast cancer, the expression level of CHST3 in 
various breast cell lines (MCF-12A, MCF7, T47D, and MDA-MB-231) was firstly 
evaluated through immunofluorescence and western blot using a CHST3-specific 
antibody. As shown in Figure 3.1, it was observed that normal breast cells, MCF-
12A, have a higher expression level of CHST3 as compared to that of the breast 
cancer cell lines (MCF7, T47D and MDA-MB-231). Hence, it is notable that the 
differences in CHST3 expression may be associated with breast tumor progression 





Figure 3.1: CHST3 expression in breast cells 
Increased CHST3 expression was observed in normal breast cells, followed by Grade 1 
breast cancer cells, and lastly Grade 3 breast cancer cells. (A) Immunofluorescence staining 
and (B) Western Blot analysis depict the protein expression level of CHST3 in the different 
breast cell lines. For the immunofluorescence staining, CHST3 expression is expressed in 
green fluorescence as an anti-CHST3 primary antibody and a secondary antibody 
conjugated with FITC are used, while the nuclei staining are shown in blue DAPI. In the 
Western Blot analysis, CHST3 expression levels were normalized against housekeeping 
protein, β-actin. From the graphs comparing (C) immunofluorescence staining and (D) 
Western Blot analysis, MCF-12A normal breast cells have increased CHST3 expression 
against MCF7, T47D and MDA-MB-231 breast cancer cell lines. Data shown was from 
one independent experiment performed with three biological replicates for each cell line. 






3.2 Functional Analysis of CHST3 in Human Breast Cancer Cells 
 
With reference to the CHST3 expression study in breast cells, of which higher 
CHST3 expression level was observed in normal breast cells, followed by Grade 1 
breast cancer cells and lastly Grade 3 breast cancer cells, it is hypothesized that the 
cells will be more metastatic and proliferative after down-regulation of CHST3 and 
vice versa, that is the cells will be less metastatic and proliferative after over-
expression of CHST3. To investigate the functional roles of CHST3 in breast cancer 
cells, silencing and over-expression studies of CHST3 were carried out. The 
execution of both silencing and over-expression experiments would validate the 
observations obtained from both experiment sets.  
 
In the silencing experiments, CHST3 was silenced in two different breast cancer 
cell lines, namely T47D (Grade 1 breast cancer cells) and MDA-MB-231 (Grade 3 
breast cancer cells), to evaluate if the silencing of CHST3 in different grades of 
breast cancer cells will lead to similar or different functional behavior changes. 
Also, CHST3 was silenced in the breast cancer cells using two different siRNA 
sequences that specifically target the gene itself. Each sequence is essential to 
validate the phenotypic outcomes observed upon silencing of CHST3 using the 
other sequence.  
 
For the over-expression studies, two breast cancer cell lines namely MCF7 (Grade 
1 breast cancer cells) and MDA-MB-231 (Grade 3 breast cancer cells) were used. 
A different breast cancer cell line, MCF7, was chosen to evaluate if CHST3 has 
similar or different functional roles in different breast cancer cell lines. Additionally, 
two over-expression clones for each cell line were generated to confirm results that 






3.2.1 Silencing and Over-expression Efficiencies of CHST3 
 
Prior to carrying out the various phenotypic assays, the silencing and over-
expression efficiencies of CHST3 at both the mRNA and protein levels were firstly 
determined. In the silencing experiments, CHST3 was silenced through transient 
transfection in T47D and MDA-MB-231 cells using Silencer Select siRNA 
accompanied by delivery reagent, Oligofectamine. From the qPCR results, CHST3 
mRNA was at least 93.7% and 85.6% silenced compared to the scrambled siRNA 
groups in T47D cells (Figure 3.2A) and MDA-MB-231 cells (Figure 3.3A) 
respectively. From the immunocytochemistry and western blot results, CHST3 
protein was at least 46.4% and 37.3% silenced in comparison to the scrambled 
siRNA groups in T47D cells (Figure 3.2B-E) and MDA-MB-231 cells (Figure 
3.3B-E) respectively.  
 
For the over-expression experiments, stable over-expression of CHST3 was carried 
out in MCF7 and MDA-MB-231 cells using over-expression plasmids 
accompanied by delivery reagent, Lipofectamine, and antibiotic for selection, 
Geneticin.  The qPCR analysis showed CHST3 mRNA was over-expressed by at 
least 17.8 folds and 1.7 folds compared to the empty vector groups in MCF7 cells 
(Figure 3.4B) and MDA-MB-231 cells (Figure 3.5B) respectively. Over-expression 
of CHST3 protein levels were measured from immunofluorescence experiments. 
CHST3 protein was over-expressed by at least 2.3 folds and 2.7 folds against the 
empty vector groups in MCF7 cells (Figure 3.4A and C) and MDA-MB-231 cells 
(Figure 3.5 A and C) respectively.  
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Figure 3.2: Silencing efficiencies of CHST3 in T47D cells 
Silencing efficiencies of CHST3 mRNA and protein levels were obtained for both siRNA 
sequences specifically targeting CHST3. In the qPCR analysis (A), the mRNA expression 
levels of GAPDH house-keeping genes were used for normalization. (D) 
Immunocytochemistry staining and (E) Western Blot analysis depict the silencing 
efficiencies of CHST3 protein expression level in T47D cells. Cells in the 
immunocytochemistry experiment was captured using differential interference contrast 
(DIC) to quantify both staining intensity and nuclei. CHST3 expression is observed in both 
nuclei and cytoplasm of the cells. In the Western blot analysis, the protein expression of 
CHST3 was normalized against house-keeping protein, β-actin. Graphs (B) and (C) show 
the silencing efficiencies of CHST3 protein observed in immunocytochemistry and 
Western blot respectively.  Data shown were each from one independent experiment set 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 
with scrambled siRNA group.  
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Figure 3.3: Silencing efficiencies of CHST3 in MDA-MB-231 cells  
Silencing efficiencies of CHST3 mRNA and protein levels were obtained for both siRNA 
sequences specifically targeting CHST3. In the qPCR analysis (A), the mRNA expression 
levels of GAPDH house-keeping genes were used for normalization. (D) 
Immunocytochemistry staining and (E) Western Blot analysis depict the silencing 
efficiencies of CHST3 protein expression level in MDA-MB-231 cells. Cells in the 
immunocytochemistry experiment was captured using differential interference contrast 
(DIC) to quantify both staining intensity and nuclei. CHST3 expression is observed in both 
nuclei and cytoplasm of the cells. In the Western blot analysis, the protein expression of 
CHST3 was normalized against house-keeping protein, β-actin. Graphs (B) and (C) show 
the silencing efficiencies of CHST3 protein observed in immunocytochemistry and 
Western blot respectively. Data shown were each from one independent experiment set 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 
with scrambled siRNA group.  
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Figure 3.4: Over-expression efficiencies of CHST3 in MCF7 cells 
Over-expression efficiencies of CHST3 mRNA and protein levels were obtained for both 
over-expression clones against the empty vector clones. In the qPCR analysis (B), the 
mRNA expression levels of GAPDH house-keeping genes were used for normalization. 
(A) Immunofluorescence staining depict the over-expression efficiencies of CHST3 
protein expression level in MCF7 cells. The immunostaining was observed in both nucleus 
and cytoplasm of the cells. Graph (C) shows the over-expression analysis of CHST3 
protein observed in the immunofluorescence experiment.  Data shown in (B) were each 
from one independent experiment performed with three biological replicates. Data shown 
in (C) were from two independent experiments performed with three biological replicates 
for each experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with empty 




Figure 3.5: Over-expression efficiencies of CHST3 in MDA-MB-231 cells 
Over-expression efficiencies of CHST3 mRNA and protein levels were obtained for both 
over-expression clones against the empty vector clones. In the qPCR analysis (B), the 
mRNA expression levels of GAPDH house-keeping genes were used for normalization. 
(A) Immunofluorescence staining depict the over-expression efficiencies of CHST3 
protein expression level in MDA-MB-231 cells. The immunostaining was observed in both 
nucleus and cytoplasm of the cells. Graph (C) shows the over-expression analysis of 
CHST3 protein observed in the immunofluorescence experiment.  Data shown in (B) were 
each from one independent experiment performed with three biological replicates. Data 
shown in (C) were from two independent experiments performed with three biological 
replicates for each experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 




3.2.1.1 CHST7 Expression after Silencing CHST3 
 
Apart from CHST3, CHST7 is also known to transfer the sulfate group from PAPS 
to the 6th carbon of the galactosamine unit. Hence, before proceeding to the 
phenotypic assays, CHST7 was examined through qPCR to observe if its expression 
level was affected after silencing CHST3. From the qPCR results shown in Figure 
3.6, CHST7 expression was similar in both scrambled siRNA and CHST3-silenced 
groups, indicating that CHST7 was not affected when CHST3 was silenced in the 
breast cancer cells. 
 
Figure 3.6: CHST7 expression in CHST3-silenced T47D and MDA-MB-231 cells 
The mRNA expression level of CHST7 was obtained after silencing of CHST3 in (A) T47D 
and (B) MDA-MB-231 cells. GAPDH mRNA expression level was used as the house-
keeping gene for normalization. CHST7 level was not affected by the down-regulation of 
CHST3 in both cell lines. Data shown were each from one independent experiment 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 




3.2.1.2 CHST3 affects Cellular Behaviors in Breast Cancer Cells  
 
Upon obtaining the silencing and over-expression efficiencies at the mRNA and 
protein levels, phenotypic assays – migration, invasion, adhesion, proliferation, cell 
cycle, and apoptosis assays – were performed to evaluate the functional roles that 
CHST3 may have in breast cancer cells. In the silencing experiments, the 
phenotypic assays were carried out post 48-hour transfection to investigate the 
effects of silencing CHST3. On the other hand, for the over-expression experiments, 
the phenotypic assays were performed after stable over-expression of CHST3 in the 
cells.  
 
3.2.1.2.1  CHST3 affects Cell Migration in Breast Cancer Cells  
 
Acquisition and enhancement of cell migration through the basement membrane is 
one of the main characteristics of malignant cells. To investigate if a change in 
CHST3 expression level in breast cancer cells would result in a change in tumor 
progression, cell migratory ability was evaluated after silencing and over-
expression of CHST3 using transwell migration chambers. After silencing of 
CHST3 in T47D (Figure 3.7A and C) and MDA-MB-231 (Figure 3.7B and D) cells, 
cell migration level was observed to be increased compared to the scrambled 
siRNA group. On the other hand, after over-expression of CHST3 in MCF7 (Figure 
3.8A and C) and MDA-MB-231 (Figure 3.8B and D) cells, decreased in cell 




Figure 3.7: Cell migration level after silencing CHST3  
Increase in cell migration was observed in the CHST3-silenced groups compared to the 
scrambled siRNA group after down-regulation of CHST3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells. Data shown were each from two independent experiment sets 
performed with three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; 





Figure 3.8: Cell migration level after over-expression of CHST3  
Decrease in cell migration was observed in the CHST3-over-expressed groups compared 
to the empty vector groups after up-regulation of CHST3 in (A and C) MCF7 and (B and 
D) MDA-MB-231 cells. Data shown in (C) were each from one independent experiment 
performed with three biological replicates. Data shown were each from two independent 
experiment sets performed with three biological replicates for each experiment set. * P < 





3.2.1.2.2 CHST3 affects Cell Invasion in Breast Cancer Cells  
 
Acquisition of cell invasion into the basement membrane and extracellular matrix 
is another main phenotypic behavior of malignant cells. Cell invasion ability was 
evaluated after silencing and over-expression of CHST3 in breast cancer cells, using 
matrigel-coated transwell chamber.  After silencing of CHST3 in T47D (Figure 
3.9A and C) and MDA-MB-231 (Figure 3.10B and D) cells, cell invasion level was 
observed to be increased compared to the scrambled siRNA group. On the other 
hand, after over-expression of CHST3 in MCF7 (Figure 3.10A and C) and MDA-
MB-231 (Figure 3.10B and D) cells, decreased in cell invasion levels for both cell 
lines was observed in comparison to the empty vector groups. 
 
Figure 3.9: Cell invasion level after silencing CHST3  
Increase in cell invasion was observed in the CHST3-silenced groups compared to the 
scrambled siRNA group after down-regulation of CHST3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells. Data shown were from one independent experiment set performed 
with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 
scrambled siRNA group.  
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Figure 3.10: Cell invasion level after over-expression of CHST3  
Decrease in cell invasion was observed in the CHST3-over-expressed groups compared to 
the empty vector groups after up-regulation of CHST3 in (A and C) MCF7 and (B and D) 
MDA-MB-231 cells. Data shown were each from one independent experiment set 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 




3.2.1.2.3 CHST3 affects Cell Adhesion in Breast Cancer Cells  
 
Cell adhesion to the basement membrane and extracellular matrix is an important 
component for malignant cells’ capability to migrate and invade into the 
surrounding tissues as well as to other organs in the body. The effects of CHST3 
down-regulation and up-regulation on breast cancer cells’ adhesion ability were 
evaluated. From the silencing experiment, it was observed that cell adhesion, using 
fibronectin- and collegen-coated plates, decreased compared to the scrambled 
siRNA group in both T47D (Figure 3.11A and C) and MDA-MB-231 (Figure 3.11B 
and D) cells. On the other hand, in the over-expression experiment,  cell adhesion 
increased in comparison to the empty vectors groups in both MCF7 (Figure 3.12A 
and C) and MDA-MB-231 (Figure 3.12B and D).  
 
 
Figure 3.11: Cell adhesion level after silencing CHST3  
Decreases in cell adhesion was observed in the CHST3-silenced groups compared to the 
scrambled siRNA group after down-regulation of CHST3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells, using fibronectin- and collagen-coated plates. Data shown were 
each from two independent experiment sets performed with three biological replicates for 
each experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with scrambled 
siRNA group.  
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Figure 3.12: Cell adhesion level after over-expression of CHST3  
Increase in cell adhesion was observed in the CHST3-over-expressed groups compared to 
the empty vector groups after up-regulation of CHST3 in (A and C) MCF7 and (B and D) 
MDA-MB-231 cells, using fibronectin- and collagen-coated plates. Data shown were each 
from two independent experiments performed with three biological replicates for each 
experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with empty vector group.  
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3.2.1.2.4 CHST3 affects Cell Proliferation in Breast Cancer Cells  
 
Increase in cell proliferation and aggressiveness is another hallmark of tumor cells. 
Proteoglycans have been reported to play a role in cell proliferation through their 
binding to growth factors, initiating cell growth and multiplication. The effects of 
CHST3 silencing and over-expression in breast cancer cells was investigated, using 
a tetrazolium reagent. After down-regulation of CHST3, cell proliferation was 
observed to be slightly increased in T47D (Figure 3.13A) and MDA-MB-231 
(Figure 3.13C) cells. Contrary to this, over-expression of CHST3 gave decreases in 
cell proliferation in MCF7 (Figure 3.14A and Figure 3.14B).   As small changes 
were observed in cell proliferation assay using MTS solution, cell cycle analysis 
was performed through flow cytometry using detergent-based method and 
propidium iodide. After down-regulation of CHST3, changes was observed at the 
sub-G1 phase, indicating possible cell death occurrence as shown for T47D (Figure 
3.13B) and MDA-MB-231 (Figure3.13D) cells. However, only T47D cells showed 
changes at the S phase that is small reductions in DNA replication phase was 









Figure 3.13: Cell proliferation level after silencing CHST3  
Slight increases in cell proliferation were observed in the CHST3-silenced groups 
compared to the scrambled siRNA group after down-regulation of CHST3 in (A) T47D and 
(C) MDA-MB-231 cells. Decreases in cell death were observed in the CHST3-silenced 
groups compared to the scrambled siRNA groups after silencing of CHST3 in (B) T47D 
and (D) MDA-MB-231 cells. Only T47D cells showed decreases in cell number in S phase 
of the cell cycle. For cell proliferation performed using MTS solution, data shown were 
each from two independent experiments performed with three biological replicates for each 
experiment set. For flow cytometry, data shown were from one independent experiment 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 











Figure 3.14: Cell proliferation level after over-expression of CHST3  
Decreases in cell proliferation were observed in the CHST3-over-expressed groups 
compared to the empty vector groups after up-regulation of CHST3 in (A) MCF7 and (B) 
MDA-MB-231 cells. Data shown were from two independent experiments sets performed 
with three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; *** P < 
0.001 compared with empty vector group.  
 
3.2.1.2.5 CHST3 affects Cell Apoptosis in Breast Cancer Cells  
 
As changes in cell proliferation were observed after regulating CHST3 expression, 
cell apoptosis assay was carried out, specifically looking at Caspase3/7 levels.  
After silencing CHST3, cell apoptosis was observed to be decreased in T47D 
(Figure 3.15A) and MDA-MB-231 (Figure3.15B) cells. 
 
 
Figure 3.15: Cell apoptosis level after silencing CHST3  
Decreases in cell apoptosis were observed in the CHST3-silenced groups compared to the 
scrambled siRNA group after down-regulation of CHST3 in (A) T47D and (B) MDA-MB-
231 cells. Data shown were each from one independent experiment performed with three 




3.3 Signaling Pathways Affected through Silencing of CHST3  
 
From the functional analyses performed, results suggest that CHST3 has a tumor 
suppressing role in breast cancer cells. To understand the pathways involved for 
CHST3 that could have potentially regulated the phenotypic behavioral changes, 
several proteins from different signaling pathways associated with tumorigenesis 
were chosen for evaluation of their expression level after silencing of CHST3. The 
proteins investigated are involved in epithelial-mesenchymal transition, JAK-
STAT pathway, and apoptosis pathway.      
 
3.3.1 CHST3 affects Proteins involved in Epithelial –Mesenchymal 
Transition  
 
The metastatic capability of breast cancer cells was observed to be enhanced by 
down-regulation of CHST3 and suppressed by up-regulation of CHST3, suggesting 
the possibility of CHST3 pathway in the epithelial-mesenchymal transition (EMT) 
process that occurs in cancer cells for the initiation of metastasis. In general, cancer 
cells will lose cell-cell adhesion as well as gain invasive and migratory 
characteristics. A wide range of well-established EMT molecules are involved in 
the EMT process including E-cadherin and ZO-1 (for the breakdown of cell-cell 
adhesion), β-catenin and Snail (for the regulation and localization of transcription 
factors and repressors), as well as cytokeratin and vimentin (for the changes in the 
cytoskeleton organization) (Quaggin and Kapus, 2011). The expression levels of 
two epithelial markers - E-cadherin and β-catenin – were examined in this study.  
 
E-cadherin belongs to the cadherin transmembrane glycoprotein family, which 
regulate cell-cell adhesion, making cells cohesive and stably immotile (Guarino et 
al., 2007, Kemler, 1993, Takeichi, 1991, Shiozaki et al., 1996). It interacts with 
catenins including β-catenin, forming cadherin/catenin complexes that anchor to 
actin filaments of the cytoskeleton (Aberle et al., 1996, Lu et al., 2012). The 
formation of the complexes is crucial for optimal epithelial cell function and tissue 
integrity (Zappulli et al., 2012). The decreased expression of E-cadherin is possibly 
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the most crucial event of EMT that leads to changed phenotypic behavior of the 
tumor cells (Schmalhofer et al., 2009, Dubois-Marshall et al., 2011). Both E-
cadherin and β-catenin expression is dys-regulated by genetic and epigenetic events 
in various cancers (including breast, prostate, lung, liver, and kidney cancers). This 
hence leads to loss of epithelial phenotype, metastases and poor survival outcome 
(Zappulli et al., 2012, Simic et al., 2013). E-cadherin plays significant role as a 
predictor of primary tumor disease-free survival and distant disease-free survival. 
It is also an independent prognostic marker in predicting reduced survival duration 
for breast cancer patients with lymph node positive status (Park et al., 2007). In 
IDC, loss of E-cadherin and β-catenin expression is reported. It has hence been 
postulated that down-regulation of E-cadherin promotes the release of membrane-
bound β-catenin into the cytosol, enhancing the tumor progression promoting Wnt 
signaling (Prasad et al., 2009). Canonical Wnt signaling is one of the key signaling 
pathways involved in the promotion of metastatic behavior in breast cancer (Prasad 
et al., 2007). 
Upon silencing of CHST3 in T47D cells, the expression levels of E-cadherin and 





Figure 3.16: E-cadherin expression after silencing CHST3  
Reductions in E-cadherin expression level were observed in the CHST3-silenced groups 
compared to the scrambled siRNA group after down-regulation of CHST3 as shown in the 
(A) immunofluorescence pictures and (B) graph comparing the fluorescence intensities of 
each group. Data shown were from one independent experiment performed with three 





Figure 3.17: β-catenin expression after silencing CHST3  
Reductions in β-catenin expression level were observed in the CHST3-silenced groups 
compared to the scrambled siRNA group after down-regulation of CHST3 as shown in the 
(A) immunofluorescence pictures and (B) graph comparing the fluorescence intensities of 
each group. Data shown were from one independent experiment performed with three 











3.3.2 CHST3 affects Proteins involved in JAK/STAT Pathway  
 
EMT also acts through the activation of the JAK/STAT pathway, affecting cancer 
cell proliferation, migration and invasion. The well-established JAK/STAT 
signaling pathway is an evolutionarily conserved cascade that regulates cellular 
processes including cell migration and survival (Ekas et al., 2010, Arbouzova and 
Zeidler, 2006). It has been well-documented to be mis-regulated in various cancers 
including ovarian cancer, pancreatic cancer, and breast cancer (Spangenburg and 
Booth, 2002, Burke et al., 2001, Toyonaga et al., 2003), It is one of the key drivers 
for breast tumor aggressive progression and metastasis (Ling et al., 2013).  
 
In this study, JAK2/STAT3 proteins from the JAK/STAT pathway are observed 
through Western Blot analyses after silencing of CHST3 in T47D breast cancer cells. 
Janus kinase 2 (JAK2) is a cystolic non-receptor tyrosine kinase, that is widely 
expressed and localized at the intracellular domains of cytokine receptors (Sayyah 
et al., 2011, Wagner and Schmidt, 2011, Gilbert et al., 2005). When phosphorylated, 
JAK2 is activated and undergoes dimerization (Sayyah et al., 2011). Despite having 
numerous phosphorylation sites, auto-phosphorylation of Tyr1007 is essential for 
JAK2 activation, function, and regulation (Nam et al., 2012). JAK2 plays vital roles 
in mammary gland development and breast cancer tumor progression (Burke et al., 
2001). A known downstream component of JAK2 is signal transducer and activator 
of transcription 3 (STAT3), a transcription factor that is also commonly expressed 
in cells and tissues (Gilbert et al., 2005, Yang et al., 2012). STAT3 is activated via 
phosphorylation by JAK2 at its primary site Tyr705, leading to the dimerization of 
STAT3 through the SH2 domain interaction (Gilbert et al., 2005, Wagner and 
Schmidt, 2011, Behera et al., 2010, Wakahara et al., 2012). From the cytoplasm, 
active STAT3 dimers will translocate into the nucleus and promote the transcription 
of specific genes, affecting cellular behaviors including cell proliferation and 
metastasis (Ekas et al., 2010, Arbouzova and Zeidler, 2006, Sansone and Bromberg, 
2012). Reported as an oncogenic transformation regulator, STAT3 is involved in 
approximately 60% of breast tumors (Behera 2009). Constitutive activation of 
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STAT3 via phosphorylation can promote cell migration, survival and angiogenesis 
in high grade breast carcinoma (Walker et al., 2009, So et al., 2013, Balanis et al., 
2013). Tumor formation and growth as well as metastasis are inhibited upon 
STAT3 knockdown (through STAT3 shRNA silencing or STAT3 phosphorylation 
inhibitors) in in vivo tumor transplant model (So et al., 2013, Ling et al., 2013) 
 
The phosphorylated forms or active molecular forms that are pJAK2 and pSTAT3, 
as well as the total JAK2 and total STAT3 protein levels were analyzed. Through 
Western Blot analyses, observations suggest that activated JAK2 over total JAK2 
(Figure 3.18), and activated STAT3 over total STAT3 (Figure 3.19) protein 
expressions did not show significant differences.  
 
Figure 3.18: pJAK2/JAK2 expression after silencing CHST3  
Non-significant changes in (B) pJAK2/JAK2 expression levels were observed in the 
CHST3-silenced groups compared to the scrambled siRNA group after down-regulation of 
CHST3 as shown in the (A) Western Blot. Protein expressions were normalized against 
house-keeping protein, β-actin. Data shown were from two independent experiments sets 
performed with three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; 





Figure 3.19: pSTAT3/STAT3 expression after silencing CHST3  
Non-significant changes in (B) pSTAT3/STAT3 expression levels were observed in the 
CHST3-silenced groups compared to the scrambled siRNA group after down-regulation of 
CHST3 as shown in the (A) Western Blot. Protein expressions were normalized against 
house-keeping protein, β-actin. Data shown were from two independent experiments sets 
performed with three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; 
*** P < 0.001 compared with scrambled siRNA group. 
 
3.3.3 CHST3 affects Protein involved in Cell Apoptosis Pathway  
 
As small changes were observed in cell proliferation and cell apoptosis levels upon 
regulation of CHST3 in breast cancer cells, the expression level of one protein from 
the apoptosis pathway, BAD, was examined to validate the observations. Pro-
apoptotic BAD is part of the B-cell lymphoma 2 (BCL2) family.  BAD is activated 
via dephosphorylation and forms an inhibitory heterodimer with Bcl-2 or Bcl-xL to 
catalyze the oligomerization of BAK and BAX (Howells et al., 2010, Berndtsson 
et al., 2005). After which, mitochondrial outer membrane permeabilization occurs 
causing cytosolic release of DIABLO and cytochrome c, eliciting cell death 
(Howells et al., 2010, Cannings et al., 2007). Three main phosphorylation sites are 
situated at position Ser112, Ser136, and Ser155. Both Ser112 and Ser136 
phosphorylation facilitates 14-3-3 binding and kinase access to Ser155, while 
Ser155 phosphorylation hinders Bcl-xL binding (Datta et al., 2000). Although 
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phosphorylation at Ser136 is necessary to regulate pro-apoptotic function of BAD, 
phosphorylation at Ser112 protects the dephosphorylation of Ser136, indicating that 
BAD function is dependent on the dephosphorylation of Ser112 (Chiang et al., 
2003). The phosphorylation of BAD protein has been associated with cell survival 
and proliferation of some cancers (Howells et al., 2010). In vitro and in vivo studies 
in non-small lung cancer revealed that the over-expression of BAD inhibits cell 
growth and promotes cell apoptosis (Huang et al., 2012). BAD in BRAF mutant 
melanoma cells is also implicated in cell proliferation (Polzien et al., 2011). 
Additionally, patients with high Bad expression in their tumors had improved 
survival outcome compared against patients with low Bad expression (Cannings et 
al., 2007). Through Western Blot analyses (Figure 3.20), observations suggest that 
inactivated BAD over BAD protein expressions were enhanced upon down-
regulation of CHST3 in T47D cells. 
 
Figure 3.20: pBAD/BAD expressions after silencing CHST3  
Increases in (B) pBAD/BAD expression levels were observed in the CHST3-silenced 
groups compared to the scrambled siRNA group after down-regulation of CHST3 as shown 
in the (A) Western Blot. Protein expressions were normalized against house-keeping 
protein, β-actin. Data shown were from two independent experiment sets performed with 
three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 
compared with scrambled siRNA group. 
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3.4 Genome –Wide Expression Profiling of CHST3-Silenced T47D Cells  
 
CHST3, from observations obtained, has thus far been found to be more expressed 
in normal breast cells as well as less aggressive breast cancer cells compared to 
more aggressive and metastatic breast cancer cells. Additionally, CHST3 is found 
to have tumor suppressor roles in breast carcinoma according to the phenotypic 
behavior studies performed. Protein expression studies have also suggested 
associations of several proteins in different cellular behavioral pathways to the 
effects observed in the phenotypic behavioral changes after regulation of CHST3 
expression level. Following this, CHST3 was silenced in T47D cells and genome-
wide microarray was carried out to identify significant gene expression changes in 
CHST3-related genes, in order to further explore potential pathways in which 
CHST3 is possibly involved in the malignant process of tumorigenesis.  
 
3.4.1 RNA Yield, Quality, and Integrity  
 
The quality and integrity of the RNA samples sent for microarray processing were 
important factors to be taken into account to ensure success of gene microarray 
hybridization. The quality of RNA samples were defined by A260/A280 
absorbance ratio as well as the RNA integrity number (RIN) value, as summarized 
in Figure 3.21A. RIN value is ranged from 1 (degraded RNA) to 10 (intact RNA) 
and is calculated based on the ratio of 28S/18S ribosomal RNA using Agilent 2100 
Bioanalyzer. All samples showed RIN values above 9 indicating that the RNA 
samples were of good quality.  
 
The gel image in Figure 3.21B showed two specific distinct bands (representing 
18S and 28S ribosomal subunits). Additionally, electropherograms as illustrated in 
Figure 3.21C depicting two sharp peaks at 18S and 28S indicate good integrity of 
the RNA samples. After strict quality control evaluation, the RNA samples were 
qualified to be used for subsequent steps in the microarray sample processing.   
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Figure 3.21: Quality and integrity of RNA samples for microarray  
The RNA quality and integrity of the samples were shown through their (A) RIN number, 
concentration, and A260/280, (B) gel image consisting 18S (lower band) and 28S (upper 
band) in every lane, and (C) electropherogram image showing sharp peaks at 18S and 28S 
indicating highly intact RNA. Triplicates for each group (scrambled siRNA and CHST3-
silenced) were used in the processing. Values in (A) are indicated as mean ± standard error.  
 
3.4.2 Target Preparation  
 
For each sample, 100ng of total RNA was used for the assay. Table 3.1 shows the 
results of the purified cRNA, that was later fragmented and the size distribution of 






Table 3.1: Spectrophotometer reading of purified cRNA  
Values are indicated as mean ± standard error.  
 
Criteria Control Silenced 
260/280 Ratio 2.076 ± 0.002 2.084 ± 0.007 
Conc (ng/ul) 1470 ± 50.00 1433 ± 46.67 
Yield (ug) 73.50 ± 2.500 71.67 ± 2.333 
 
3.4.3 Gene Microarray Data Analysis  
 
Synthesized biotin-labeled cRNA were hybridized on to the Human U133 Plus 2.0 
Arrays. Arrays were washed and stained prior to scanning using Affymetrix 3000 
7G scanner. The resultant scanned image file and raw signal intensities for all probe 
sets were obtained. After which, Expression Console and Genespring softwares 
were utilized to process the microarray data. Based on stringent criteria including 
p-value below 0.05 and fold change of at least 2 folds, 58 genes obtained showed 
significant alteration after silencing of CHST3 in T47D cells. Of the 58 genes, 15 
genes were up-regulated and 43 genes were down-regulated after silencing of 
CHST3. 
 
3.4.4 Functional Categorization of Genes Affected from Silencing CHST3  
 
The list of 58 differentially expressed genes were categorized in accordance to their 
gene function(s) using Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) microarray analysis software. Figure 3.22 depicts the number 
of genes involved in various cellular processes upon down-regulation of CHST3. 
Table 3.2 shows the various up-regulated and down-regulated genes regulated after 
silencing of CHST3 in T47D cells. It is noted that a substantial number of genes are 
involved in cell migration and invasion as compared to genes involved in other 
phenotypic behaviors, which suggests consistency with the phenotypic behavioral 
changes observed.  
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Figure 3.22: Functional categorization of affected genes after CHST3 silencing  
Graphs (A) and (B) depict the functional categorization of up-regulated and down-
regulated genes respectively (≥ 2 folds change) after down-regulation of CHST3 in T47D 
cells.  
 










FLRT3 fibronectin leucine rich transmembrane protein 3 5.48 
 TGFB2 transforming growth factor, beta 2 4.37 
 GPNMB glycoprotein (transmembrane) nmb 2.94 
 DUSP1 dual specificity phosphatase 1 2.91 
 PCLO piccolo (presynaptic cytomatrix protein) 2.86 
 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 
2.61 
 CYR61 cysteine-rich, angiogenic inducer, 61 2.36 
 ANXA1 annexin A1 2.30 
 PAX6 paired box 6 -2.01 
 ADAMTS1
5 
ADAM metallopeptidase with thrombospondin 
type 1 motif, 15 
-2.03 
 RDX radixin -2.07 
 SLC7A11 solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11 
-2.09 
 ANTXR1 anthrax toxin receptor 1 -3.24 
 ELK3 ELK3, ETS-domain protein (SRF accessory 
protein 2) 
-4.15 
    
Cell Invasion FLRT3 fibronectin leucine rich transmembrane protein 3 5.48 
 TGFB2 transforming growth factor, beta 2 4.37 
 FGF12 fibroblast growth factor 12 3.84 
 GPNMB glycoprotein (transmembrane) nmb 2.94 
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 DUSP1 dual specificity phosphatase 1 2.91 





ADAM metallopeptidase with thrombospondin 
type 1 motif, 15 
-2.03 
 
    
Cell Adhesion FLRT3 fibronectin leucine rich transmembrane protein 3 5.48 
 TGFB2 transforming growth factor, beta 2 4.37 
 GPNMB glycoprotein (transmembrane) nmb 2.94 
 PCLO piccolo (presynaptic cytomatrix protein) 2.86 
 CYR61 cysteine-rich, angiogenic inducer, 61 2.36 
 KRTAP3-1 keratin associated protein 3-1 2.01 
 RDX radixin -2.07 
 ANTXR1 anthrax toxin receptor 1 -3.24 
    
Cell 
Proliferation 
TGFB2 transforming growth factor, beta 2 4.37 
 FGF12 fibroblast growth factor 12 3.84 
 DUSP1 dual specificity phosphatase 1 2.91 
 CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 
2.58 
 CYR61 cysteine-rich, angiogenic inducer, 61 2.36 
 ANXA1 annexin A1 2.30 
 PAX6 paired box 6 -2.01 
 DNAJC2 DnaJ (Hsp40) homolog, subfamily C, member 2 -2.02 
 MDFIC MyoD family inhibitor domain containing -2.05 
 MCM10 minichromosome maintenance complex 
component 10 
-2.06 
 HIPK1 homeodomain interacting protein kinase 1 -2.08 
 BRCC3 BRCA1/BRCA2-containing complex, subunit 3 -2.20 
 LAMP3 lysosomal-associated membrane protein 3 -2.28 
 ASNS asparagine synthetase (glutamine-hydrolyzing) -2.31 
 KIF23 kinesin family member 23 -2.40 
 PRIM2 primase, DNA, polypeptide 2 (58kDa) -2.62 
 DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 -2.73 
 PRKAR2B protein kinase, cAMP-dependent, regulatory, type 
II, beta 
-2.88 
 PDZK1 PDZ domain containing 1 -3.00 
 PSAT1 phosphoserine aminotransferase 1 -4.47 
    
Cell apoptosis TGFB2 transforming growth factor, beta 2 4.37 
 FGF12 fibroblast growth factor 12 3.84 
 DUSP1 dual specificity phosphatase 1 2.91 
 ANXA1 annexin A1 2.30 
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 STRADB STE20-related kinase adaptor beta 2.23 
 DICER1 dicer 1, ribonuclease type III 2.01 
 WT1 Wilms tumor 1 -2.07 
 HIPK1 homeodomain interacting protein kinase 1 -2.08 
 ASNS asparagine synthetase (glutamine-hydrolyzing) -2.31 
 RNF130 ring finger protein 130 -2.37 
 BRCC3 BRCA1/BRCA2-containing complex, subunit 3 -2.20 
    
Angiogenesis TGFB2 transforming growth factor, beta 2 4.37 
 DUSP1 dual specificity phosphatase 1 2.91 
 DICER1 dicer 1, ribonuclease type III 2.01 
 HIPK1 homeodomain interacting protein kinase 1 -2.08 
 ELK3 ELK3, ETS-domain protein (SRF accessory 
protein 2) 
-4.15 
    
Metabolic 
Process 
SLC16A9 solute carrier family 16, member 9 
(monocarboxylic acid transporter 9) 
2.38 
 OBFC2A oligonucleotide/oligosaccharide-binding fold 
containing 2A 
2.15 
 GNG11 guanine nucleotide binding protein (G protein), 
gamma 11 
-2.00 
 RFK riboflavin kinase -2.02 
 TMX3 thioredoxin-related transmembrane protein 3 -2.08 
 EIF2S1 eukaryotic translation initiation factor 2, subunit 1 
alpha, 35kDa 
-2.11 
 ALDH1L2 PDZ domain containing 1 -3.00 
 PDZK1 PDZ domain containing 1 -3.00 
    
Transcription 
Regulation 
GTF2E2 general transcription factor IIE, polypeptide 2, beta 
34kDa 
-2.03 
 EIF3J eukaryotic translation initiation factor 3, subunit J -2.08 
 PHTF2 putative homeodomain transcription factor 2 -2.10 
 MBNL1 muscleblind-like (Drosophila) -2.12 
 CBX3 chromobox homolog 3 (HP1 gamma homolog, 
Drosophila) 
-2.35 
 PRIM2 primase, DNA, polypeptide 2 (58kDa) -2.62 
 DPY30 dpy-30 homolog (C. elegans) -3.86 
    
Signal 
Transduction 
STRADB STE20-related kinase adaptor beta 2.23 
 GNG11 guanine nucleotide binding protein (G protein), 
gamma 11 
-2.00 
 SLITRK4 SLIT and NTRK-like family, member 4 -2.03 
 ODZ2 odz, odd Oz/ten-m homolog 2 (Drosophila) -2.08 
 RAB12 RAB12, member RAS oncogene family -2.12 
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 CBS cystathionine-beta-synthase -2.20 
 PRKAR2B protein kinase, cAMP-dependent, regulatory, type 
II, beta 
-2.88 
    
Ion/Protein 
Transport 
DNAJC24 DnaJ (Hsp40) homolog, subfamily C, member 24 -2.10 
 C11orf54 chromosome 11 open reading frame 54 -2.19 
 LARS leucyl-tRNA synthetase -2.22 
 DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 -2.28 
 NXT2 nuclear transport factor 2-like export factor 2 -2.34 
 LMAN2 lectin, mannose-binding 2 -2.40 
 
3.5 Downstream Molecules of CHST3 Silencing  
 
An extensive literature review was carried out to evaluate the potential functions of 
the genes from the microarray list. Among the genes, a few genes were found to be 
potentially involved in the observed phenotypic changes after regulation of CHST3 
in breast cancer cells. Two genes, that were up-regulated of their expression after 
CHST3 was silenced in T47D breast cancer cells, were chosen to be examined 
further: glycoprotein transmembrane nbm (GPNMB) and fibronectin leucine-rich 
transmembrane (FLRT3).  
 
GPNMB (or sometimes known as osteoactivin) is a type I transmembrane 
glycoprotein, localized on the cell surface and lysosomal membrane. It can also be 
secreted by cells (Tsui et al., 2012, Safadi et al., 2001). GPNMB has been studied 
in various carcinomas including melanoma, hepatocellular carcinoma, lung cancer, 
stomach cancer, as well as breast cancer (Loging et al., 2000, Nielsen et al., 2002, 
Haralanova-Ilieva et al., 2005, Borczuk et al., 2003, Rich et al., 2003). In skin 
malignancies, GPNMB expression level was significantly higher than that in 
normal and benign skin tissues. Also, GPNMB was positively immunostained in 
87% of malignant melanoma cases and 80% of squamous cell carcinoma cases 
(Zhao et al., 2012).  
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GPNMB has been shown to have an oncogenic role in breast carcinoma; the over-
expression of GPNMB in breast cancer cells caused increased cell invasion and 
metastasis (Rose et al., 2007). This result supports the phenotypic behavior changes 
observed in this study as cell invasion and cell migration were both reduced after 
down-regulating GPNMB in breast cancer cells. In another study (Rose et al., 2010), 
high expression of GPNMB can be observed in basal and triple negative types of 
breast cancer compared to normal breast tissues. Furthermore, high GPNMB level 
has been correlated to increased tumor recurrence risk, shorter time to tumor 
recurrence, and decreased overall patient survival (Rose et al., 2010). GPNMB was 
hence identified as a candidate gene that could be regulated by CHST3 and is 
potentially involved in breast cancer metastasis, invasion, and growth.  
 
As for FLRT3, no known expression profile and functional study of this cell surface 
protein have been carried out in human cells or tissues. In the developmental 
biology field, in Xenopus embryos, Flrt3 expression was observed at sites with 
higher occurrences of epithelial-mesenchymal (EMT) interactions, such as eyes, 
developing tooth buds, and hair follicles, hence indicating its importance in 
mediating cell migration (Gong et al., 2009). Apart from regulating cell migration, 
Flrt3 has been reported to inhibit C-cadherin-mediated cell adhesion after it is 
induced by Tgfβ signaling (Chen et al., 2009b). Additionally, Flrt3 co-expresses 
with Fgf8, interacts with Fgf receptors (Fgfr) to activate MAPK signaling cascade 
(Karaulanov et al., 2006). As FLRT3 is not well-studied yet in cancer, it was chosen 
in order to examine its expression and functions in human breast cancer. 
Additionally, its association with CHST3 would be examined.  
 
In order to evaluate whether CHST3 and GPNMB or FLRT3 works together in 
regulating phenotypic behaviors of breast cancer cells, the functional assays were 
performed after double silencing CHST3 together with either GPNMB or FLRT3 in 
T47D cells.  The hypothesis then would be that GPNMB and FLRT3 are 
downstream molecules of CHST3, whereby CHST3 regulates their expression 
levels and hence, brings rise to the observed phenotypic changes.  
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To elaborate more on the double silencing experiment design, four groups were 
performed namely (Group 1) double negative, (Group 2) CHST3-silenced, (Group 
3) GPNMB- or FLRT3- silenced, and (Group 4) double silenced of either CHST3 
and GPNMB silenced or CHST3 and FLRT3 silenced. For Groups 1 to 3, additional 
scrambled siRNA was included to match the volume and concentration of siRNAs 
in Group 4.  
 
3.5.1 CHST3 modulates GPNMB  
3.5.1.1 Silencing Efficiency of CHST3 and GPNMB  
 
GPNMB mRNA expression level was validated in CHST3-single-silenced T47D 
cells. As shown in Figure 3.23, GPNMB expression level increased by almost 2 
folds after down-regulation of CHST3. Also, prior to carrying out the phenotypic 
assays, the expression levels of CHST3 and GPNMB in double silenced groups were 
evaluated at mRNA (Figure 3.24 A and B) as well as protein level (Figure 3.24 (C 
to F). As observed from qPCR, CHST3 was down-regulated by more than 80% in 
the CHST3-silenced group and CHST3-GPNMB silenced group. Its expression was 
not affected in the GPNMB-silenced group. As for GPNMB expression level, it was 
up-regulated by 41.1% in the CHST3-silenced group. GPNMB level was down-
regulated by at least 65% in the GPNMB-silenced group and CHST3-GPNMB 
silenced group.  
 
From the western blot results, a similar trend was observed. CHST3 was down-
regulated by more than 45% in the CHST3-silenced group and CHST3-GPNMB 
silenced group. Its expression was not affected in the GPNMB-silenced group. 
Looking at GPNMB, it was up-regulated in both of its protein forms (80kDa and 
115kDa) GPNMB expression was down-regulated in the GPNMB-silenced group 





Figure 3.23: GPNMB expression in CHST3 single-silenced T47D cells 
The mRNA expression level of GPNMB was enhanced by almost 2 folds in T47D cells 
after single-silencing CHST3. GAPDH mRNA expression level was used as the house-
keeping gene for normalization. Data shown was from one independent experiment 
performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared 




Figure 3.24: CHST3 and GPNMB levels after different silencing treatments in T47D cells  
qPCR was carried out to evaluate the mRNA expression levels of (A) CHST3 and (B) 
GPNMB in the various groups. GAPDH mRNA expression level was used as the house-
keeping gene for normalization. From (C) western blot analyses, (D) CHST3 and (E and 
F) GPNMB protein levels were examined for the various silencing treatment groups. Β-
actin was used as the house-keeping protein for normalization. Data shown in (A) and (B) 
were from one independent experiment set performed with three biological replicates. Data 
shown in (D), (E), and (F) were from two independent experiment sets performed with 
three biological replicates each.* P < 0.05; ** P < 0.01; *** P < 0.001 compared with 
double negative group.  
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3.5.1.2 Regulation of Cellular Behaviors by CHST3 and GPNMB  
3.5.1.2.1 Regulation of Cell Migration by CHST3 and GPNMB  
 
Migration assay was carried out to examine the effect of double silencing CHST3 
and GPNMB on cell migration ability of T47D cells compared to the double 
negative, CHST3-silenced, and GPNMB-silenced groups. Post 48 hours 
transfection, the transfected cells were re-seeded into migration chambers and 
incubated for 24 hours. Silencing CHST3 alone increased cell migration level. 
Silencing of GPNMB alone decreased cell migration. Rose et al had previously 
showed an increase in cell migration upon ectopic expression of GPNMB (Rose et 
al., 2007). As depicted in Figure 3.25, double silencing of CHST3 and GPNMB 





Figure 3.25: Effects of CHST3 and GPNMB double silencing on cell migration  
As shown in the (A) pictures and (B) graph, silencing of CHST3 caused an increase in cell 
migration; while on the other hand, down-regulation of GPNMB caused a reduction in cell 
migration. Double silencing of CHST3 and GPNMB abrogated these changes in cell 
migration level. Data shown were from two independent experiment sets performed with 
three biological replicates for each experiment set. * P < 0.05; ** P < 0.01; *** P < 0.001 






3.5.1.2.2 Regulation of Cell Invasion by CHST3 and GPNMB  
 
   
Invasion assay, using Matrigel chambers, was carried out to evaluate the effect of 
double silencing CHST3 and GPNMB on cell invasion ability of T47D cells 
compared to the double negative, CHST3-silenced, and GPNMB-silenced groups. 
After 48 hours transfection, the transfected cells were re-seeded into the invasion 
chambers and incubated for 24 hours. From the single-silenced experiment, it was 
observed that silencing of CHST3 increased cell invasion level. Upon silencing of 
GPNMB, cell invasion decreased. From Figure 3.26, double silencing of CHST3 
and GPNMB abrogated these changes in cell invasion level.   
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Figure 3.26: Effects of CHST3 and GPNMB double silencing on cell invasion  
As shown in the (A) pictures and (B) graph, silencing of CHST3 caused an increase in cell 
invasion; while on the other hand, down-regulation of GPNMB caused a reduction in cell 
invasion. Double silencing of CHST3 and GPNMB abrogated these changes in cell invasion 
level. Data shown was from one independent experiment set performed with three 








3.5.1.2.3 Regulation of Cell Adhesion by CHST3 and GPNMB  
 
Adhesion assay, using fibronectin- and collagen-coated plates, was performed to 
examine the effect of double silencing CHST3 and GPNMB on regulating the 
adhesion capability of T47D cells on ECM components. Post 48 hours transfection, 
transfected cells were re-seeded into fibronectin- and collagen-coated plates. From 
the single-silenced experiment, it was observed that silencing of CHST3 decreased 
cell adhesion level in the fibronectin-coated plate. Upon silencing of GPNMB, cell 
adhesion increased.  Results in Figure 3.27A (using fibronectin-coated plate) 
suggest that double silencing of CHST3 and GPNMB abrogated these changes in 
cell adhesion level.  On the other hand, no significant changes were observed in the 
collagen-coated plate experiment.  
 
 
Figure 3.27: Effects of CHST3 and GPNMB double silencing on cell adhesion  
From the fibronectin-coated plate (A), silencing of CHST3 caused a decrease in cell 
adhesion; while on the other hand, down-regulation of GPNMB caused an increase in cell 
adhesion. Double silencing of CHST3 and GPNMB abrogated the changes in cell adhesion 
level. In contrast, no significant changes was observed in cell adhesion level in the 
collagen-coated plate. Data shown were from two independent experiment sets performed 
with three biological replicates each. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 








3.5.1.2.4 Regulation of Cell Proliferation by CHST3 and GPNMB  
 
Proliferation assay, using MTS assay, was performed to evaluate the effect of 
double silencing CHST3 and GPNMB on cell proliferation capability of T47D cells. 
Cell proliferation levels were assessed 48 hours after transfection. From the single-
silenced experiment, it was observed that silencing of CHST3 increased cell 
proliferation level. Upon silencing of GPNMB, cell proliferation decreased. From 
Figure 3.28, results suggest that double silencing of CHST3 and GPNMB abrogated 
these changes in cell proliferation level.   
 
Figure 3.28: Effects of CHST3 and GPNMB double silencing on cell proliferation  
Silencing of CHST3 caused an increase in cell proliferation; while on the other hand, down-
regulation of GPNMB caused a decrease in cell proliferation.  Double silencing of CHST3 
and GPNMB caused cell proliferation level to return to basal level (similar to double 
negative group). Data shown were from two independent experiment sets performed with 
three biological replicates each. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 











3.5.2 FLRT3 in Breast Cancer Cells 
 
Prior to carrying out double silencing experiments of CHST3 and FLRT3, single 
silencing of FLRT3 in T47D and MDA-MB-231 cells was performed. As no 
literature on FLRT3 functional role in cancer is known thus far, it would be 
necessary to examine FLRT3’s role in the various cellular behaviors. Two breast 
cancer cell lines as well as two siRNA sequences specifically targeting FLRT3 were 
used to validate the phenotypic changes observed. 
 
3.5.2.1 Silencing Efficiency of FLRT3  
 
The silencing efficiencies of FLRT3 at both mRNA and protein levels were firstly 
determined before carrying out of phenotypic assays. FLRT3 was silenced through 
transient transfection in T47D and MDA-MB-231 cells using Silencer Select 
siRNA accompanied with delivery reagent, Oligofectamine. From the qPCR 
results, FLRT3 mRNA was at least 72.3% and 74.3% silenced as compared to the 
scrambled siRNA groups in T47D cells (Figure 3.29B) and MDA-MB-231 cells 
(Figure 3.30B) respectively. From the immunofluorescence results, FLRT3 protein 
was at least 50.1% and 60.2% down-regulated in comparison to the scrambled 
siRNA groups in T47D cells (Figure 3.29A and C) and MDA-MB-231 cells (Figure 





Figure 3.29: Silencing efficiencies of FLRT3 in T47D cells 
Silencing efficiencies of FLRT3 mRNA and protein levels were obtained for both siRNA 
sequences specifically targeting FLRT3. In the qPCR analysis (B), the mRNA expression 
levels of GAPDH house-keeping genes were used for normalization. (A) 
Immunofluorescence staining depict the silencing efficiencies of FLRT3 protein 
expression level in T47D cells. Graph (C) shows the silencing efficiencies of FLRT3 
protein observed in immunofluorescence.  Data shown were each from one independent 
experiment performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 
0.001 compared with scrambled siRNA group. 
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Figure 3.30: Silencing efficiencies of FLRT3 in MDA-MB-231 cells 
Silencing efficiencies of FLRT3 mRNA and protein levels were obtained for both siRNA 
sequences specifically targeting FLRT3. In the qPCR analysis (B), the mRNA expression 
levels of GAPDH house-keeping genes were used for normalization. (A) 
Immunofluorescence staining depict the silencing efficiencies of FLRT3 protein 
expression level in MDA-MB-231 cells. Graph (C) shows the silencing efficiencies of 
FLRT3 protein observed in immunofluorescence.  Data shown were each from one 
independent experiment performed with three biological replicates. * P < 0.05; ** P < 0.01; 








3.5.2.2 FLRT3 affects Cell Migration in Breast Cancer Cells 
 
The various phenotypic assays were performed to evaluate the role of FLRT3 in 
breast cancer cells. Cell migration ability was assessed using the transwell 
migration chambers post 48 hours transfection in T47D and MDA-MB-231 cells. 
After silencing of FLRT3 in T47D (Figure 3.31A and C) and MDA-MB-231 
(Figure 3.31B and D) cells, migration level was observed to have decreased 
compared to the scrambled siRNA group.  
 
Figure 3.31: Cell migration level after silencing FLRT3  
Decrease in cell migration was observed in the FLRT3-silenced groups compared to the 
scrambled siRNA group after down-regulation of FLRT3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells. Data shown were from one independent experiment performed 
with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 




3.5.2.3 FLRT3 affects Cell Invasion in Breast Cancer Cells 
 
Cell invasion ability was also assessed using the matrigel-coated transwell 
chambers post 48 hours transfection. After silencing of FLRT3 in T47D (Figure 
3.32A and C) and MDA-MB-231 (Figure 3.32B and D) cells, invasion level was 
observed to have decreased compared to the scrambled siRNA group.  
 
Figure 3.32: Cell invasion level after silencing FLRT3  
Decrease in cell invasion was observed in the FLRT3-silenced groups compared to the 
scrambled siRNA group after down-regulation of FLRT3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells. Data shown were from one independent experiment performed 
with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 








3.5.2.4 FLRT3 affects Cell Adhesion in Breast Cancer Cells 
 
Cell adhesion ability was next assessed using fibronectin- and collagen-coated 
plates, after a 48-hour transfection period. After silencing of FLRT3 in T47D 
(Figure 3.33A and C) and MDA-MB-231 (Figure 3.33B and D) cells, adhesion 
level was observed to be enhanced compared to the scrambled siRNA group.  
 
Figure 3.33: Cell adhesion level after silencing FLRT3  
Increases in cell adhesion was observed in the FLRT3-silenced groups compared to the 
scrambled siRNA group after down-regulation of FLRT3 in (A and C) T47D and (B and 
D) MDA-MB-231 cells, using fibronectin- and collagen-coated plates. Data shown were 
from one independent experiment performed with three biological replicates. * P < 0.05; 






3.5.2.5 FLRT3 affects Cell Proliferation in Breast Cancer Cells 
 
Cell proliferation capability was examined using MTS assay after a 48-hour 
transfection period. After silencing of FLRT3 in T47D (Figure 3.34A) and MDA-
MB-231 (Figure 3.34B) cells, proliferation level was observed to be decreased 
compared to the scrambled siRNA group.  
 
 
Figure 3.34: Cell proliferation level after silencing FLRT3  
Small decreases in cell proliferation were observed in the FLRT3-silenced groups 
compared to the scrambled siRNA group after down-regulation of FLRT3 in (A) T47D and 
(B) MDA-MB-231 cells. Data shown were from one independent experiment performed 
with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with 
scrambled siRNA group. 
 
3.5.3 CHST3 modulates FLRT3  
 
From the single-silenced experiments, the down-regulation of FLRT3 showed 
decreases in metastatic capability and aggressiveness, suggesting FLRT3 to be a 
tumor promoter gene. Double silencing experiments were next performed to 
evaluate whether CHST3 acts through FLRT3, giving rise to the various phenotypic 
changes observed in the CHST3-silenced experiments.  
 
3.5.3.1 Silencing Efficiency of CHST3 and GPNMB  
 
FLRT3 mRNA expression level was firstly validated in CHST3-single-silenced 
T47D cells. As shown in Figure 3.35, FLRT3 expression level increased by almost 
2 folds after down-regulation of CHST3. Also, prior to carrying out the phenotypic 
assays, the expression levels of CHST3 and FLRT3 in double silenced groups were 
evaluated at mRNA (Figure 3.36A and B) as well as protein level (Figure 3.36C to 
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E). As observed from qPCR, CHST3 was down-regulated by more than 67% in the 
CHST3-silenced group and CHST3-FLRT3 silenced group. Its expression was not 
affected in the FLRT3 -silenced group. As for FLRT3 expression level, it was up-
regulated by 94.5% in the CHST3-silenced group. FLRT3 level was down-regulated 
by at least 61.7% in the FLRT3-silenced group and CHST3-GPNMB silenced group. 
FLRT3 returned to basal level (similar to the double negative group) in the CHST3-
FLRT3 silenced group. 
 
From the western blot results, the same trend was observed. CHST3 was down-
regulated by more than 44.5% in the CHST3-silenced group and CHST3-FLRT3 
silenced group. Its expression was not affected in the FLRT3-silenced group. 
Looking at FLRT3, it was up-regulated of its expression level in the CHST3-
silenced group. Also, FLRT3 expression was down-regulated by 38.2% in the 
FLRT3-silenced group and similar to the double negative group in the CHST3-
FLRT3 silenced group.  
 
 
Figure 3.35: FLRT3 expression in CHST3 single-silenced T47D cells 
The mRNA expression level of FLRT3 was enhanced by almost 2 folds in T47D cells after 
single-silencing CHST3. GAPDH mRNA expression level was used as the house-keeping 
gene for normalization. Data shown was from one independent experiment performed with 
three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with scrambled 




Figure 3.36: CHST3 and FLRT3 levels after different silencing treatments in T47D cells  
qPCR was carried out to evaluate the mRNA expression levels of (A) CHST3 and (B) 
FLRT3 in the various groups. GAPDH mRNA expression level was used as the house-
keeping gene for normalization. From (C) western blot analyses, (D) CHST3 and (E and 
F) FLRT3 protein levels were examined for the various silencing treatment groups. Β-actin 
was used as the house-keeping protein for normalization. Data shown was from one 
independent experiment performed with three biological replicates. * P < 0.05; ** P < 0.01; 





3.5.3.2 Regulation of Cellular Behaviors by CHST3 and FLRT3  
3.5.3.2.1 Regulation of Cell Migration by CHST3 and FLRT3  
 
 
After obtaining the silencing efficiencies of FLRT3, phenotypic assays were 
performed. Cell migration ability was assessed with transwell migration chambers 
to examine the effect of double silencing CHST3 and FLRT3 against double 
negative, CHST3-silenced, and FLRT3-silenced groups. The transfected cells were 
re-seeded into the migration chambers after a 48-hour transfection period. From the 
single-silenced experiments, it was observed that silencing of CHST3 increased cell 
migration level while silencing of FLRT3 decreased cell migration level. From 
Figure 3.37, double silencing of CHST3 and FLRT3 abrogated these changes in cell 
migration level.  
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Figure 3.37: Effects of CHST3 and FLRT3 double silencing on cell migration  
As shown in the (A) pictures and (B) graph, silencing of CHST3 caused an increase in cell 
migration; while on the other hand, down-regulation of FLRT3 caused a reduction in cell 
migration. Double silencing of CHST3 and FLRT3 caused cell migration level to return to 
basal level (similar to double negative group). Data shown was from one independent 
experiment performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 




3.5.3.2.2 Regulation of Cell Invasion by CHST3 and FLRT3  
 
Cell invasion ability was next evaluated to compare the effect of double silencing 
CHST3 and FLRT3 with the double negative and other silencing treatment groups. 
After 48 hours transfection, the transfected cells were re-seeded into matrigel 
invasion chambers and incubated for 24 hours. From the single-silenced 
experiments, it was observed that silencing of CHST3 increased cell invasion level 
while silencing of FLRT3 decreased cell invasion level. Figure 3.38 shows double 
silencing of CHST3 and FLRT3 abrogated these changes in cell invasion level.  
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Figure 3.38: Effects of CHST3 and FLRT3 double silencing on cell invasion  
As shown in the (A) pictures and (B) graph, silencing of CHST3 caused an increase in cell 
invasion; while on the other hand, down-regulation of FLRT3 caused a reduction in cell 
invasion. Double silencing of CHST3 and FLRT3 caused cell invasion level to return to 
basal level (similar to double negative group). Data shown was from one independent 
experiment performed with three biological replicates. * P < 0.05; ** P < 0.01; *** P < 




3.5.3.2.3 Regulation of Cell Adhesion by CHST3 and FLRT3  
 
Cell adhesion capability to ECM-components, fibronectin and collagen, was 
examined for the effect of double silencing CHST3 and FLRT3 in T47D cells 
compared to double negative and other silencing treatment groups. After a 48-hour 
transfection period, transfected cells were re-seeded into fibronectin- and collagen-
coated plates. From the single-silenced experiments, it was observed that silencing 
of CHST3 decreased cell adhesion level while silencing of FLRT3 increased cell 
adhesion level. Results in Figure 3.39 suggest that double silencing of CHST3 and 
FLRT3 abrogated these changes in cell adhesion level.  
 
 
Figure 3.39: Effects of CHST3 and FLRT3 double silencing on cell adhesion  
Silencing of CHST3 caused a decrease in cell adhesion; while on the other hand, down-
regulation of FLRT3 caused an increase in cell adhesion for both fibronectin- and collagen-
coated plates.  From the (A) fibronectin- and (B) collagen-coated plate, double silencing 
of CHST3 and FLRT3 caused cell adhesion level to return to basal level (similar to double 
negative group). Data shown was from one independent experiment performed with three 















3.5.3.2.4 Regulation of Cell Proliferation by CHST3 and FLRT3  
 
Cell proliferation was also examined after double silencing CHST3 and FLRT3. 
Evaluation was performed post 48 hours transfection using MTS assay. From the 
single-silenced experiments, it was observed that silencing of CHST3 increased cell 
proliferation level while silencing of FLRT3 decreased cell proliferation level. 
Results in Figure 3.40 depict double silencing of CHST3 and FLRT3 abrogated 
these changes in cell proliferation level.  
 
 
Figure 3.40: Effects of CHST3 and FLRT3 double silencing on cell proliferation  
Silencing of CHST3 caused a small increase in cell proliferation; while on the other hand, 
down-regulation of FLRT3 caused a small decrease in cell proliferation.  Double silencing 
of CHST3 and GPNMB caused cell proliferation level to return to basal level (similar to 
double negative group). Data shown was from one independent experiment performed with 
three biological replicates. * P < 0.05; ** P < 0.01; *** P < 0.001 compared with double 












3.5.4 Relationship of GPNMB and FLRT3 
 
From the in vitro results, it is observed that both GPNMNB and FLRT3 are tumor 
promoters. After down-regulation of the genes in breast cancer cells, cellular 
behavior became less proliferative and metastatic. The next step would be to 
evaluate whether GPNMB and FLRT3 regulate one another in the cellular process. 
qPCR was performed whereby GPNMB expression was examined in FLRT3-
silenced cells and FLRT3 expression was evaluated in GPNMB-silenced cells. 
Results as shown in Figure 3.41 unveil that both GPNMB and FLRT3 do not 
regulate one another as there were no significant changes observed from the qPCR 
results.  
 
Figure 3.41:  GPNMB and FLRT3 correlation in T47D cells 
(A) FLRT3 expression in GPNMB-silenced T47D cells showed no significant difference 
between the scrambled siRNA and GPNMB-silenced groups. (B) GPNMB expression in 
FLRT3-silenced T47D cells showed no significant difference between scrambled siRNA 
and FLRT3-silenced groups. This indicates that FLRT3 expression level is not affected or 
regulated by GPNMB change in expression, as well as vice versa. Data shown was from 
one independent experiment performed with three biological replicates. * P < 0.05; ** P < 












3.6 Expression Analysis of CHST3 in Invasive Ductal Carcinoma Tissues  
 
From the in vitro studies, it is observed that CHST3 plays a tumor suppressor role 
in breast cancer tumorigenesis; the down-regulation of CHST3 brings forth more 
aggressive and metastatic behaviors in breast cancer cells. Therefore, investigation 
was further extended to clinical patient samples. It was hypothesized that low 
expression of CHST3 in human breast cancer tissue is correlated with worse 
prognosis and clinical parameters.  
 
3.6.1 Clinicopathological Parameters of IDC Patient Cases  
 
A total of 255 human IDC cases and 77 normal non-malignant ductal tissue cases, 
in tissue microarray format, were used for immunohistochemical evaluation of 
CHST3 protein. The patients’ age ranged from 23 to 89 years old, with a mean of 
56.1 years and a median of 55.5 years. As a result of tissue loss during the 
immunohistochemistry process, the expression patterns of CHST3 were examined 
in 259 cases (218 IDC cases and 41 normal ductal cases). The clinicopathological 
features of the malignant cases and normal cases are summarized in Table 3.3 and 
3.4 respectively. 
 
Patient survival and tumor recurrence data were available for 213 (97.7%) of the 
218 IDC cases studied. The follow-up period ranged from 0 to 175.5 months. There 
was death occurrence in 22.5% of patients, with the mean and median of OS period 
being 106.7 and 99.9 months respectively. All death cases arose from the cancer 
disease itself. Tumor recurrences were found in 30.7% of cases, and the mean and 
median DFS time were 100.2 months and 98.0 months. Among patients with tumor 
recurrence, 19.6% of them had died of the cancer at the end of the study period, 






Table 3.3 Clinicopathological features of 218 cases of IDC tissues 
Clinicopathological features  Clinicopathological features  
Age (years) 
     Mean 
     Median 
     Minimum 






Tumor size (mm) 
     Mean 
     Median 
     Minimum 






Clinicopathological features No. of cases Clinicopathological features No. of cases 
Age (years) 
     ≤ 56 






     Absent 
     Present 







     Chinese 
     Malay 
     Indian 
     Others 







Lymphovascular invasion stage 
     1 
     2 
     3 







Tumor size (mm) 
     ≤ 30 
     > 30 






Lymph node status 
     1 
     2 
     3 







Histological tumor grade 
     1 
     2 
     3 






Tubule Formation Stage 
     1 
     2 
     3 








     1 
     2 
     3 







Estrogen receptor status 
     Negative 
     Positive 






     1 
     2 
     3 







Progesterone receptor status 
     Negative 
     Positive 






     1 
     2 
     3 







HER2 receptor status 
     Negative 
     Positive 










Table 3.4 Clinicopathological features of 41 cases of normal ductal cases 





     Mean 
     Median 
     Minimum 








     Chinese 
     Malay 
     Indian 
     Others 









3.6.2 CHST3 Expression Pattern in Breast Tissues  
 
CHST3 expression staining was positive in the epithelial compartment of both 
normal and malignant breast tissues as shown in Figure 3.42. Additionally, Figure 
3.42 depicts the CHST3 staining intensities of 0, 1+, 2+, and 3+ in breast ductal 
tissues.   
 
 
Figure 3.42:  Staining pattern of CHST3 in breast tissues  
CHST3 staining intensities of 0, 1+, 2+, and 3+ were observed in the epithelial 
compartment of breast tissues. Images indicating staining intensities of 0, 1+, and 2+ were 
taken from malignant tissue samples while the image indicating staining intensity 3+ was 
taken from a non-malignant sample.  
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3.6.3 CHST3 Selected Cut-off Point  
 
To select a suitable cut-off point for CHST3, the distribution curve was first 
analysed. As a non-normal distribution curve (Figure 3.43A) was observed, the 
median was selected to be the cut-off point for CHST3 (Figure 3.43C). Also, an 
ROC curve analysis was performed to evaluate the sensitivity and specificity of the 
median cut-off point of CHST3 (Figure 3.43B). The median cut-off point shows a 
sensitivity score of 0.732 (Figure 3.43D), false positivity score between 0.413 and 





Figure 3.43:  Frequency distribution and ROC curve of CHST3 expression among normal 
and malignant tissues  
(A) Histogram illustrates the frequency distribution of the WAI score of CHST3 expression 
across both normal and malignant tissues. (B) ROC curve depicts WAI score of CHST3 
expression of normal and malignant tissues following their sensitivity and 1-specificity 
score. The area under curve is 0.667, which is above 0.500.   
 
 131 
3.6.4 CHST3 Expression in Normal and Malignant Breast Tissues  
 
Expression of CHST3 epitope was evaluated in the epithelial (cytoplasm) 
compartment of ductal specimens. Analysis of the tissue microarrays showed that 
normal ductal tissues had enhanced staining in comparison to malignant IDC 
tissues as shown in Figure 3.44 and Table 3.5 (p-value = 0.000). Further analysis 
was also performed on paired normal and malignant breast tissues, of which results 
showed higher CHST3 expression level in the normal tissues compared to its paired 
malignant counterpart tissue (Figure 3.45). 
 
 
Figure 3.44:  CHST3 immunostaining in normal and malignant breast tissues  
Higher expression of CHST3 was observed in normal ductal tissues compared to malignant 
breast tissues. Staining intensities of 2+ and 3+ are shown in the above normal tissues 










Table 3.5: Analysis of CHST3 expression between normal and malignant breast tissues  
CHST3 expression is significantly enhanced in normal ductal tissues in comparison to 
malignant tissues.  
 
 Weighted Average Score (WAI) 
 ≤ 1.06 > 1.06 p-value 
Diagnosis 
     Normal 











Figure 3.45:  Paired analysis of CHST3 expression in 33 paired normal and malignant 
breast tissue samples.  
Normal tissues shows enhanced expression level of CHST3 compared to malignant tissues.  
 
3.6.5 CHST3 Correlations with Clinicopathological Parameters  
 
Among the malignant tissues, higher CHST3 expression was significantly 
correlated with lower tumor stage (Figure 3.46 and Table 3.6) and borderline 





Figure 3.46:  CHST3 immunostaining in breast tissues of different tumor stage  
Higher expression of CHST3 was observed in IDC of lower tumor stage. Stage 1 shows 
staining intensity of 2+, stage 2 depicts intensities of 1+ and 2+, and stage 3 displays mostly 




Table 3.6:  Correlations between CHST3 expression and clinicopathological features of 
IDC  













     ≤ 56 
     > 56 














     Absent 
     Present 
















     Chinese 
     Malay 
     Indian 
     Others 

















     1 
     2 
     3 

















Tumor size (mm) 
     ≤ 30 
     > 30 
     NA 











Lymph node status 
     1 
     2 
     3 
















     1 
     2 
     3 


















     1 
     2 
     3 


















     1 
     2 
     3 















     Negative 
     Positive 
     NA 












     1 
     2 
     3 















     Negative 
     Positive 
     NA 













     1 
     2 
     3 

















HER2 receptor status 
     Negative 
     Positive 
     NA 











NA = Not Available 
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3.6.6 urvival Analysis of CHST3 Expression  
 
3.6.6.1 Survival Analysis using Kaplan Meier  
 
Survival analysis was first performed using Kaplan Meier curves to observe any 
general trends between CHST3 expression and tumor recurrence and mortality rate. 
No significant trends were observed for CHST3 expression with patients’ tumor 
recurrence and mortality rate, as shown in Figure 3.47. 
 
 
Figure 3.47: Kaplan Meier curves using CHST3  
No significant trend was observed between CHST3 expression and (A) tumor recurrence, 





3.6.6.2 Survival Analysis using Cox Regression Univariate  
 
Cox regression analysis using univariate method was performed to determine the 
hazard ratio of CHST3 expression as well as for the clinicopathological parameters. 
Several significant hazard ratios were obtained for various clinical parameters. 
However, no significant hazard ratios were attained for CHST3 expression in 
disease-free survival (Table 3.7), overall survival (Table 3.8), as well as survival 
after recurrence (Table 3.9) time period. 
 
Table 3.7: Univariate Cox regression analysis of CHST3 and clinicopathological 
parameters using DFS time period 
 
Disease Free Survival 
p-value Hazard ratio 
95% CI  
 
Lower Upper 
Increased CHST3 expression  
.531 1.451 .452 4.673 
Presence of lymph node invasion 
.448 1.508 .522 4.360 
PR+ status 
.036 4.713 1.106 20.080 
ER+ status 
.327 .603 .219 1.659 
HER2+ status 
.328 .557 .173 1.798 
Increased lymphovascular invasion stage 
.898 .000 .000 3.426E52 
Increased tumor stage 
.496 1.570 .429 5.743 
Race 
.366 .745 .393 1.411 
Increased histological grade 
.802 1.266 .199 8.041 
Increased tubule formation stage 
.716 .792 .226 2.775 
Increased pleomorphism stage 
.313 2.010 .518 7.802 
Increased mitotic index 
.685 1.227 .457 3.299 
Increased lymph node stage 
.901 3778.146 .000 6.341E59 
Larger tumor size  
.382 .640 .236 1.738 
Increased age  







Table 3.8: Univariate Cox regression analysis of CHST3 and clinicopathological 
parameters using OS time period 
 
Overall Survival 
p-value Hazard ratio 
95% CI  
Lower Upper 
Increased CHST3 expression  
.198 .362 .077 1.699 
Presence of lymph node invasion 
.302 1.955 .547 6.983 
PR+ status 
.036 6.572 1.134 38.084 
ER+ status 
.331 .541 .157 1.867 
HER2+ status 
.759 .818 .227 2.950 
Increased lymphovascular invasion stage 
.904 .000 .000 6.920E57 
Increased tumor stage 
.838 .833 .144 4.802 
Race 
.247 .619 .275 1.394 
Increased histological grade 
.634 1.784 .165 19.262 
Increased tubule formation stage 
.383 .501 .106 2.372 
Increased pleomorphism stage 
.305 2.434 .445 13.310 
Increased mitotic index 
.497 1.530 .449 5.212 
Increased lymph node stage 
.906 5364.575 .000 2.233E65 
Larger tumor size  
.513 .656 .185 2.323 
Increased age  




















Table 3.9: Univariate Cox regression analysis of CHST3 and clinicopathological 
parameters using SAR time period 
 
Survival after Recurrence 
p-value Hazard ratio 
95% CI  
Lower Upper 
Increased CHST3 expression  
.480 .566 .117 2.742 
Presence of lymph node invasion 
.956 .967 .292 3.202 
PR+ status 
.285 2.372 .487 11.562 
ER+ status 
.352 .490 .109 2.199 
HER2+ status 
.457 1.712 .415 7.060 
Increased lymphovascular invasion stage 
.926 .000 .000 1.132E77 
Increased tumor stage 
.875 .863 .137 5.417 
Race 
.284 .546 .180 1.653 
Increased histological grade 
.974 .962 .092 10.099 
Increased tubule formation stage 
.646 .708 .162 3.086 
Increased pleomorphism stage 
.583 1.689 .260 10.973 
Increased mitotic index 
.791 1.179 .349 3.986 
Increased lymph node stage 
.925 7595.428 .000 6.112E84 
Larger tumor size  
.898 .919 .256 3.303 
Increased age  














3.6.6.3 Survival Analysis using Cox Regression Multivariate  
 
Following this, Cox regression multivariate survival analysis (Table 3.10-3.12) 
using clinicopathological parameters were carried out for DFS, OS, and SAR time 
period respectively. This was performed to examine if CHST3 is a good prognostic 
marker after adjusting for various important clinical parameters. No significant 
hazard ratio was obtained for CHST3 expression level. However, tumor size was 
found to have significant hazard ratio after adjusting for confounding factors in all 
time periods.    
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Table 3.10: Multivariate Cox regression analysis of CHST3 expression using DFS.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased CHST3 expression .952 .973 .402 2.354 
Presence of lymph node invasion .224 1.659 .734 3.752 
PR+ status .225 1.848 .685 4.982 
ER+ status .131 .510 .213 1.223 
HER2+ status .204 .535 .204 1.405 
Increased tumor stage .717 1.197 .452 3.168 
Race .999 1.000 .575 1.738 
Larger tumor size  .023 2.969 1.161 7.594 
Increased age  .812 1.107 .479 2.557 
Step 2 Increased CHST3 expression .952 .973 .403 2.353 
Presence of lymph node invasion .215 1.659 .745 3.694 
PR+ status .225 1.848 .686 4.979 
ER+ status .130 .510 .214 1.218 
HER2+ status .197 .535 .207 1.384 
Increased tumor stage .713 1.197 .459 3.121 
Larger tumor size  .022 2.969 1.168 7.550 
Increased age  .807 1.107 .489 2.504 
Step 3 Increased CHST3 expression .982 .990 .413 2.374 
Presence of lymph node invasion .214 1.661 .746 3.697 
PR+ status .195 1.898 .720 5.001 
ER+ status .122 .505 .213 1.200 
HER2+ status .197 .535 .207 1.383 
Increased tumor stage .705 1.201 .464 3.110 
Larger tumor size  .021 2.991 1.179 7.587 
Step 4 Increased CHST3 expression .866 .933 .414 2.102 
Presence of lymph node invasion .185 1.707 .774 3.764 
PR+ status .179 1.939 .739 5.088 
ER+ status .114 .497 .209 1.182 
HER2+ status .167 .518 .204 1.315 
Larger tumor size .008 3.201 1.346 7.611 
Step 5 Increased CHST3 expression .847 .924 .413 2.069 
PR+ status .210 1.841 .709 4.778 
ER+ status .131 .516 .219 1.219 
HER2+ status .201 .549 .219 1.377 
Larger tumor size .003 3.532 1.514 8.238 
Step 6 Increased CHST3 expression .967 1.017 .459 2.252 
ER+ status .275 .636 .282 1.433 
HER2+ status .142 .504 .202 1.257 
Larger tumor size .003 3.593 1.540 8.382 
Step 7 Increased CHST3 expression .992 1.004 .452 2.229 
HER2+ status .235 .588 .245 1.413 
Larger tumor size .004 3.501 1.501 8.167 
Step 8 Increased CHST3 expression .931 .965 .437 2.135 
Larger tumor size .006 3.237 1.402 7.476 
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Table 3.11: Multivariate Cox regression analysis of CHST3 expression using OS.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased CHST3 expression .340 .579 .189 1.779 
Presence of lymph node invasion .373 1.558 .587 4.132 
PR+ status .543 1.432 .450 4.553 
ER+ status .199 .487 .162 1.459 
HER2+ status .234 .502 .162 1.559 
Increased tumor stage .709 .795 .239 2.646 
Race .849 .938 .485 1.814 
Larger tumor size  .009 5.188 1.502 17.921 
Increased age  .886 1.077 .389 2.981 
Step 2 Increased CHST3 expression .347 .587 .193 1.780 
Presence of lymph node invasion .376 1.552 .586 4.112 
PR+ status .498 1.467 .484 4.447 
ER+ status .186 .481 .162 1.424 
HER2+ status .233 .502 .162 1.557 
Increased tumor stage .717 .803 .244 2.639 
Race .824 .929 .487 1.772 
Larger tumor size  .009 5.202 1.508 17.949 
Step 3 Increased CHST3 expression .354 .592 .195 1.795 
Presence of lymph node invasion .344 1.586 .610 4.121 
PR+ status .502 1.464 .481 4.453 
ER+ status .180 .475 .160 1.409 
HER2+ status .214 .492 .161 1.506 
Increased tumor stage .669 .778 .245 2.467 
Larger tumor size .010 5.158 1.492 17.829 
Step 4 Increased CHST3 expression .408 .640 .222 1.842 
Presence of lymph node invasion .363 1.551 .602 3.993 
PR+ status .537 1.411 .473 4.209 
ER+ status .190 .491 .170 1.423 
HER2+ status .236 .511 .168 1.552 
Larger tumor size .008 4.659 1.487 14.603 
Step 5 Increased CHST3 expression .466 .678 .239 1.925 
Presence of lymph node invasion .390 1.510 .590 3.867 
ER+ status .249 .555 .204 1.511 
HER2+ status .205 .490 .163 1.476 
Larger tumor size .007 4.784 1.533 14.935 
Step 6 Increased CHST3 expression .440 .664 .235 1.877 
ER+ status .255 .562 .209 1.516 
HER2+ status .231 .515 .173 1.527 
Larger tumor size .005 5.087 1.650 15.683 
Step 7 Increased CHST3 expression .426 .655 .231 1.856 
HER2+ status .384 .629 .222 1.783 
Larger tumor size .006 4.920 1.597 15.163 
Step 8 Increased CHST3 expression .374 .625 .222 1.762 
Larger tumor size .007 4.633 1.517 14.147 
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Table 3.12: Multivariate Cox regression analysis of CHST3 expression using SAR.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased CHST3 expression .448 .640 .203 2.025 
Presence of lymph node invasion .997 1.002 .355 2.832 
PR+ status .874 1.102 .332 3.660 
ER+ status .297 .529 .160 1.749 
HER2+ status .541 .697 .218 2.223 
Increased tumor stage .728 .787 .205 3.029 
Race .654 .826 .359 1.903 
Larger tumor size  .028 4.120 1.167 14.542 
Increased age  .934 .960 .361 2.551 
Step 2 Increased CHST3 expression .448 .640 .203 2.024 
PR+ status .873 1.102 .334 3.637 
ER+ status .296 .529 .161 1.745 
HER2+ status .533 .697 .224 2.168 
Increased tumor stage .726 .787 .207 2.995 
Race .634 .826 .375 1.817 
Larger tumor size  .025 4.122 1.191 14.261 
Increased age  .935 .960 .362 2.545 
Step 3 Increased CHST3 expression .439 .637 .203 1.995 
PR+ status .882 1.094 .336 3.565 
ER+ status .294 .534 .165 1.725 
HER2+ status .536 .700 .226 2.168 
Increased tumor stage .728 .788 .207 3.010 
Race .638 .827 .376 1.821 
Larger tumor size  .023 4.079 1.211 13.734 
Step 4 Increased CHST3 expression .447 .648 .211 1.985 
ER+ status .266 .557 .199 1.560 
HER2+ status .540 .702 .227 2.173 
Increased tumor stage .744 .802 .213 3.013 
Race .644 .831 .379 1.823 
Larger tumor size  .023 4.059 1.209 13.625 
Step 5 Increased CHST3 expression .481 .674 .225 2.018 
ER+ status .281 .571 .206 1.581 
HER2+ status .559 .715 .232 2.204 
Race .491 .780 .385 1.581 
Larger tumor size  .023 3.854 1.204 12.337 
Step 6 Increased CHST3 expression .384 .624 .216 1.805 
ER+ status .338 .615 .228 1.662 
Race .450 .761 .375 1.545 
Larger tumor size  .027 3.624 1.156 11.365 
Step 7 Increased CHST3 expression .466 .676 .237 1.934 
ER+ status .432 .681 .262 1.774 
Larger tumor size .037 3.337 1.074 10.370 
Step 8 Increased CHST3 expression .494 .693 .243 1.980 
Larger tumor size .037 3.354 1.077 10.442 
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3.7 Expression Analysis of FLRT3 in Invasive Ductal Carcinoma Tissues  
 
The evaluation of FLRT3 was also extended to clinical tissue work as no studies 
thus far have reported on FLRT3 expression in breast cancer. FLRT3 expression in 
IDC patient cases was evaluated using the same tissue microarray used for CHST3 
expression analysis. From the in vitro studies, it can be concluded that FLRT3 plays 
a tumor promoter role in breast cancer tumorigenesis; the down-regulation of 
FLRT3 brings forth less aggressive and metastatic behaviors in breast cancer cells. 
Therefore, we would like to investigate if these observations can be extended to 
clinical patient samples. We would hypothesize that high expression of FLRT3 in 
human breast cancer tissue is correlated with worse prognosis and clinical 
parameters. As a result of tissue loss during the immunohistochemistry process, the 
expression patterns of CHST3 were examined in 258 cases (208 IDC cases and 50 



















3.7.1 FLRT3 Expression Pattern in Breast Tissues  
 
FLRT3 expression staining was positive in the epithelial compartment of both 
normal and malignant breast tissues as shown in Figure 3.48.   
 
 
Figure 3.48: Staining pattern of FLRT3 in breast tissues.  
FLRT3 expression was observed in the epithelial compartment of normal and malignant 









3.7.2 FLRT3 Selected Cut-off Point  
 
Selecting a suitable cut-off point for FLRT3 was also carried out first analysing the 
distribution curve of the staining intensities gathered from the breast tissues. 
Though a non-normal distribution curve (Figure 3.49A) was observed, the mean 
was selected to be the cut-off point for FLRT3 (Figure 3.49C) as the mean 
compared to the median cut-off point has a better balance in terms of sensitivity 
and false positivity scores. The mean cut-off point shows a sensitivity score of 
0.601 (Figure 3.49D), false positivity score between 0.000 and 0.180 (Figure 
3.49D), and area under curve is 0.719 (Figure 3.49B), which is above 0.500.  
 
 
Figure 3.49:  Frequency distribution and ROC curve of FLRT3 expression among normal 
and malignant tissues  
(A) Histogram illustrates the frequency distribution of the WAI score of FLRT3 expression 
across both normal and malignant tissues. (B) ROC curve depicts WAI score of FLRT3 
expression of normal and malignant tissues following their sensitivity and 1-specificity 
score. The area under curve is 0.719, which is above 0.500.   
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3.7.3 FLRT3 Expression in Normal and Malignant Breast Tissues  
 
 
Expression of FLRT3 epitope was evaluated in the epithelial (cytoplasm) 
compartment of ductal specimens. Analysis of the tissue microarrays showed that 
malignant IDC tissues had enhanced staining in comparison to normal ductal 
tissues as shown in Figure 3.50 and Table 3.13 (p-value = 0.000). Further analysis 
was also performed on paired normal and malignant breast tissues, of which results 
showed decreased FLRT3 expression level in the normal tissues compared to its 
paired malignant counterpart tissue (Figure 3.51). 
 
 
Figure 3.50:  FLRT3 immunostaining in normal and malignant breast tissues  
Higher expression of FLRT3 was observed in malignant breast tissues (with overall 
staining intensities of 1+ and 2+) compared to the normal breast tissues (with overall 











Table 3.13: Analysis of FLRT3 expression between normal and malignant breast tissues  
FLRT3 expression is significantly enhanced in malignant breast tissues in 
comparison to normal breast tissues.  
 
 Total Percentage Staining 
 ≤ 0.55 > 0.55 p-value 
Diagnosis 
     Normal 











Figure 3.51:  Paired analysis of FLRT3 expression in 26 paired normal and malignant 
breast tissue samples.  
Normal tissues shows reduced expression level of FLRT3 compared to malignant 
tissues.  
 
3.7.4 FLRT3 Correlations with Clinicopathological Parameters  
 
Following expression analysis using WAI (cutoff at 0.55), FLRT3 expression level 
was analyzed against the various clinicopathological parameters (Table 3.14).  
Enhanced FLRT3 staining was observed in patients with enhanced lymphovascular 






Table 3.14 Correlations between FLRT3 expression and clinicopathological features of 
IDC 
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HER2 receptor status 
     Negative 
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     NA 
    















3.7.5 Survival Analysis of FLRT3 Expression  
 
3.7.5.1 Survival Analysis using Kaplan Meier  
 
Survival analysis was performed using Kaplan Meier curves to observe any general 
trends between FLRT3 expression and tumor recurrence and mortality rate. No 
significant trends were observed for FLRT3 expression with patients’ tumor 
recurrence and mortality rate, as shown in Figure 3.52. 
  
 
Figure 3.52: Kaplan Meier curves using FLRT3  
No significant trend was observed between FLRT3 expression and (A) tumor recurrence, 







3.7.5.2 Survival Analysis using Cox Regression Univariate 
 
Cox regression analysis using univariate method was performed to determine the 
hazard ratio of FLRT3 expression as well as for the clinicopathological parameters. 
Several significant hazard ratios were obtained for various clinical parameters. 
However, no significant hazard ratios were attained for FLRT3 expression in 
disease-free survival (Table 3.15), overall survival (Table 3.16), as well as survival 
after recurrence (Table 3.17) time period. 
 
Table 3.15: Univariate Cox regression analysis of FLRT3 and clinicopathological 
parameters using DFS time period 
 
Disease Free Survival 
p-value Hazard ratio 
95% CI 
Lower Upper 
Increased FLRT3 expression  
.795 1.164 .371 3.663 
Presence of lymph node invasion 
.813 1.158 .345 3.889 
PR+ status 
.051 5.512 .993 30.600 
ER+ status 
.638 .763 .247 2.357 
HER2+ status 
.353 .487 .107 2.219 
Increased lymphovascular invasion stage 
.915 .000 .000 1.365E63 
Increased tumor stage 
.328 1.942 .514 7.338 
Race 
.152 .532 .224 1.263 
Increased histological grade 
.863 1.191 .164 8.646 
Increased tubule formation stage 
.788 .834 .222 3.133 
Increased pleomorphism stage 
.590 1.508 .338 6.721 
Increased mitotic index 
.299 1.764 .605 5.143 
Increased lymph node stage 
.918 3303.709 .000 1.893E70 
Larger tumor size  
.780 .854 .282 2.583 
Increased age  







Table 3.16: Univariate Cox regression analysis of FLRT3 and clinicopathological 
parameters using OS time period 
 
Overall Survival 




Increased FLRT3 expression  
.291 2.445 .466 12.838 
Presence of lymph node invasion 
.463 1.837 .363 9.297 
PR+ status 
.054 12.006 .956 150.760 
ER+ status 
.358 .481 .101 2.290 
HER2+ status 
.775 1.305 .211 8.076 
Increased lymphovascular invasion stage 
.920 .000 .000 2.575E74 
Increased tumor stage 
.842 .826 .126 5.401 
Race 
.109 .256 .048 1.359 
Increased histological grade 
.540 2.533 .130 49.446 
Increased tubule formation stage 
.422 .416 .049 3.536 
Increased pleomorphism stage 
.688 1.503 .206 10.944 
Increased mitotic index 
.100 3.507 .786 15.641 
Increased lymph node stage 
.921 9873.267 .000 2.754E82 
Larger tumor size  
.883 .889 .186 4.253 
Increased age  














Table 3.17: Univariate Cox regression analysis of FLRT3 and clinicopathological 
parameters using SAR time period 
 
Survival after Recurrence 




Increased FLRT3 expression  
.073 5.272 .857 32.434 
Presence of lymph node invasion 
.711 1.352 .274 6.677 
PR+ status 
.160 7.163 .458 111.954 
ER+ status 
.182 .288 .046 1.794 
HER2+ status 
.647 1.600 .215 11.931 
Increased lymphovascular invasion stage 
.899 .000 .000 4.808E53 
Increased tumor stage 
.701 .666 .083 5.310 
Race 
.071 .118 .012 1.199 
Increased histological grade 
.970 .940 .039 22.774 
Increased tubule formation stage 
.770 .708 .070 7.160 
Increased pleomorphism stage 
.599 1.952 .162 23.565 
Increased mitotic index 
.093 4.030 .793 20.486 
Increased lymph node stage 
.901 4376.959 .000 1.113E61 
Larger tumor size  
.496 1.874 .307 11.451 
Increased age  














3.7.5.3 Survival Analysis using Cox Regression Multivariate 
 
As no significant hazard ratio was obtained through the univariate method, analysis 
using Cox regression multivariate survival analysis (Table 3.18-20) using 
clinicopathological parameters were performed. A borderline significant trend that 
high FLRT3 expression in IDC patients was associated with higher tumor 
recurrence with a hazard ratio of 2.445 (p-value = 0.054) when adjusted for the 
clinicopathological parameters.  Tumor size was also found to have significant 





Table 3.18: Multivariate Cox regression analysis of FLRT3 expression using DFS.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased FLRT3 expression .088 2.247 .887 5.714 
Presence of lymph node invasion .746 1.161 .471 2.864 
PR+ status .212 2.038 .666 6.243 
ER+ status .380 .656 .256 1.681 
HER2+ status .121 .413 .135 1.262 
Increased tumor stage .451 1.508 .519 4.383 
Race .341 .689 .321 1.482 
Larger tumor size  .040 2.830 1.048 7.645 
Increased age  .369 1.502 .618 3.652 
Step 2 Increased FLRT3 expression .085 2.262 .893 5.714 
PR+ status .219 2.014 .659 6.149 
ER+ status .390 .663 .260 1.693 
HER2+ status .128 .426 .142 1.277 
Increased tumor stage .389 1.576 .560 4.439 
Race .307 .674 .316 1.437 
Larger tumor size  .035 2.886 1.078 7.729 
Increased age  .349 1.524 .631 3.682 
Step 3 Increased FLRT3 expression .054 2.445 .983 6.061 
PR+ status .340 1.659 .586 4.701 
HER2+ status .165 .462 .155 1.373 
Increased tumor stage .339 1.673 .582 4.804 
Race .276 .655 .306 1.403 
Larger tumor size  .036 2.852 1.069 7.604 
Increased age  .350 1.529 .628 3.726 
Step 4 Increased FLRT3 expression .068 2.294 .942 5.587 
PR+ status .248 1.828 .656 5.094 
HER2+ status .212 .508 .176 1.471 
Increased tumor stage .374 1.587 .573 4.392 
Race .214 .618 .290 1.320 
Larger tumor size  .029 2.972 1.120 7.884 
Step 5 Increased FLRT3 expression .093 2.075 .885 4.854 
PR+ status .263 1.788 .646 4.948 
HER2+ status .179 .487 .171 1.390 
Race .272 .667 .324 1.373 
Larger tumor size  .004 3.660 1.526 8.776 
Step 6 Increased FLRT3 expression .072 2.198 .932 5.181 
HER2+ status .099 .420 .150 1.179 
Race .270 .665 .323 1.372 
Larger tumor size  .003 3.734 1.550 8.996 
Step 7 Increased FLRT3 expression .100 2.041 .872 4.785 
HER2+ status .098 .420 .150 1.174 




Table 3.19: Multivariate Cox regression analysis of FLRT3 expression using OS.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased FLRT3 expression .345 1.733 .554 5.405 
Presence of lymph node invasion .910 1.066 .351 3.239 
PR+ status .584 1.454 .380 5.564 
ER+ status .465 .636 .189 2.139 
HER2+ status .141 .346 .084 1.421 
Increased tumor stage .875 .890 .210 3.780 
Race .331 .513 .133 1.974 
Larger tumor size  .014 5.279 1.392 20.017 
Increased age  .600 1.336 .452 3.948 
Step 2 Increased FLRT3 expression .337 1.742 .561 5.405 
PR+ status .590 1.443 .380 5.477 
ER+ status .469 .644 .195 2.124 
HER2+ status .139 .352 .088 1.405 
Increased tumor stage .893 .908 .223 3.698 
Race .321 .507 .133 1.936 
Larger tumor size  .014 5.314 1.409 20.036 
Increased age  .592 1.343 .457 3.946 
Step 3 Increased FLRT3 expression .298 1.783 .600 5.291 
PR+ status .595 1.433 .380 5.402 
ER+ status .475 .650 .200 2.116 
HER2+ status .141 .354 .089 1.412 
Race .301 .498 .133 1.865 
Larger tumor size  .006 5.092 1.585 16.360 
Increased age  .592 1.343 .457 3.942 
Step 4 Increased FLRT3 expression .236 1.908 .656 5.555 
ER+ status .604 .754 .260 2.190 
HER2+ status .124 .338 .085 1.347 
Race .312 .508 .137 1.887 
Larger tumor size  .006 5.162 1.606 16.592 
Increased age  .514 1.421 .495 4.082 
Step 5 Increased FLRT3 expression .215 1.957 .677 5.650 
HER2+ status .148 .372 .098 1.419 
Race .310 .509 .138 1.875 
Larger tumor size  .006 5.119 1.598 16.400 
Increased age  .541 1.388 .485 3.978 
Step 6 Increased FLRT3 expression .221 1.931 .842 5.524 
HER2+ status .165 .393 .105 1.469 
Race .280 .487 .132 1.797 
Larger tumor size  .005 5.273 1.650 16.849 
Step 7 Increased FLRT3 expression .413 1.529 .554 4.219 
Race .274 .454 .111 1.867 
Larger tumor size  .008 4.699 1.491 14.814 
Step 8 Increased FLRT3 expression .468 1.458 .528 4.016 
Larger tumor size .013 4.287 1.364 13.480 
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Table 3.20: Multivariate Cox regression analysis of FLRT3 expression using SAR.  
  
p-value Hazard Ratio 
95% Confidence Interval 
  Lower Upper 
Step 1 Increased FLRT3 expression .919 1.062 .334 3.378 
Presence of lymph node invasion .686 .782 .238 2.571 
PR+ status .672 1.359 .329 5.619 
ER+ status .374 .554 .150 2.039 
HER2+ status .254 .437 .105 1.812 
Increased tumor stage .790 .804 .161 4.012 
Race .279 .416 .085 2.039 
Larger tumor size  .027 4.500 1.191 16.999 
Increased age  .582 1.364 .451 4.126 
Step 2 Increased FLRT3 expression .846 1.115 .371 3.356 
Presence of lymph node invasion .623 .751 .239 2.358 
PR+ status .697 1.318 .328 5.298 
ER+ status .388 .574 .162 2.027 
HER2+ status .264 .451 .111 1.825 
Race .225 .388 .084 1.788 
Larger tumor size  .021 4.211 1.239 14.307 
Increased age  .576 1.371 .454 4.136 
Step 3 Increased FLRT3 expression .797 1.153 .387 3.436 
Presence of lymph node invasion .600 .737 .235 2.308 
ER+ status .447 .653 .218 1.956 
HER2+ status .277 .464 .116 1.854 
Race .238 .406 .091 1.813 
Larger tumor size  .022 4.186 1.232 14.216 
Increased age  .541 1.406 .471 4.198 
Step 4 Increased FLRT3 expression .854 1.106 .376 3.257 
ER+ status .433 .643 .214 1.936 
HER2+ status .241 .440 .111 1.737 
Race .263 .431 .099 1.882 
Larger tumor size  .026 3.876 1.179 12.740 
Increased age  .586 1.348 .461 3.943 
Step 5 Increased FLRT3 expression .834 1.121 .385 3.268 
ER+ status .442 .648 .215 1.958 
HER2+ status .265 .459 .117 1.803 
Race .266 .435 .100 1.888 
Larger tumor size  .017 4.137 1.283 13.337 
Step 6 Increased FLRT3 expression .806 1.144 .391 3.344 
HER2+ status .356 .540 .146 1.998 
Race .296 .467 .112 1.948 
Larger tumor size  .021 3.892 1.223 12.383 
Step 7 Increased FLRT3 expression .990 1.007 .351 2.890 
Race .281 .440 .099 1.957 
Larger tumor size  .027 3.688 1.157 11.751 
Step 8 Increased FLRT3 expression .889 1.076 .384 3.012 
Larger tumor size .043 3.296 1.040 10.444 
 157 
3.8 Correlation of CHST3 and FLRT3 Expression in Invasive Ductal 
Carcinoma 
 
Evaluation was also performed on whether the expression levels of CHST3 and 
FLRT3 are correlated in human tissue samples of IDC. No significant association 
was observed between the expression levels of CHST3 and FLRT3 in the evaluated 
set of IDC tissues (Table 3.21).    
 
Table 3.21: Correlation of CHST3 with FLRT3 expression in IDC tissues  
No significant association was obtained between CHST3 and FLRT3 expression levels in 
IDC breast tissues.  
 
 FLRT3 expression 
 WAI ≤ 0.55 WAI > 0.55 p-value 
CHST3 expression 
    WAI ≤ 1.06 
    WAI  > 1.06 





























3.9 Summary of Results 
 
This study first focused on the significance of CHST3 in breast cancer phenotypic 
behaviors. The regulatory roles of CHST3 were examined in T47D, MCF7 and 
MDA-MB-231 cell lines through various functional experiments including cell 
migration, invasion, adhesion, proliferation, cell cycle, and apoptosis assays. Also, 
several potential molecules were studied on their associations with CHST3 pathway. 
This study would be the first evaluation performed to elucidate the functional roles 
as well as expression studies of CHST3 and FLRT3 in breast cancer. Table 3.22 and 
3.23 summarize the results obtained.  
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3.9.1 CHST3 Regulates Cell Migration  
 
Cancer cells have the potential to reach metastatic potential, migrating from the 
primary tumor to a distant secondary site (organ) via the blood vessels and 
lymphatic vessels (Simpson et al., 2010, Moutasim et al., 2011). To evaluate the 
effect of CHST3 on cell motility, migration assay using migration chambers was 
carried out after silencing as well as over-expression of CHST3. Significant 
increase in cell migration was observed upon silencing of CHST3 whereas 
significant decrease was observed after over-expression of CHST3 in the breast 
cancer cells.  
 
3.9.2 CHST3 Regulates Cell Invasion  
 
Cell invasion of the tumor cell arise from the interaction of the cancer cells with 
surrounding cells as well as the extracellular matrix and stroma. Invasive tumors 
can metastasize to adjacent tissues as well as migrate to other organs in the body. 
In the case of breast cancer, the tumor cells usually metastasize to the lungs, liver, 
bone, and brain. The cancer cells will invade the basement membrane that lines the 
epithelial cells, hence invading to the surrounding environment. To replicate this 
event, invasion assay using matrigel invasion chambers was performed. Down-
regulation of CHST3 increased cell invasion whereas over-expression of CHST3 
decreased cell invasion.   
 
3.9.3 CHST3 Regulates Cell Adhesion  
 
Cell adhesion also has a major role in cancer cell aggressive and metastatic behavior. 
Cancer cells will usually have weaker cell adhesion compared to normal cells, 
causing the cancer cells to metastasize more easily to surrounding tissues and other 
organs (Ruoslahti, 1984). Adhesion assay was performed using either collagen I or 
fibronectin coated plates. Upon silencing of CHST3, small decreases in cell 
adhesion in both coated plates were observed. The opposite observation was 
obtained for cells over-expressed with CHST3, which is an increase in cell adhesion. 
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These would suggest that CHST3 modulates the expression level of adhesion 
molecule(s), which would in turn adhere to collagen and/or fibronectin, and 
regulates cell adhesion level.  
 
3.9.4 CHST3 Regulates Cell Proliferation  
 
In the proliferation assay performed using MTS solution, silencing of CHST3 
resulted in a small increase in the number of viable T47D and MDA-MB-231 cells. 
On the other hand, over-expression of CHST3 in MCF7 and MDA-MB-231 cells 
led to a small decrease in cell proliferation. It should be noted that the change in 
cell viability can not only be attributable to rate of cell proliferation but also rate of 
cell apoptosis or both events. Flow cytometry was also performed to further analyze 
cell proliferation and to observe whether cell death occurred after silencing of 
CHST3. Cell cycle analysis showed decreases in cell death at the sub-G1 phase for 
T47D and MDA-MB-231 cell lines. However, only T47D cell line showed a slight 
change (reduction) at the DNA replication phase (S phase). This may signify the 
changes in cell numbers could be due more to cell death.  
 
3.9.5 CHST3 Regulates Cell Apoptosis  
 
To verify the sub-G1 observations, apoptosis assay was performed. Fluorescence 
measurement showed reductions in caspases 3 and 7 levels upon down-regulation 
of CHST3. This hence indicates the potential ability of CHST3 in regulating cell 
viability through cell apoptosis. 
 
3.9.6 CHST3 Effects on Downstream Molecules  
 
Moving on to the downstream molecular work, based on the microarray analysis, 
both GPNMB and FLRT3 were found to be up-regulated after down-regulation of 
CHST3. Therefore, the downstream relationship of GPNMB or FLRT3 and CHST3 
was validated through functional studies. Silencing of CHST3 increased cell 
survival and cell motility whereas silencing of GPNMB or FLRT3 showed 
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otherwise, decreased cell survival and cell motility. Upon double silencing of 
CHST3 and GPNMB or FLRT3, the levels of cell proliferation, cell adhesion, cell 
migration, and cell invasion were similar to that of the control group, indicating 
that phenotypic behavior changes observed during single silencing of either CHST3 
or GPNMB or FLRT3 were diminished and returned to basal level. This suggests 
that GPNMB and FLRT3 are downstream molecules of CHST3 given that the 
cellular behaviors were similar to the double negative group after double silencing.  
 
In addition to GPNMB and FLRT3, silencing of CHST3 in T47D cells gave rise to 
reduced expression of E-cadherin and β-catenin as well as enhanced expression of 
pBAD/BAD, all of which have involvement in the various cellular behavior 
changes especially for the main alterations in cell migration and invasion. This will 
be further elaborated later in this chapter. 
 
3.9.7 CHST3 and FLRT3 in Breast Tissues  
 
From the immunohistochemistry analysis, CHST3 and FLRT3 expression levels 
were observed to be significantly higher and lower respectively in the epithelial 
compartment of normal ductal tissues as compared to that of the malignant tissues. 
Significant associations were also found between CHST3 expression and several 
clinicopathological parameters that are low CHST3 expression is significantly 
linked to higher tumor stage. Additionally, CHST3 expression is borderline 
significantly associated with larger tumor size. Significant correlations were also 
found between FLRT3 expression and clinicopathological parameters – higher 
FLRT3 expression was associated with patients with older age and greater stage of 
lymphovascular invasion. In terms of prognosis, from the multivariate survival 
analysis, no observable trend was observed for CHST3. For FLRT3, there was 
borderline significance in that higher tumor recurrence risk was observed for 
enhanced FLRT3 expression upon adjusting for confounding factors. Additionally, 
there was no significant association between CHST3 and FLRT3 expression levels 





















4.1 Potential Role of CHST3 in Breast Cancer 
 
With growing evidence that proteoglycans and their glycosaminoglycan chains 
play substantial roles in regulating cancer behavior, the roles of chondroitin- and 
heparan-related enzymes have also been investigated in recent years. A few of the 
more well studied enzymes in this field are heparanase (Ilan et al., 2006, Vlodavsky 
et al., 2007a, Vlodavsky et al., 2007b) and chondroitin sulfotransferase 11 or 
CHST11 (Cooney et al., 2011, Potapenko et al., 2010), both enzymes having been 
associated with tumorigenesis. CHST3, or otherwise known as chondroitin-6-
sulfotransferase 1 (C6ST1), has been investigated in greater detail in the field of 
musculoskeletal disease; the de-regulation of CHST3 expression level is associated 
with the diagnosis of spondyloepiphyseal dysplasia which has a deficiency in the 
expression level of CHST3 (Tuysuz et al., 2009, van Roij et al., 2008). The interest 
to pursue evaluations of CHST3 built up when it is also found to be potentially 
regulating cancer cell behavior, such as those studied by Kalathas et al and Maupin 
et al (Kalathas et al., 2010, Maupin et al., 2010) in laryngeal and pancreatic cancer 
respectively. Being a relatively new enzyme, CHST3 is yet to be evaluated for its 
potential roles in breast cancer and its signaling pathways is yet to be uncovered.  
 
This study has been carried out with a focus on evaluating the expression level as 
well as the functional roles of CHST3 in breast cancer and whether CHST3 is a 
potential marker for diagnosis, prognosis, or therapy in breast cancer. The in vitro 
experiments that were carried out included cell migration, invasion, adhesion, 
proliferation, and cell cycle assays, which were performed to investigate CHST3’s 
potential role in regulating typical cancer cell behaviors or hallmarks. Taken 
together the observations obtained from this study, they potentially support the 
notion that CHST3 expression level in epithelial breast cancer cells affect 
metastatic phenotype. Upon silencing or overexpressing CHST3 in the three 
different breast cancer cells (T47D, MCF7, and MDA-MB-231), CHST3 is 
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observed to regulate cell migration and cell invasion substantially and at greater 
extent compared to the other phenotypic assays carried out. Further evaluations of 
microarray-analyzed genes (GPNMB and FLRT3), EMT markers (E-cadherin and 
β-catenin), and other signaling pathways’ molecules (JAK2, STAT3, and BAD) 
showed expression changes after modulation of CHST3 expression level, pointing 
to the possibility of CHST3 having a substantial role in their signaling processes. 
In the IDC tissue expression study, it is observed that low CHST3 expression levels 
is correlated with malignant tissues as compared to normal ductal tissues. 
Additionally, lower levels of CHST3 expression is found to be associated with 
higher tumor grade in IDC tissue samples. 
 
The next critical question then would be on how CHST3 potentially regulates the 
phenotypic behaviors observed. To have a certain understanding of how CHST3 
functions or regulates, one may look into its substrate’s functional roles, expression 
levels, and regulation in breast cancer instead. CHST3 is a sulfotransferase enzyme 
responsible for the carbon-6 sulfation pattern of galactosamine unit in chondroitin 
sulfate. The chondroitin sulfate itself or together with the proteoglycan portion, 
chondroitin sulfate proteoglycan, has been evaluated in breast cancer and has 
shown regulating capabilities towards cellular behavior in breast cancer. Also, the 
closest related gene or protein studied to date in breast carcinoma would be 
CHST11, which will be elaborated later on.  
 
4.1.1 Potential Role of CHST3 through Chondroitin Sulfate 
 
Past studies conducted have shown significant associations of CS expression with 
regards to breast cancer. Researchers studied CS expression in general, showing 
that changes in the cell surface CS expression level consequently alters ECM-
degradative enzymes, such as matrix metalloproteinases, which in turn affects the 
breast cancer cells’ invasiveness and cell-matrix interactions (Yip et al., 2006). 
From in vitro studies, breast cancer cells have been seen to have general increased 
expression of CS levels and are linked to augmented cell proliferation and 
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migration, making the cells more aggressive and metastatic (Kieber-Emmons et al., 
2011, Alini and Losa, 1991, Olsen et al., 1988). At the tissue level, CS levels are 
observed to be significantly elevated in the stromal compartment of breast tumors 
(Ricciardelli et al., 2002, Suwiwat et al., 2004). Cooney et al evaluated the effect 
of specific chondroitin sulfate types in breast cancer. Carbon-4 sulfated CSA is 
shown to be expressed at increased levels in human breast cancer cells with high 
metastatic capacity (MDA-MB-231 and MDA-MET) compared to less aggressive 
cell line, MCF7 (Cooney et al., 2011)). CSE, another CS containing carbon-4 
sulfation pattern, has also been considered a tumor promoter molecule, whereby 
functional studies in vitro showed over-expression of CSE promotes angiogenesis 
and anti-apoptotic cell behavior (Cooney et al., 2011, Grose and Dickson, 2005). 
Unlike their carbon-4 sulfated CS counterparts, carbon-6 sulfated CSC and CSD 
chains have been observed to be down-regulated in breast carcinomas (Potapenko 
et al., 2010), hence may be characterized as tumor suppressors. The differential 
roles of the various chondroitin sulfate types are also observed in other cases. In 
wound healing, Zou et al studied the effects of chondroitin-4-sulfate (CSA) and 
chondroitin-6-sulfate (CSC) on wound healing in which the group observed CSC 
to increase while CSA decreases cell adhesion levels in palatal fibroblasts (Zou et 
al., 2004).  
 
At the sulfotransferase level, CHST11 is responsible for the transfer of a sulfate 
group to the carbon 4 of galactosamine unit to form CSA and CSE. The epithelial 
expression level of CHST11 is significantly up-regulated in more aggressive breast 
cancer cells (MDA-MB-231, MDA-MB-468, and MDA-MET) in comparison to 
their less aggressive metastatic cell line counterpart (MCF7). The same trend is also 
displayed at the tissue level, whereby CHST11 is over-expressed in malignant 
specimens against their adjacent non-malignant breast tissues (Cooney et al., 2011, 
Potapenko et al., 2010). One of CHST11 product, CSA, as mentioned has increased 
expression level in breast cancer cells of higher tumor grade. This would lead to 
further plausibility that CHST11 and its product, CSA are correlated to aggressive 
and metastatic capacities of breast cancer cells.  
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In view of these observations, the expression level of CHST3 as well as potentially 
its product, CSC, may then be suppressed when there are enhanced levels of 
CHST11 and its CS products, causing tumor suppressing effects to be reduced. 
From the observations in this study, CHST3 has shown the opposite trends 
compared to CHST11. Through the patient IDC tissue samples, it is observed that 
a significant proportion of IDC tissues samples display lower levels of CHST3 as 
compared to the normal ductal tissues. This observation is similar to that observed 
in vitro whereby the breast cancer cells have decreased levels of CHST3 in 
comparison to MCF12A normal breast cells. Both cell line work and tissue study 
show expression of CHST3 within the epithelial cells. In the tissue study, it is noted 
that CHST3 is not expressed in the stroma region of the ductal tissue for both 
malignant and normal types. Further examination of the expression levels of 
CHST3 in the malignant tissues showed significant association between low levels 
of CHST3 and greater tumor stage. Again, this can be observed from the in vitro 
studies of which Grade 1 breast cancer cell lines T47D and MCF7 have higher 
levels of CHST3 against Grade 3 MDA-MB-231 breast cancer cells. It is to be noted 
that tumor size has a borderline association with CHST3 expression level. Further 
evaluations would be necessary to investigate whether both CHST3 and CHST11 
act from within the epithelial regions and affects the CS chains as well as CSPGs 
that are on the cell surface and stroma regions.  
 
Another notion in this study was to investigate whether the regulation of CHST3 
has different effects on different grades and hormonal status of breast cancer cells. 
The establishment of the hormonal type and grade of cancer the patient has 
determined the type of therapy strategy as well as most importantly, ascertain the 
survival rate of the patient. Molecular diagnosis using various established 
biomarkers such as BRCA1, BRCA2, ER, PR, and HER2 are performed for 
diagnostic examination in breast cancer (Huston, 2005). In recent years, CSPGs 
such as versican (VCAN or CSPG2) and CSPG4 have been evaluated of their 
diagnostic and prognostic capabilities as a biomarker in breast cancer. Both VCAN 
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and CSPG4 are up-regulated in malignant breast tissues compared to normal breast 
tissues (Yee et al., 2007, Wang et al., 2010b). Survival analysis indicated VCAN 
expression is a good predictor of relapse-free survival; enhanced expression of 
VCAN in the stromal is associated with higher risk and rate of relapse in breast 
cancer patients (Ricciardelli et al., 2002, Suwiwat et al., 2004). Additionally, it is 
evaluated that increased VCAN expression is associated with higher expression 
levels of ER and PR in malignant–appearing microcalcifications (MAMCs) 
(Skandalis et al., 2011). In the case of CSPG4, CSPG4-specific antibody has been 
shown to inhibit tumor growth and metastasis as well as reduce risk of tumor 
recurrence in vivo in a lung metastasis model (Wang et al., 2010a). No associations 
of CSPG4 with ER or PR status have since been reported.  
 
Comparing the changes in phenotypic behavior in the three breast cancer cells 
examined in this study, the extent of changes are relatively similar with the 
exception of cell invasion. Compared against T47D and MCF7 Grade 1 (ER+/PR+) 
breast cancer cells, MDA-MB-231 Grade 3 (ER-/PR-) breast cancer cells showed 
lesser extent of changes in cell invasion for both silencing and overexpression 
studies. Moreover, there were no significant correlation between CHST3 
expression levels with the various hormonal biomarker statuses in the IDC tissue 
expression study. The reason(s) to this limitation will need to be explored further; 
a difference in gene expression may potentially be the cause to the difference in 
extent of changes observed. One possible method will be to carry out microarray 
studies on CHST3-silenced and CHST3-overexpressed MDA-MB-231 cells. The 
gene list generated from the microarray studies can then be compared against those 
obtained from the microarray study carried out using T47D cells.  
 
From past CS-related in vitro studies, there has been associations of CS levels and 
its effect on cellular behavior such as cell proliferation, apoptosis, migration, and 
invasion. From the various cell lines experimented on in this study, little impact has 
been observed for cell proliferation phenotype. There are also observations that 
differ between the observations from the in vitro studies and that in the expression 
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studies on human IDC tissues. While the in vitro work showed impact towards 
cellular migratory and invasive behaviors, the analysis carried out on the ductal 
tissues showed otherwise. As an example, there is no significant association 
between CHST3 expression level and lymphovascular invasion. Though CHST3 
has some diagnostic value, no significant value is found in this population of 
patients’ tissues in terms of it being a potential prognostic marker.  
 
Looking further into detail from the results of the experiments, in the case of cell 
adhesion, apart from investigating whether cell adhesion would be affected upon 
regulation of CHST3 expression, it was also to be evaluated whether the breast 
cancer cells’ adhesive behavior would be similar or different towards various 
extracellular matrix components such as fibronectin and collagen. In the case of 
chondroitin sulfate cousin molecules - heparan sulfate - depending on the cell type, 
cell surface heparan sulfate can have different binding affinity towards different 
ECM components; in myeloma, heparan sulfate can attach to collagen but has no 
adhesiveness towards fibronectin (Stamatoglou and Keller, 1983). It is firstly 
observed, in the in vitro study, that the changes are to a small extent for the cell 
adhesion experiments performed, signifying that CHST3 may not have much 
biological importance in cell adhesion in breast cancer cells. Similar extent of 
changes are also observed when either collagen or fibronectin was used in the 
experiments for the three breast cancer cell lines. This may indicate that CHST3 
effects are similar in the different breast cancer cells during the presence of collagen 
or fibronectin.  
 
Cell proliferation changes are also not as substantial as cell migration and cell 
invasion in all the experiments carried out; the small extent of changes are 
consistent throughout the silencing and overexpressing experiments as well as for 
the various breast cancer cells used. Nevertheless, cell cycle assays were also 
carried out to validate the observations. The cell cycle assay showed that cell death 
may be at play and that the cell growth changes may potentially be affected by 
changes in the S phase (DNA replication) of cell cycle. Additionally, from the 
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microarray carried out for the CHST3-silenced T47D cells, a total of 20 genes 
having functional roles in cell proliferation are seen to have more than 2-fold 
changes. For cell migration, 14 genes having migratory roles are picked up after 
analysis. This may indicate that there are cancelation effects by the genes affected 
or that some of the genes that have been regulated do not serve any functional 
importance for cell proliferation. 
 
Apart from understanding CHST3’s regulatory effect on the functional roles 
observed in breast cancer from this main potential angle, there are other possibilities 
of how CHST3 regulates the various phenotypic behaviors in breast cancer. 
 
4.1.2 CHST3 affects Downstream Molecules GPNMB and FLRT3 
 
The CHST3 pathway was evaluated through a microarray study. GPNMB and 
FLRT3 genes were selected from the microarray list for further evaluation on 
whether both molecules are involved in CHST3 pathway that affected the 
phenotypic changes occurred. Results from the double silencing experiments have 
suggested that GPNMB and FLRT3 are downstream of CHST3 in regulating the 
phenotypic changes observed. As mentioned previously, it is important to note the 
small changes in cell proliferation observed in this study, as compared to the more 
substantial changes seen in cell migration and invasion. GPNMB has been 
previously studied by Rose et al (Rose et al., 2010) whereby it was observed that 
overexpression of ectopic GPNMB increases the invasive and migratory 
phenotypes in BT549 breast cancer cells by at least 50%. Their complementary 
experiments through silencing of GPNMB in SUM1315 cells brought forth 
reduction in cell invasion capability. The cell invasion assays carried out in this 
study validates the research group’s findings whereby T47D cells’ invasive 
capability decreased upon silencing of GPNMB. This effect is observed to be 
neutralized upon double silencing of CHST3 and GPNMB, indicating GPNMB to 
be downstream of CHST3. Additionally, Rose et al observed that cell growth was 
unaffected after overexpressing GPNMB in BT549 cells. In this study, GPNMB-
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silenced cells was observed to have non-substantial change in cell proliferation 
level. This possibly indicates that the effects of GPNMB in breast cancer cell 
migration and invasion is not, at a large extent, attributed to the enhancement in 
cell proliferation. Additionally, this may suggest that CHST3 have a biologically 
non-important cell proliferation role in breast cancer.  
 
Similar to CHST3, FLRT3 is also a relatively new gene of which its expression 
level and functional roles are yet to be unraveled in the cancer field. From the in 
vitro work carried out, it is observed that FLRT3 plays an oncogenic role as 
compared to tumor suppressor CHST3. Indeed, the pro-metastatic changes by 
FLRT3 are neutralized by CHST3 in the double silencing study of both genes. 
Additionally, to note, the effects of FLRT3 on cell proliferation and cell adhesion 
are similar to the effects shown from regulation of CHST3 or GPNMB, whereby 
smaller degree and non-substantial changes were observed in both of these 
phenotypic behaviors.  
 
For FLRT3, the observations from the in vitro work are partly extended to the 
observations collected in the tissue expression study. FLRT3 expression is seen to 
display greater intensity in malignant ductal cells compared to its normal ductal cell 
counterpart. In vitro, it is only observed that FLRT3 expression is greater in Grade 
3 breast cancer cells compared to Grade 1 breast cell lines. This observation or 
association is not significant when analysis was carried out between FLRT3 
expression in the malignant ductal tissues and grades of the tissues. Nevertheless, 
from the FLRT3 tissue study, FLRT3 expression in the invasive ductal tissues is 
significantly correlated to lymphovascular invasion stage. Also, its expression level 
is analyzed to be not significantly correlated to tumor size. This potentially 
indicates that there are certain extensity of the observations from in vitro to human 
tissue samples. This is as, from the cell line work, silencing of FLRT3 caused 




Due to the similar characteristics observed for GPNMB and FLRT3, it was 
hypothesized that GPNMB and FLRT3 may potentially be regulated by one 
another’s cellular processes. The down-regulation of GPNMB or FLRT3 had a 
similar extent of changes in T47D cells’ phenotypic behaviors; there are decreases 
in cell migration and cell invasion by about 50% and small changes in cell 
proliferation and adhesion in T47D breast cancer cells.  However, from the qPCR 
experiment carried out, it is seen that GPNMB and FLRT3 do not regulate one 
another’s expression level. This may possibly indicate that these two downstream 
molecules of CHST3 work independently of one another and may not have 
cumulative effects on the evaluated phenotypic behaviors. 
 
In addition, as CHST3 and FLRT3 are observed to have associated functional roles 
in breast cancer cells, it is appropriate to test their association in human ductal 
tissues as well. As the same human patient samples were used in both CHST3 and 
FLRT3 expression studies, analysis was carried out to test both molecules’ 
expression in terms of their correlation with one another. No significant correlation 
is found between the expression levels of CHST3 and FLRT3 in the breast tissues. 
An additional tissue expression study in a different Singapore cohort of breast 
cancer patients should be studied to validate the expression studies carried out. 
Moreover, an expression study of GPNMB in the Singapore patient cohort 
diagnosed with IDC should also be performed. This will allow evaluation of the 
associations of the three molecules (CHST3, FLRT3, and GPNMB) as well as 
analyses with associated clinicopathological factors. Overall, from the two tissue 
studies, CHST3 and FLRT3 preliminarily has potential as diagnostic markers when 
evaluating a patient’s malignant ductal tissues and surrounding normal tissues in 
terms of the epithelial cells’ expression levels of CHST3 and FLRT3. Low CHST3 
expression is correlated with larger tumor size and higher tumor stage, while high 
FLRT3 expression is associated with patients with older age and enhanced stage of 
lymphovascular invasion. This could also potentially lead CHST3 and FLRT3 as 
diagnostic biomarkers to detect the possibility of the patients having metastasis. 
However, CHST3 and FLRT3 did not appear to be potential prognostic biomarkers 
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in breast cancer in this study. No significant association was observed between their 
expression levels and tumor recurrence or mortality risk. Nevertheless, it is 
observed that tumor size has prognostic prediction for both tumor recurrence and 
survival after adjusting for confounding factors.  
 
One factor, however, to be noted from the expression studies in the ductal tissues 
is that both CHST3 and FLRT3 are not associated to the expression levels of the 
well-established biomarkers ER, PR, and HER2. Hence, there is the possibility of 
both CHST3 and FLRT3 being non-associated with particular breast cancer 
subtypes such as luminal breast cancer (mostly having ER/PR positive statuses) or 
basal breast cancer type (usually having ER/PR/HER2 negative statuses). This may 
somewhat explain why ER/PR positive breast cancer cell lines MCF7 and T47D as 
well as ER/PR negative MDA-MB-231 breast cancer cells display similar extensity 
of changes when CHST3 expression is affected. 
 
One common signaling pathway that CHST3, GPNMB, and FLRT3 have is the 
MAPK signaling cascade. GPNMB has been shown to be enhanced of its 
expression level in breast cancer tissues (Rose et al., 2010, Rose et al., 2007), of 
which its up-regulated expression level and aggressive phenotype features have 
been associated with increasing tumor grade of the breast tissues and  enhanced 
MAPK signaling (Vaklavas et al., 2013). In the case of regulation through FLRT3, 
its effect has been observed in regulating cell migration and adhesion in Xenopus 
tissues. Upon Tgfβ signaling induction, Flrt3 co-expresses with Fgf12 growth 
factor to activate Mapk signaling cascade (Karaulanov et al., 2006, Chen et al., 
2009b). Hence, it is possible that CHST3 together with GPNMB and FLRT3 have 
a role to play in the MAPK signaling pathway. Further studies will be needed to 
investigate whether there are associations between CHST3, GPNMB, FLRT3 and 
MAPK-related molecules as well as whether the molecules are upstream or 
downstream of CHST3, GPNMB, and FLRT3. 
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4.1.3 Potential Regulatory Role of CHST3 through Other Pathways 
 
EMT is an important event during embryogenesis and normal development (Thiery 
et al., 2009). However, EMT also takes place in tumor progression during late 
cancer stages, promoting metastases and treatment resistance (Polyak and 
Weinberg, 2009). It involves the detachment of tumor cells from the primary tumor 
site, whereby intercellular contacts are disrupted and cell motility is enhanced. The 
progression of the epithelial cell phenotype to mesenchymal phenotype would 
allow tumor cell invasion and migration allowing metastases and secondary tumor 
site formation (Guarino et al., 2007, Simic et al., 2013). Also, the transformed 
epithelial cells would adopt capabilities resisting cell apoptosis to allow increased 
survivability of the transformed tumor cells (Hanahan and Weinberg, 2000).  
 
Nadanaka et al showed that either the exogenous treatment of CSE or regulation of 
CSE levels via modulating CHST11 expression has a downstream effect in 
reducing β-catenin expression levels (Nadanaka et al., 2011). In this study, through 
immunofluorescence observations, EMT markers (E-cadherin and β-catenin) were 
observed to be down-regulated after silencing of CHST3 in T47D cells. These 
corroborate with the phenotypic behavior changes, promoting metastatic-like 
events and cell invasion in the breast cancer cells studied. 
 
Transforming growth factor-β (TGFβ) that is up-regulated as observed from the 
microarray study and other growth factors (such as midkine (MK) and fibroblast 
growth factor 2 (FGF2)) are involved  in initiating extensive crosstalk and feedback 
control of different gene expression levels (Lamouille and Derynck, 2007, Wang et 
al., 2010c). In breast cancer cells, FGF2 is observed to down-regulate E-cadherin 
via the activation of MAPK signaling pathway (Lau et al., 2013, Pece and Gutkind, 
2000). In the example of MK, it decreases epithelial markers E-cadherin and β-
catenin, through activation of downstream molecule neurogenic locus notch 
homolog protein 2 (NOTCH2) (Huang et al., 2008a, Huang et al., 2008b). 
Additionally, transcription factor Wilms’ tumor suppressor gene (WT1), which is 
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down-regulated by 2.07 folds in the microarray study, regulates expression level of 
E-cadherin (Hosono et al., 2000, Brett et al., 2013, Morrison et al., 2008). Moreover, 
WT1 is regulated by MK via MK’s binding site for WT1 (Adachi et al., 1996) of 
which the over-expression of MK down-regulates WT1 (Konishi et al., 1999). 
Hence, MK and other growth factors may potentially be upstream of CHST3, 
initiating various EMT markers (E-cadherin and β-catenin) and intermediary 
molecules (MAPK, NOTCH2, and WT1).  
 
The EMT process also includes the survival capability of tumor cells which is vital 
for the cells to migrate, invade, and to grow a distant secondary tumor successfully. 
Cell proliferation, from this study’s observations, may possibly be non-biogically 
important in terms of CHST3 functional roles in breast cancer cells, due to the small 
changes observed after regulating CHST3. The change in cell death, while slightly 
more in extent compared to cell proliferation change, is still considerably small and 
may only be a minor functional role comparing with that in cell migration and 
invasion. Pro-apoptotic BAD was also observed to be slightly increased of its 
deactivated protein form after silencing of CHST3, indicating CHST3 has some 
potentiality to regulate cell survival through BAD and thereafter caspase 3/7 
pathway. Growth factors such as TGFβ and FGF2 (Dufour et al., 2008) are also key 
molecules in this case for EMT. The growth factors signal transducts mitogen 
activated protein kinase (MAPK) signaling pathways, of which the activated 
MAPK pathway will phosphorylate pro-apoptotic BAD protein, prohibiting 
mitochondrial death cascade, promoting cell survival and EMT event (Lahiry et al., 
2010, Suman et al., 2012). These provide insight to possibilities in the CHST3 
pathway. Further studies will be needed to evaluate the signaling order of CHST3 
pathway, possibly starting from the signal transducting growth factors to 





4.1.4 Potential Role of CHST3 through Non-Enzymatic Activity Role 
 
To be noted, the phenotypic behavior observations in this study should be analyzed 
with caution of their source of regulation, which remains uncertain at this point in 
time. To elaborate, even after down-regulating CHST3 in the breast cancer cells, it 
is uncertain whether the phenotypic changes were due to the active CHST3 
molecule itself or changes in level/sulfation pattern of CHST3’s known substrate, 
6-O-sulfated CS. The phenotypic changes observed in this study could be due to 
the fact that CHST3 had modulated the cellular behavior changes through sulfation 
at the carbon 6 of galactosamine of CS. In laryngeal cancer, an association was 
observed whereby both CHST3 and C-6 sulfation of galactosamine were shown to 
decrease as tumor stage increases (Kalathas et al., 2010). Hence, the difference in 
levels of C6S molecules would affect cell signaling behavior through different 
binding of ligands such as growth factors, cytokines, and apoptotic factors. On the 
other hand, CHST3 may have enzymatic activity-independent function that 
regulates breast cancer cell behaviors. To elaborate, CHST3 may regulate cancer 
cell behaviors via upstream or downstream molecular targets such as GPNMB and 
FLRT3, without having to pass through the effect of C-6 sulfation level. Heparanase 
is of one example of a GAG-related enzyme that has enzymatic activity-
independent function (Kessenbrock et al., 2010). It is has been known to be 
involved in degradation of heparan sulfate. Studies however showed that 
heparanase also exhibit non-enzymatic related activities that are independent of its 
involvement in the degradation of heparan sulfate (Levy-Adam et al., 2010). 
Amongst such activities include stimulating AKT signaling pathway, enhancing 
PI3K-dependent cell migration and up-regulating VEGF, all of which are involved 
in cancer metastasis and angiogenesis (Ilan et al., 2006, Vlodavsky et al., 2007a, 
Vlodavsky et al., 2007b). To address this, the effect of C-6 sulfation can be 
investigated by treating breast cancer cells with C6S, prior to carrying out the 
phenotypic assays. Changes observed and caused by C6S in the assays would be 
compared to the changes obtained from regulating CHST3. This would hence allow 
observations as of whether CHST3 has indeed enzymatic activity-independent 
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functions in breast cancer. For now, one should look at the potential signaling 
pathways that CHST3 may be involved in such as the follows. 
 
4.2 Regulation of CHST3 Expression 
 
As downstream targets like GPNMB and FLRT3 of CHST3 pathway have been 
identified, it is also important to evaluate potential upstream molecules that may 
regulate CHST3 expression, hence giving rise to the phenotypic behavioral changes 
observed. As the focus in this study tended towards the downstream molecules of 
CHST3 regulation, one may hypothesize on the possible upstream molecules that 
can regulate CHST3 expression and functions.  
 
4.2.1 Regulation by Ligands 
 
Studies have determined the interactions of growth factors and cytokines with 
CSPGs at the cell surface. One likely mechanism CHST3 may regulate and may be 
regulated is through the interaction and effect of different ligands at the cell surface 
level, which in turn stimulate different signaling pathways, affecting its expression 
level. TGFβ, in this study, has shown up-regulated expression level of 4.37 folds 
after down-regulation of CHST3. TGFβ, in breast cancer, has been controversial. 
One analysis showed that high TGFβ expression in breast cancer patients is 
associated with better prognosis than those with low TGFβ expression level. 
However, some studies have depicted the opposite whereby the overexpression of 
TGFβ is correlated with worse prognosis and associated with metastatic events 
(Kubiczkova et al., 2012).     
 
Nevertheless, in the case of CHST3, the variation in levels of ligands such as TGFβ 
can affect the composition of cell surface CS expression, which in turn can 
potentially lead to altered regulation of CHST3 expression and carbon-6 sulfation 
pattern. In human arterial cells, TGFβ was observed to stimulate the synthesis of 
C4S and C6S (Chen et al., 1991), and regulate CHST11 or chondroitin-4-
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sulfotransferase 1 (Kluppel et al., 2012), suggesting higher possibility that TGFβ is 
upstream of CHST3. Additionally, TGFβ can regulate the expression levels of 
CSPGs such as neurocan and brevican, as seen in vitro in astrocytes that were 
treated with TGFβ. It has been suggested by the research group that TGFβ may 
regulate CSPG expression via the PI3K-AKT-mTOR pathway (Jahan and Hannila, 
2015). Perhaps, similar to heparanase, CHST3 may exert part of its role through 
this pathway, bringing rise to regulation of cell migration Hence, TGFβ can affect 
both CS chains and CSPGs which in turn will have an effect on CHST3 and cellular 
behaviors.  
 
Another example will be the association of CSPG (lumican) with TGFβ. In acute 
lung injury, reduced expression of lumican is associated with enhanced levels of 
TGFβ, affecting its downstream molecules E-cadherin and β-catenin by reducing 
their expression levels (Li et al., 2013). Syndecan 4 proteoglycan, in breast cancer, 
is able to bind to FGF2 at the cell surface and promote FGF signaling pathway 
(Mundhenke et al., 2002). Therefore, CHST3 expression may potentially be 
regulated by CS and CSPG pool at the cell surface level, which affects ligands such 
as MK, TGFβ, and FGF2 that subsequently affects their downstream molecules, 
one of which may be CHST3. Also, as CHST11 and lumican proteoglycan are both 
associated with TGFβ and (for the latter molecule) associated with effect on 
biomarkers E-cadherin and β-catenin, this raises the possibility of CHST3 as well 
as CHST11 and lumican to be involved in the metastatic events. 
 
In the EMT signaling pathway, as mentioned, TGFβ is upstream of E-cadherin and 
β-catenin (both molecules’ expression level decreased after silencing of CHST3), 
causing loss of E-cadherin-β-catenin complexes at the cell membrane and re-
localization of β-catenin to the cytosol and nucleus (Ma et al., 2010, Onder et al., 
2008, Prasad et al., 2009). This will in turn cause loss of cell-cell junctions 
(adhesion), re-organization of the actin cytoskeleton, leading to cells turning 
spindle-like mesenchymal in morphology (Huber et al., 2005), and hence 
promoting further EMT-inducing stimuli, cell invasion and migration (Guarino et 
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al., 2007). Cytokine midkine is also a potential upstream molecule of CHST3 
considering downstream molecules of MK studied (E-cadherin, β-catenin, and 
WT1) are affected in its signaling pathway. Another cytokine that has potentiality 
to be upstream of CHST3 is interferon-gamma (IFNγ). IFNγ has been reported to 
have tumor suppressing effects such as inhibition of cell proliferation in breast 
cancer cells. In an IHC study, the expression level of IFNγ was observed to be 
higher in in situ carcinoma against benign and infiltrating tumors (Garcia-Tunon et 
al., 2007). In skin fibroblasts, enhanced levels of IFNγ were found to down-regulate 
4-O-sulfation and up-regulate 6-O-sulfation of CS chains (Praillet et al., 1996). This 
suggests the possibility of IFNγ regulating the expression level of CHST3, which 
subsequently affects the sulfation pattern type of the CS chains and thereafter the 
cellular behaviors.   
 
From another perspective, CS sulfation pattern may affect potential upstream 
molecule such as MK, to subsequently have an effect in regulating CHST3. MK 
has been evaluated to have strong affinity to CS proteoglycans such as versican, 
CSPG4, and syndecans (Nakanishi et al., 1997, Zou et al., 2000, Ichihara-Tanaka 
et al., 2006) via their CS chains particularly tumor promoting CSE units 
(Muramatsu, 2010). Removal of the CS chain from the proteoglycans reduces 
binding of the proteoglycans to MK, which may affect the subsequent signaling 
pathway and CHST3 pathway.   
 
4.2.2 Regulation at Gene Expression Level 
 
Gene expression can be modulated at various steps; one of which include epigenetic 
regulation (e.g. methylation and acetylation). The expression of a gene can be 
highly dependent on its epigenetic regulation (Bergmann 2012). Epigenetic 
mechanisms define mitotically heritable differences in gene expression potential 
without changing the DNA sequence. These epigenetic changes can occur due to 
random mutation or environmental factors. Some examples of epigenetic marks 
include DNA methylation and chromatin modifications through histone acetylation 
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(Inbar-Feigenberg 2013). In general, DNA methyltransferases (DNMT) catalyze 
the methylation of cytosine to 5-methylcytosine. DNA methylation is able to cause 
failure in binding of a protein such as a transcription factor to its cognate DNA 
sequence, resulting in repression of tumor suppressor genes and enhancement of 
tumor promoter genes (Bird 2002). 5-aza-2’-deoxycytidine (5-AZA) is a DNMT 
inhibitor, capable of reversing promoter hypermethylation in cancers (Palii 2008).  
 
Histone acetylation, on the other hand, is regulated by the antagonistic actions of 
two families of enzymes, namely histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (Haberland 2009). Catalyzed by HATs, histone acetylation 
involves the transfer of an acetyl group to the ε-amino group of lysine residues in 
N-terminal histone tail. This neutralizes the positive charge of lysine residues, 
weakens the charge-dependent interactions between histones and DNA, and hence 
relaxes the chromatin structure for transcription initiation (Feigenberg 2013 and 
Bannister 2011). In an opposing manner, histone deacetylation can occur catalyzed 
by HDACs, condensing the chromatin structure and repressing gene expression 
(Haberland 2009). Trichostatin A (TSA) is an antifungal antibiotic, used to inhibit 
HDAC and thereby restoring gene transcription (Dokmanovic 2007).  
 
Initial evaluation of CHST3 expression from Gene Expression Omnibus (GEO) 
microarray databases has shown little changes in CHST3 expression level after 
treatment of either 5-AZA or TSA on various breast cancer cell lines (T47D, MCF7, 
and MDA-MB-231) (Dedeurwaerder et al., 2011, Sun et al., 2009). Till further 
validation is carried out, this initial literature review currently suggest that CHST3 
expression level is not regulated through epigenetic regulation methylation or 
acetylation.  
 
Apart from epigenetic regulation, gene expression can also be regulated at the 
transcription level by transcription factors, defined as regulatory proteins that 
activate, or at times, inhibit, DNA transcription through their binding to specific 
DNA sequences, hence promoting or inhibiting gene expression (Phillips, 2008).  
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The binding of transcription factors to the DNA is the fundamental step to 
regulating gene expression. A certain transcription factor bound at a site can 
regulate genes that are of close proximity and possibly those that are further away 
with the aid of enhancers. A number of transcription factor-related genes (as shown 
in Table 4.1) have been noted from the microarray in this study. Though the change 
in expression of the genes were affected after down-regulation of CHST3, further 
evaluation is necessary to determine if the affected genes regulate CHST3 
expression in the transcription as well as translation processes, and whether the 
genes are upstream or downstream of CHST3. Future experiments such as 
chromatin immunoprecipitation (ChIP) can be performed to evaluate the genes 
affected by particular transcription factor binding sites (Maienschein-Cline et al., 
2012). 
 
Table 4.1 Potential transcription factors regulating CHST3  






ELK3 Down-regulated 4.15  Member of the ETS-domain transcription 
factor and ternary complex factor (TCF) 
 Activates transcription when Ras is present 
DPY30 Down-regulated 3.86  Member of the MLL1/MLL complex 
 Role in methylation of histone for 
transcriptional activation 
PRIM2  Down-regulated  2.62  Subunit of DNA primase 
 Role in DNA replication, specifically to aid 
in synthesizing small RNA primers to 
create Okazaki fragments 
LARS  Down-regulated  2.62  Member of the tRNA synthetase family 
 Role in catalysing ATP-dependent ligation 
of leucine to tRNA (Leucine) 
EIF2S1 Down-regulated 2.27  A translation initiation factor 
 Role in catalysing protein synthesis 
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 Role in promoting binding of tRNA to 40S 
ribosomal subunits 
MBNL Down-regulated 2.12  Role in pre-mRNA alternative splicing 
regulation 
HIPK1 Down-regulated 2.08  Member of the HIPK subfamily  
 Member of the Ser/Thr family of protein 
kinases 
 Role in phosphorylating homeodomain of 
transcription factors 
EIF3J Down-regulated 2.08  Member of the eukaryotic initiation factor 
3 complex 
 Role in translation initiation 
 Role in recruiting mRNA and protein 
components to 40S ribosome 
WT1 Down-regulated 2.07  Consists of a DNA-binding domain 
 Regulates other genes’ expression and 
activity through binding to specific regions 
of the DNA 
MCM10 Down-regulated 2.05  Member of the mini-chromosome 
maintenance proteins (MCM) 
 Role in initiation of genome replication 
 Role in formation of replication forks 
DICER1 Up-regulated 2.01  Role in production of miRNA 
 miRNA regulates gene expression via 









4.3 Proposed CHST3 Pathway 
 
Putting everything together, the evaluations in this study are of importance in terms 
of diagnosis and treatment response in breast cancer. A CHST3 pathway (as shown 
in Figure 4.1) was hence proposed based on the regulated genes picked up from the 
microarray as well as from candidate proteins potentially involved in the 










4.4 Limitations in Study 
 
4.4.1 Evaluation of CHST3 and CHST7 Functional Activities 
 
It should be noted that CHST3 and CHST7 functional activities were not evaluated 
in this study. Hence, it remains unclear whether the down-regulation of CHST3 led 
to a decrease in 6-O-sulfation of CS. High performance liquid chromatography 
(HPLC) to determine CS content should be carried out after silencing or over-
expressing CHST3. Also, it is also uncertain whether CHST7 is functionally active 
and has compensated for the loss of CHST3 functional role. An enzyme activity 
assay needs to be performed to evaluate the functional activities of CHST3 and 
CHST7 after silencing or over-expressing CHST3.   
 
4.4.2 Evaluation with Clinical Samples and Animal Models 
 
In the tissue expression study, 218 cases were analyzed of the expression levels of 
CHST3 and FLRT3 with the various clinicopathological parameters. The 
preliminary analyses give a sense of the expression levels of both molecules in 
human ductal tissues and whether they are associated with any of the 
clinicopathological parameters. One should evaluate the associations using a larger 
patient sample size as well as a different cohort of patients diagnosed with IDC. 
Additionally, it is important to extend the investigation to animal models, such as 
to evaluate if an overexpression of CHST3 in the cancer cells of the animal model 
will suppress cell migration or cell growth.  
 
4.4.3 Evaluation using Different Assays 
 
In experimental cell biology, phenotypic behaviors can be investigated via various 
methods depending on the objectives of the study. Through different methods, one 
is able to better understand the cellular behaviors of breast cancer cells upon 
regulation of CHST3. For cell migration in this study, the focus was on using a 
filter-assay method (transwell membrane chambers) to measure cell migration 
towards chemoattractant FBS. Other types of migration assays can also be carried 
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out such as (i) random walk assay which evaluates the rate of random motion of the 
cells that are sparsely distributed on a matrix-coated surface, (ii) wound healing 
assay that evaluates quantification and characterization of collective cell motility 
by measuring the wound geometry after a gentle wound scratch through a confluent 
cell monolayer, and (iii) cell-populated agarose drop which characterizes cell 
motility on various extracellular substrates by trapping cells within an agarose 
group, in which the cells will diffuse progressively out from the drop onto the 
surrounding extracellular substrate (Rosello et al., 2004). 
 
Evaluation of cell proliferation was performed using MTS solution, a quantitative 
colorimetric assay that measures enzyme activity of mitochondrial dehydrogenase 
reflecting the metabolic status of a cell. Therefore, the absorbance change in color 
of the MTS solution is proportional to the number of metabolically active cells. 
Though simple and rapid, there must be precaution in concluding cell proliferation 
observations done using indirect measuring methods. MTS assay is sensitive 
towards cell size, hence there can be an increase in cell size without any cell 
division (Mosmann, 1983). More direct methods require measurements of DNA 
synthesis or cell division or cell number itself. Flow cytometry using propidium 
iodide and detergent-based method was also hence performed in this study to 
further evaluate cell growth and cell death based on the cellular DNA contents and 
cell cycle phases (Nunez, 2001). Other methods include 5-bromo-2’-deoxyuridine 
(BrdU) that specifically label DNA with a precursor molecule. BrdU can be 
detected through immunocytochemistry using an anti-BrdU antibody that labels the 
nuclei. Results will be generated based on the quantification of stained nuclei in 
different random fields (Gratzner, 1982, Waldman et al., 1991). Apart from BrdU, 
cells can also be immunostained with proliferation markers such as Ki-67 and 
proliferating cell nuclear antigen (PCNA) (Scholzen and Gerdes, 2000, Hughes and 
Mehmet, 2003). Cell proliferation can also be measured at its membrane integrity 
state through the usage of chemicals like trypan blue. A healthy viable cell with 
intact cell membrane will prevent trypan blue from entering the cell membrane. On 
the other hand, a dying or dead cells will allow trypan blue to enter their cell 
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membrane. The number of unstained viable cells hence can be counted manually 
or via an automated cell counter, making it less labor-intensive (Hughes and 
Mehmet, 2003).  
 
As for cell adhesion, it is a complex cellular process involving various types of 
interactions, including cell-cell interactions, cell-matrix interactions, and cell 
receptor-ligand binding. In this study, adhesion assay (static cell-matrix attachment 
method) was used to evaluate the ability of the cancer cells to adhere to an adhesive 
substrate (collagen or fibronectin) (Kucik and Wu, 2005, Humphries, 2009). As the 
washing protocol is the most critical for cell-attachment method, the number of 
washing cycles had been optimized (Kueng et al., 1989). Also, to have an 
estimation for 100% cell attachment, unwashed wells containing cells attached to 
an adhesive substrate were measured by their absorbance level using MTS solution . 
It should also be noted that cell number was quantified using metabolic measuring 
MTS solution. In addition, as washing was carried out through manual pipetting, 
adhesion assay with hands-free agitation can be performed, that is placing the 
coated 96-well plate containing cell suspension on a shaker with mild rotation 































CONCLUSION AND FUTURE WORK 
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5 CONCLUSION AND FUTURE WORK 
 
Biomarkers have been making their mark in cancer history in the last decades, 
having important roles in regulating signaling pathways involved in tumor 
progression. Some of the biomarkers have progressed to become diagnostic, 
prognostic, and/or therapeutic markers in breast cancer as well as other 
malignancies. This has led to improved early detection of breast cancer as well as 
better decision-making in administering the optimal personalized treatment. Today, 
more efforts are being made to achieve the “personalized medicine” vision. 
Developing biomarkers in breast cancer is one way to characterize a tumor’s 
sensitivity towards a particular form of therapy and to improve diagnosis as well as 
prognosis estimation for the patients.  
This study has unraveled the first insights of CHST3 and its function as well as its 
clinical relevance in breast cancer. From the in vitro study, it was shown that 
CHST3 plays a tumor suppressor role, of which higher expression of CHST3 
reduces cell migration, invasion, and proliferation as well as increases cell adhesion 
and cell apoptosis of breast cancer cells. In the immunohistochemical analysis, 
CHST3 was found to be down-regulated in invasive ductal tissues compared to 
normal ductal tissues. From this study, CHST3 shows potential to be diagnostic 
biomarker, but not a prognostic biomarker as no associations were obtained from 
the survival analyses. Genome wide microarray analysis revealed a list of genes 
altered after down-regulating CHST3 in breast cancer cells. From the list of genes, 
two selected genes, GPNMB and FLRT3 had significant importance in the CHST3 
pathway, whereby both genes are downstream molecules of CHST3 in breast cancer. 
FLRT3 was also found to be a potential diagnostic biomarker as it is up-regulated 
of its expression in malignant ductal tissue compared to normal ductal tissue. 
Additionally, alteration in CHST3 expression affected the E-cadherin/β-catenin, 
and apoptotic (BAD) pathways. 
The findings from this study are of considerable significance as an interesting gene, 
CHST3, has been uncovered to regulate breast cancer cells’ behaviors, specifically 
in the metastatic portion. Nevertheless, further studies should be carried out to fully 
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understand the functions and molecular pathways of CHST3 before extending the 
study to in vivo studies as well as other cancers.  
The potentiality of CHST3 and FLRT3 as diagnostic biomarkers should also be 
further evaluated. For example, both biomarkers could be examined in different 
cancers such as ovarian cancer as well as other breast cancer types such as lobular 
carcinoma and phyllodes tumor. Additionally, evaluation of the biomarkers should 
be carried out at the global level. The current study involves the Singaporean breast 
cancer patient cohort and hence, the two biomarkers should be further tested on 
other populations to investigate if the correlations observed in this study are 
consistent in other populations. 
Additionally, as mentioned, the phenotypic changes observed in this study could be 
due to the fact that CHST3 had modulated the cellular behavior changes through 
sulfation at the carbon 6 of galactosamine of CS or via its own enzymatic activity-
independent role. Therefore, the effect of C-6 sulfation should be investigated by 
treating breast cancer cells with C6S, prior to carrying out the phenotypic assays. 
Cellular behavior changes observed and caused by C6S in the assays would then be 
compared to the alterations obtained from regulating CHST3. This would hence 
allow observations as of whether CHST3 has indeed enzymatic activity-
independent functions in breast cancer. Also, after treating the breast cancer cells 
with exogenous C6S, the expression levels of the downstream molecules inclusive 
of GPNMB, FLRT3, E-cadherin, β-catenin, pBAD as well as the speculated 
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